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B 0: f) U' G ~ l 
Tb.• <tleoovet-J o£ lnsult.n bJ Bantt:os &nd lea' 
ln. 1921 wa.e the c1t.max ot years ot paS.utald.·ns !'elieal'ob. 
tn dlabetes e4 111\roduced a SJ'iGat era .S.a 41abetS.o 
tt-eatment. 
Th1e dlsooverr S'esultod 'Jars•J.J tram lmlmal 
experlmet'lta. lt waa fo\md tb.at pancreatectomy i.a 
an1&tJa1a prodttced d'Lab&t:et (von Mer1ns am M1nkowsld. 
1889) ·and that lnsu11a corrected ·the pb.J&lo1ogloa1 
atmormall~g tbua p.o<lucea. tt .·thus became "W14elr 
as.&Wtl$d that dl.abetea .mellitu.a wac 41iie to a 
pancl'e.atlc tslet abnwma11tJ wt.th detective formation 
(ol' pro4uct1cm.) of tnsultn. 
As we began to unaer$t&n4 more abo"t Cilabetea 
however. lt be·came evident tbat the alabetes ot 
paaci'eatectomr did not :represent tbe whole spect;rum ·of 
diabetes ln man.; tb.e.t 1n man, the laatg&r pou.p of 
atabetics or tbe matlll'lt,J-onl$ti tJpe, aa tb&J ~e oa11e4, 
had ineal.S.a avalla.ble h.· tbeizt pltsa (Bomsteln aa4 
tawrenoe 1951). 
QeaeqYeatl', treatmeat 'bi meetUS otb.er t'ban 
S.naul1n tn tbJ.s dAtut-'itJ-on•et ·,group seemed logl.oal 
and th• oatoome waa the advent ot the eulphonrlu.rea 
2 
and elmt~ dl'Uga or tbe teat 4eoa4e. ~I.e~ .Sa tu.n, 
ha.e lect .. to a .ttoursenoe of l~:&le:a-eet lD Haeuob. oa •u 
lDStaboltc leeton til CJlabet••• 
•r own mtenat lt\ 'tlle OJ~al. t;natment of 
' . 
dS.o.,.tea eo~e•d ln 194.7 (wb&A l ·wee attadle4 to the 
4tmtlc oltalo ot G.roote Scbl.le loo.pltal) tMton the 
lrltMdUCtlOD Of tl\o ·Oral Uti. .t!f.a.betogenlo *SeA'tlt DC* 
sa oar••' ••• 
TbO ma3or1tr •t dlabt•&oe attenalng tbt ollnlc 
aeo.med to tell lllto tbc '-0 woll•eooSJ'lleed QHllpa • the 
pottth-ouet» (or Juvenile tJJt) O)d ate matut•r-ouet 
trte. ln ept.te ·of ·~ tact. •••: tta,e two IJ"'\l~Pfa •••• 
c1lal.ce11J. tietlttot tt.ere wu 1\\o enomalr that) both •••• 
be:la! tHato4 w1tll taaullh. It ••• aot&woJtthJ.t too, 
er.t l.naulln tallef to l.rdlueace the l'lli)l iaeltSeue ef 
oomp11oat;1oae ln thla matu.rlt·I.OUet group. 
'fo tbe oll.a1Ga1 obaetvor lt wae e•.t.cJen' \bat 
&ntu1J.D bad aot •ol••• tile Pl'i)bl«ml ot INatmeat .s.a •u 
mat\tPltJ-oHet tJpe ot dlabetea. Perha,pa cmotho• 
:pbJa.toloatoe,l aaeat 1t1igbt JMVe bo1$)hl ln oaet1h8 tol'tb.eP 
.Uab:t ora tbe aett.olog or 4ldetoa t.a MD ad &l\fe a n•• 
ep,._ch to tNatmeo\ lA tbe •tuttltr-cmaet BPOUP• 
3. 
fowa~J~da thte ena j 1 d'tOS.Clfrill to S.a;veattgat& th6 
ettect ot a Jlb.'et.o~,ogt.o•11J. oec~l'lDS egeat,, rd.cotlnamlde, 
on the couJS&e ot dlab&tets. 
lloottnamlde ls .the most aotlve conett•uent of 
the coanzr-e wl\tcb ocour ln all llvlns cells of the 
• < ' I I 
bodr. ib..eae ooeas,mes are of 11t~a1. l•nence tn 
caPbOhJdl!'ate metabolism. aa.d lt baa b&en eu.ggeated t'b.at 
nlc()tlaamtdo .le ·tb.e most vulne~able por-t.S.on ot the 
,ooeneJnm moletB. 
Wae t;b.1s, th&llt th6 .J)Olnt tibel'& tl\G metaboUo 
l.e&l.on 1D <ll·abetee ooourred t 
1\' stu<ll·ee on tho . e:tt-ect ot nt.oot1aam16.o 1ft 
4labote8 led to Qn lnvaet1satto-. Of the rllGW 
fllUMnCOlog1enl antS...,dl.abetogenle eg4nta *lob. cema lnto 
'togu.e about thl& tlme,. 
:Mg patlenta had altteadJ btllezt obsePved ova• a 
loDg perlo<l .8ft4 theJ ocu.1CJ r10w act ea their ·own oontttola 
tn f'w:-ther lnveetlsatloas o. ~ ·comparatl.ve otteote ot 
vartoua hrpog1J.eael111·o aaenta. 
Ia tb.ls tl\e.a1& ·then• the auba tan~•• cho•en for 
speola1 etudr .are ntootbamlde aod the .~~cople•d oral 
l 
e.al>sttn\ce_a to the wll•l'ecosr.&..otd ·dtabetosente a-sect, 
co.Ptlcone.; ls .. a~ .iaveatt.sa~te4, • .. 
A blthet"to poo~1J &-e~gat.oea phenomenon 
became e'Wtde.' la thle atu.a, = Deve~sl ot the _pa;ttents 
Wife• obaof!lvatlon ahowe4 a: retd.•elon lD dlabete~• · 
Could wt get more tntormatlon about theae patlente b 
tt$mlaalort -~ notlq the •ttect or oort.1·son1t 7 . PaJa.ne; 
aa Corm (19tltJ opened up a11 fatoHattas new tleld blf 
WilliS COJ't-lsone foJt cmb.anoe!fltttt e)f the 81uoose 
. tolet'uoe -st. What wou14 be the. influence ·ot 
eo:-t;ls.- oa the carbohl<lrato _tol••e:n.oe ta these eaeoa 
who mo.-ea eP<m.taneotUJ oz-. b,.duce4 .-e.S.aalons f 
the atu4J ~at been exlerutet tc 1nclu4o o 
.ln.-.estl.g&tlon c~ ·GVbOb:Jdl'ate to~r-en~e _ln gout because 
ot tho beat-lna tb.J.s d1at®ban·ee mar bave on uturalli 
. oect.trrlng 41abetogea1o agents. 
Xt hna bean .Sl.tggeat.,d _hf ~ et a1 (1945) la 
th&lP otu,df.M on tbe dS.abe·tfpliS.O etfG·ct ot al:1oJ:an that 
then inaJ be a naturallr oeoUl'l*t.ng dl.abetcgent..c agent Ia 
5 
ot I.Dtema'l .metabo1lam. 
Al.lOSf:lG roaemblee the.:Pfl"l.mtall\e pai't ot urio 
.aold 'l\D.4 .lt hae beeA abo~ t~t Wl4tr oertaS.ft ooncli.tlona 
' 'I ~ 
. aa tnJ"tloa ot u..l.c acs.a ca prcduQt 4labetea ln .· 
anlmab (OJ!'ttfltha 1948 aaa 1950). · ·. 
gout s1va eomo ·clue as to wnotb.~, tl\ere le euon, a . 
fQO'OP bp$JtGttvt!.i .SA .man, ? 
l 
A.epeete or 11 tt)ptU%'& •~lell&iit to tbe theal.a 
ba'te bet:n l"evlewed wttb empbaf!lls on the poasJ.ble 
. correlat:lcn .ct ·the varlot.~s tlgintG ·dtscu~eel! and t:lt.e 
~sibl& l1gbt. :they mS.gb.t tb~ ol\ the metabollo .lealOD. 
in diabetes. 
fhla tb.eale repr.teeenttt the work ot .. tt 1ons term 
stu.cl;r.. It deals w1tb f.1\ietuf,\t1one and retd.eslona lD 





The Oasea Studl•cl 9 
Methode ot Investlgatlon.. 10 
1.. 24 Hour Ul'lne G lu.oose 
Eetlmatlone 10 
2. Fasting Blood Glucose 'l'e•t• 10 
;. Glucose Tolerance 'feats 10 
4.. Oortlsone/Glucos$ Tolerance 
Teats 14 
Interpretat1on ot Glu.ooae Tolerance Teets 15 
... 
. THE OASES STUDIED. : . . . . 
168 patients were investigated during the 
course of this long term study at Groote Schuur 
Hospital.. 
I. 46 diabetic patients who formed the nucleus 
of' this studJ at the D1abet1c Ol1nlc
1
ot the Hospital 
received n1cot1nam1de. 
As the investigation proceeded, new patients 
were seen by me at the cllnlc and the .following were 





Patients who could act as controls of the 
nlcot1nam1de t.reated patients, 
Patients who would demonstrate the comparative 
etfect of various hypoglycaemic agents, 
Patients who might be latent or potential 
diabetics, 
Patients who showed 1ntereJtlng remissions. 
II. S6 gouty patients were investigated. 
82 patients termed part ot the 1nveat1gat1on 
of carbohJdrate tolerance 1n gout and 4 additional 
patients vho showed the asaoo1at1on ot gout and diabetes 
were 1n.clu4ed. 27 non•goaty arthrl tic patients (not 
lncluc1ed ln the total 168) acted as controls in this 
section. 
All the diabetic pa t1ents . 1n th~s atttdy were 
personally auperv1s•d by me with regard to their 
treatment, their tests and all 1nves.t1gatlons. 
METHODS OF INVESTIGATION: 
The following tests were done on patients 1n 
the va,.-1 ows sec t1 ons of thla a tud.y: 
1. 24 hour urine glucoee eatlmatlons ln patients 
admitted to hospital 
Fasting blood glucose tests 
Gluccae tolerance tests 
Cortisone/Glucose. tolerance teats. 
q 
/0 
1. The 24 hour q~antitative urtne glucose eatimationa 
This 1a a ver1 ••luable method ot aaaeaa1ng progreaa or 
a caae ot d1abetea. Fluctuation• 1n the quantltJ ot 
gluooae excreted in tne ~rtn. reveal improvement or 
otherwiae. 
Tbia is a relatively simple proced~e b~t 
caret~l •~perviaion ot tbe patient and conatanc1 ot 
diet are nevertheless req~ired. These eatimationa were 
done by me. Benedict'• method was uaed tor the 
q~antitative ~1ne glucose eat1mat1ona. 
2. Fasting blood gl~ooae teataJ 
For the aake ot ~1form1tJ all patient. (except 
a tew on 1naul1n) were aakect to report to the Diabetic 
Clinic after taat1ng tor at least 12 hour a. Th1a 
a1mpl1t1ed the aaaeaa .. nt ot progress on aome form ot 
treatment and acted aa a preliminary g~1de to neceaaity 
tor a more detailed 1nveat1gat1on bJ gl~coae tolerance 
test. 
3• GLUCOSE TOLERANCE TESTS: 
Preparation tor glucose tgleranct te!!t 'l!wo 
pointa require special mention at thia atage1 
(1) Diet; Conn (1940) has shown that the patient 
should be on an adequate carbohydrate diet before the 
glucoae tolerance teat 1a done. 
Hlmaworth (1935) also sb.owed that a severelJ 
restricted diet could impair glucose tolerance. 
In a panel discuealon Duncan (1955) pointed 
out tbat a diet containing ;oo G. carbohydrate daily 
tor 3 da1• 1a an adequate preparation for the glucose 
tolerance teat. Ricketta atated that a normal curve 
waa obtained if the dally intake waa above 12 5 G. 
Irving and Wang (1954) bave concluded trom their 
observations on carbohJdrate intake that the normal 
diet or an adequatelJ nourished patient need not be 
augmented before a glucose tolerance teat la carried out. 
In ~ etudy the patients were allowed a diet 
containing 300 o. carbohydrate tor a week prior to the 
glucose tolerance teat. 
(il) Activity: It bas been Shown by Blotner (1945) 
that prolonged conf'S.nement to bed 1s reaponaible tor 
an abnormal carbohydrate tolerance and t~at resumption 
I( 
of activity causea a reversion to normal. 
In m, atudy, the blood glucose teats were made 
on ambulant out-patients in practically all cases. 
Studies were conducted on a tew in•pat1ents as well aa 
e.g. those ln Whom tbe quantitative urtne glucose 
eatimations were done. Theae patients were not confined 
to bed. 
ChOice or Glucoae Tolerance Teat: 
Ot tbe teats, ~e •standard' one-dose (50 G. 
gluco ae) OJtal teat appears to be the aost valid • being 
moat specific and aenait1ve (Moyer et al 1950). 
Attention was paid to tne followipg cond~tiona 
in pertorm~s She slucose tolerance teats 1n this atu~za 
(a) For a week prior to the glucose tolerance teat 
the patients were allowed a diet containing JOO G. 
carbohJdrate. 
(b) There was a minimum fast1ng interval of 12 hours 
be tore the teat waa pert.ormed. 
(c) Capillary blood obtained by the finger prick 
12 . 
method was used throughout. Blood was taken tasting, 
generally at halt-hourly intervals tor 2 hours 
afterwards. (Departures from th1s are clearly 1nd1oated 
ln the results). 
(4) The Hagedorn - Jensen metbod of estimating 
glucose was used tbrougbout 1n all the sections ot the 
study (Hagedorn et al 192,). 
(e) The same teobn1c1an/a were as a rule responsible 
tor doing the teat 1n any particular section. 
To a Yery large extent tnis applied also in 
the long term follow-up which proceeded througnout the 
investigation. From the inception ot this study 1n 
1947 for approxlmatelJ 10 years the same tecbo1o1an in 
the Department of Chemical Pathology was apeclally 
associated witn the estimations ot the tasting blood 
glucose and glucose tolerance testa. This helped to 
add uniformity to the teats. Glucose tolerance testa 
and 24 hour urine glucose teats were done by the author 
personally 1n the flrst year or the investlgatlon (1947>· 
The glucose tolerance teat is unnecessary tor 
diagnosis when definitely abnormal blood glucose levels 
have been round but in this investigation the glucose 
13 
tolerance teet waa uaed •• a means ot asaeaalng the 
fluctuations pro<Suced b;r val"ious agents. A normal 
tasting blood glucose teat does not necessarily mean 
a normal glucose tolerance test and the glucose 
tolerance teat vaa therefore a more •enalt1ve metbod ot 
eatabllshlng whether there were tlu.ctuatlons ln 
carbohydrate tolerance; lt gave information which a 
tasting glucose test could not posalbly glve. 
It acted as a natural bridge to the next test ·• 
enhancement ot the glucose tolerance teat by cortlaone 
ln patients who showed remissions in their dlabetea, 
i.e. the cortisone tolerance tests. 
(i) Patient$ who showed spontaneous remlaaiona, 
(11) Patients who showed remissions whlle an 
h1Poglycaem1c agents, 
(111) Patients who might be latent or potential 
diabetics, 
(lv) Selected gouty patl~ts. 
/If. 
The Cortisone/glucose tolerance teet ia 
diacuaaed in greater detail in the section dealing 
with Adrenal Cortical Steroids. 
> 
Interiretatlon ot Glucose Tolerance Teata: 
The generall7 accepted figure• tor the upper 
limit ot normalitJ in the gl~cose tolerance teet bJ 
the Hagedorn - Jensen m.~od (ualng caplllar1 blood) 
are (Moaenthal et al 1950J Lawrence 1947): 
Faatlng Blood glucose 
l hour leYel 




Moyer et al (1950) (using the Folin•Wu method) 
consider a 2 hour level between 125 • 1.40 mg. aa 
preauJD.ptively abnormal. 14.0 mg. and over ia det1nitelJ 
abnoraal or diab•tio. 
BJ our preaent daJ criteria, tne d1agnoa1a ot 
diabetes would be untenable 1n tne preaence ot a normal 
glucose tolerance teat, t.e. where the taat1Dg and 2 hour 
levels are below 120 mg. 
15 
~bese figures are accepted as the upper 
levels tor a normal glucose tolerance test in this 
investigation. 
~he border line between normal and abnormal 
blood glucose levels varies within a narrow range from 
one authority to another. 
In this stud7 when a patient is stated to have 
a diabetic glucose tolerance test, more r1g1d or1ter1a 
tor abnormality (than those generally accepted) are used1 
Both the fasting and the 2 hour levels bad to be abnormal. 
The following figures would therefore be considered 
abnormal by all standards 1 
Fasting blood glucose 
2 hour level 
1 hour level 
1 Greater than 150 mg. 
: Greater than 150 mg. 
1 Greater than 230 mB• 
(fhe fasting and 2 bour levels are the figures 
emphasised by most authorities). 
There are various factors which influence the 
glucose tolerance test. 
In this study small fluctuations 1n blood glucose 
lb. 
levels are not relied on tor the assessment of progress 
ot dlabetea. Factors like emotion or preceding 
exercise, would not appreciably lntluence the assessment 
of glucose tolerance teat. Patients with aepala or 
infection were excluded from the investigation. Where 
an unpredictable factor (like coronary thrombosis) 
oce~red during tbe course of tho study this was noted. 
The age, aex and weight ot the patients were 
recorded 1n the results and these factors need not 
be discussed here. 
Special attention was paid to activity and 
previous diet. }~ of the inconsiatenciee in earlier 
repoxats on glucose tolerance tests may be due to the 
tact that the influence ot these were not clearly 
understood before their importance was pointed out by 
Conn (1940) and Blotner (1945) e.g. there is a much 
quoted article on a study of glucose tolerance teats 1n 
an old 838 home when the importance of both these taotora 
was not yet tully reallaed and tak$n into account. 
In the long term study, each patient was 
observed over a oontro·l period .. generally tor some 
months • and aga1n dttrlng the trial p&riods w1 th 
var1ous agel').t$ whtcb a.galn .m1ght last tor monthS or 
rears. '!hue the patt&~n ot blood g~ucose. r1':1Ctu.a~1one 
·rot- each patt$nt_was known -~nd ~ach pat~ent cou1ct.aep 
as h!.s own. -eontrol, but attention had to be pa:Ld to 
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!HE ROLE OF NICOTINAMIDE IN CARBOHYDRATE METABOLISM. 
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Nicotinic acid or nicotinamide occurs in all 
living ·Cells, mainly as constituents of certain coenzymes 
(Warburg et al 1935 (a) and (b)J v. Euler et al 1955}, 
t:Qe liver containing more than any other organ. So tar 
ae is known, nicotinic acid has no metabolic function 
pther than that exerted throB8h th!_coenzymes of which it 
is part (Sebrell et al 1952) (Fig,I). 
rhe ooenzpe 4er1vati v~es ot uioot1Dam14e are 
dlphoepbopyridlne nucleotide (DPU, coa,maee, 
co4eh,-4rogenase I, coeneJm• I o.r Co. I) (J1g.II) and. 
tr1phcsphopyridtae nucleotide (!'PB, Warburg'e cotermeDtt 
eodehydrogqase II, Ocen~Z)'i!e II) (Warbt.trg et al 19'5 
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Pormuln. O·.f Dipho.sphopyridiae nucl~eot14e (DPN), 
a key eubota.nce .of biological oxtaatione. 
2..1 
The coenzymes together with an apoenzyme are · 
the components o:t an enzyme system which oata.ltse 
' Certain impo.rtan t metabolic reactions. !rhe apoen~jme 
' 
22. 
is a speciti.c protein., 11hich combines with and activates 
substrate and coenzyme. 
I 
Th~.nuoleotide acts ae e. hydrogen acceptor, i.e. 
it is reduced by the substrate and is then reoxidised 
indirectly by molecular oxygen. This cycle of oxidation 
9.lld .reduction oo9ure in the pyridine ring, i .• e. in the. 



















1 + H+ 
R 
REDUCED DPN 
<DPNH OR DPNH2> 
F1g.III. 
The nico'(:inamide portion ie thus the most.aotive 
part ot the enz1rne system, in so fa.r as it ia the nicotinamide 
portion which is involved in a. transfer 
In this discussion it will be shown that the 
reduced pyridine nucleotide formed by this transfer may 
be looked upon ae the fundamental fuel of biological 
,oxidationsw 
ltcotmut4e moDotulcleottae (m.cotttuuntte• 
fi1to•o-phottphate) oaa be .epthesiao4 bl' nli bloo4 .oells 
. tftcubtltefl •1 th atoottaamtde and sluoot~o (Leder et al 1951) • 
'IPD can •• .to~ea tttoloaloallf bJa reaotto• 
'between ct.octlDI.o amide~ s.oaonuo1eot1te ani A'lP • Ubt.·ob le 
the ppophoestkate ct edalLae taOl'lODlloleot14e. tbue l' 
lt.octlrllc amide mqooauo1.oot:J.4e + AU~· .DPR + ir.o~puto 
PJI'OphOe!p'Ute. 
·In eu be euerme.tlcall:v torme:a b7 phosphate 't»ueter to 
U:U fs-cm AlP t 
·· .DPI + Aft ~ IPIJ + UP (Bal4v4n 1951) • . . 
tbero Ia a · 4:1nct co.ft"'el·atlon htwe-fm the 'tleeue 
l.'liOotin:t.c eeld u4 'the J>PB ooatent of mueole anct ltver 
e.n4 tbe oicot1n1o aeld intake to tbe <!let (Anderson et &1 
1944). 
Arll.mala 91lth • de1'lcleect ot Dicctinlc aol4 etbow 
a 11utuu1 4ecreaee b the ooeDeJIIe ooJJteDt ct 'liYer &D4 
muacle (AXelrod •t al 1939) •. 
the DPlf level iD the ret oelle of !'ate 4eoreaee4 
with restriction ot nicotinamide and increased with 
nicotinamide addition to diet (Burch et al 1955). 
lhen rats are fed a non-protein, niootinaaide-
free ration, the addition ot increasing amounta of 
tryptophan or nicotinic acid to the ration, causes an 
increase in liver pyridine nucleotide concentration 
(Jeigelaon 1951). 
In man, too, the concentration of DPH and TPH can 
be inQreaaed by the ingestion of large amounts of nicotinic 
acid (Axelrod et al 1940, Kohn et al 1939, Handler et a1 1943). 
Aa the rate of a:ny enzyme catalJaed prootaa dependa, 
other things being equal, upon the concentrations of the 
enzyme and ita aubetrate (Baldwin 1957), it ia likely that 
nicotina.ide by increaaing the oonoentration of coenzyme 
will accelerate ita metabolic funotionea that ie, if 
nicotinamide deficiency ia the rate deteraining factor. 
lliCO!lliAiliDE, COEBZDES AND CARBOHYDRATE KETABOLI SJ4. 
Inaulin haa been ahown to facilitate the entry of 
glucose into the cella. However, once glucoae has entered 
the cell insulin ia believed to have little or no further 
action on its intracellular metabolism (Levine et al 1950J 
Parle et al 1955 (a)) and (b), 1956 (a) and (b) }, which is 
lao111tate4 or aot1Yate4 bJ ens,ae ayetema. 
!heae en11pe •J•t•m• facilitate the complex 
proeeaaea 1DY01Ye4 iD tbe OODYere1on Of llUCOae for 
atoraa• •• clJooaen, or 1 te oonyereicm to protein. o:r 
tat, or breakdown to proYide ener&r• 
2.5 
fbla dieouaaion will oonoern aome of the 
prooeaaea ot intracellular •etabol1 .. ot oarbob74rate 
4epe~t4eDt OD the ttmottonal 1Dte¢t7 ot thoae ea•111• 
•1•'-• of wbieh :nicotlrlaide ia aa •••eatial ooeponen t. 
It will beoo•• elear that ... oarboh7drat••• tat• and 
pJOte1na all contribute to a co.mon ••tabol1o pool, the 
tnte~e41&r7 aetabolt.a of all the•• eubatancea ta 
1uterrelate4. A 41eturb&Dce ot aetaboli .. affeottDs 
oae ot theae aroupa will atfeot the othera aleo. 
the n1oot1aaa14e-oontaiaina ooena,m•• are of 
1•portaaoe in the ener87-pro4uotns reaction• ot •etabolt ... 
IIOLOGIQAL lt!JRGY !lWfSJOWTIOI'S Ol !BB PJlUPJII 
WUCLEO'!IW§. 
All 11 nag cells requi:re a ern. fh1• aercr 
ia obtaiae4 fro• the 4esra4at1on of toodatutt•. It le la 
the tiaauea where the eDergr tranefo~at1ou proper take• 
pl•••· 
~ 
Kre~e (1'954) po.ints out that the striking feature 
ot the· picture of energy p~oduction in living matter is 
t:tle relatiVe simpiicity of the basic principl~s. 
. . ... ~· .... ' 
) ' ! • • ~-- I 
0 
: i 
'·, ' - - . . -. - , - - . . -- . ' ' ' , ... ·, :_ . J ~ I '_ :- -- - - . ' 
·'· e~ul-produote being:; apart·from carb•n dioxtde and water, .... · ) ···. . . . . . . ' .· . 
.... . :. one ot i;n:r:~e .tntb$t:ancesi, Acetic· acid (oH:3 ~coolt)' in the 
.. ~ f~m .of .aoettl coenzyme< A;:· :al.phs•ketog1utaric acid 
I. • ,'' • ' ' ' '' 
· (aooH.cH2 .aH2 .crG~OOOH) or .~xalo-aoet_ic, a(lt4 (ooo~~os2oo.oooH) •. 
¥. ~., ' 'I·: :-, ·:-· '· ! - , ·• ' r '~, ; ' r! . , . ' • , ' ; 
· The fir·st of ·these three contributes the greater amount: . 
I \" two-tP.ix-ds,.. Of; the carbon Of oarbohydirate·,··: till 'carbon atoms 
.. :'; •:_\•,. . ..... ,• 
·;·of, 1;he .. •o~on •. f~1itY~ ac:tctsi ·and ·a;pproxiiru:~teit· 'b.alf 'the carbon .... ·.:. ,· . 
~·, .. ,9f. .. amine) .. aei~s . yield acetyl· ·coenzyme· 1. · · Al'pha.,.K.~tbglutaric 
:jl ,,· \ I ' ' ' • ' • 
,,· 
· .. acid e.ris~s Gf;fom ·several amino acids ('e.g. ·glutari:d.~'· acid), 
'.·,,. .; , <I' ' ' ' ' ·' . ' ' • , ' 
oxaloacet:l .. e,. acid' f~om, aspartic ·• acid · (etc.):~. · 
... : ;, ,· ' . . 
·, , : 1 • ; , : ~ I 
· · These three products are metabolically closely 
. ~nterr.elatect. : T~ey take' part'·1n the tric&ziboxylic ·acid 
. cycle, • which represents th-e comm,on term:i.nai. patb.wax·.of 
oxidation ,of. all fOodstuffs ( se·e Fig. IV for Ci trio 
Acid Oy(eJ.e). 
'' 
... '· :rthe figure shows· that· oile of ·the results· of thts 
cycle :11 "the. supply of pai~$ : ot ·hydrogen. atoms frena the 
I •,' 
organic .moleeule.tf. · 
> . 
'' ' 
' I.· ·. 
!he hydrogen is transferred to molecular oxygen 
in a special way, the first step being the transfer of 
hydrogen to diphosphopyridine nucleotide (Seo Fig. IV 
for Citric Acid Cycle). 
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!he reduced PJ~idine nucleotide formed by this 
transfer may be lQoked upon as the fundamental ~el of 
biological oxidations. It is the further transfer of 
hydrogen atoms from this eubstaDce to molecular oxygen 
~hich causes a release of energy. therefore, tho main 
effect of the metabolic reactions of foodstuffs, as far as 
they serve to supply energy, is to reduce pyridine 
nucleotide. 
Green et al (1955) conclude from the evidence 
now availaple that the pyridine nucleotide coenzymes are 
indeed 'the work-horses of biological oxidations•. They 
list amongst some of the reactions mediated by one or other 
pyridine nucleotide' Four of the five oxidative steps in 
the tricarboxy'lic (or citric acid) cycle, the -two oxidative 
steps in glycolysis or fermentation, one of the two oxidative 
ctaps in fatty acid oxidation, a key oxidative reaction in 
tho pyrimidine synthesis (Lieberman et al 1953), all the 
2f, 
o~ydati ve steps in the gluco.se to tetrose sequence of 
reactions (Ra.cker 19$4)'. . 
-· 
By virtue of their function in the trtc_arboxylio 
t\e1d cycle, .it has b.een pointed out (Sing-er _et al 1954); 
that pyr14.ine-rnlcl.eotic:les participate .in the complete 
' . . ' 
oxida.t1on,- i!lterconvereion end b1oeynthes1s of .carbohydrates, 
(a.t$ and amino acids. the fact that all ~own major routes ·, 
,.of ta.oetyl Co A ~ormation ultimately :bl'volve pyridice-protein 
catalysis iea prime example of their importartce in 
· metabolism. 
'' 
Fig. IV. shows at which points in the energy. · . 
pxooduoiag reactions o£ metabolism the nicotinamide. · contairaing 
ooenzpes DPN and \Tl?N operate~: 
. Gj,YCOl.l'.fiO PATHWAYS AND IJ!HEIR RELA!l!ION TO THE. SYNfHESIS 
OF .lAITY A!ID AND CHOLES'.fEROLi 
The addi tiol'l of either DPN or TPN stin.ntlates the 
oxtda.t~on ot labeled glucose to oo2• 
· .It has been. shown that D:PN 1$ act1 vely invol vea 
irt .the Embd&l'l•Meyerhot pathways,, while TPN influences the 
. b.exo~emonophoephate shti.nt (S1perete1n 1958) .• 
' .. ~ \ .. 
' 0 
'fhe importance of tPN in fattzac1ds:vpthesist 
• ' ~ .• 1 ; !. / # '. 
!he Bf~P ahunt 1s the only, rout• .which can. ·Jiela 
'' •;) I ,i·,•, • \ •' • ' ; ' ; •; I ', •, • .' 
reduced. fPIH~: 
' . ' •' ... ' . ' '· .. r 
j; · " ,. ·The' ·!PN ~ :~r::en t:i1stem !.t:s k:nowti to ·be ~required 
. J 
:for f~s:tt7. acta l!iynthesia ·(Langdon 1955, 1957) ~ 
. ';',! ' . ,: ~· ; ' ' ; ~ ' ' . 
. . . , : 'the t~eding of excess glucose to. n~J'Ilal animal$ 
. . ' ·~ . . ' ' . '· ' . ' ' . . . 
'··' 
. 1E(k~o~ to produceta marked et·tmulatory effect on the . 
• ~ • • • :' • '.,· ' . • (1 
. -.ynth.esif~! of fatty acids (Chernick et al 1950; Weppermail 
et all957) • · OD · the · o·ther hand, 1 t is pointed out that 
' ae~rivat1on ot' glucose oxidatifl>lt as se~n . ilf diabete~'; or ·,; I 
'in th~ fasting state re$'ults'in a depre.saion.of fatty· 
· ·acid synthesis (Chernick et · al l950f , Maeoro ~t a.l 19.5()).:• 
~he impaired syzitheeis of fatty ac~d which .is 
' . 
· · .cl:laraoter,istic ot tiabete~ is .ascribe4 primarily to, ~~, .,, 
' ' r ' ' '' ' ' '• • • l'. ,. ' '·' • 
. <lt;'ficiency .·in this diseas~ of glycolysis via the DP 
· .. , .'~· . ; f , • : : I • , , , • • ·, • : 1 , ; .• • • , . . , - ' • 
· · shunt, leading to a lack of red~eed WPN normall1 
. '. 
• . • .• ~. ~ ; ~ ; . • i ~ .. • ' ' \ . . .. · .. ,' .. 
[ . 
: . . . ' ' ' .· •• .•. I . ;,, -I !,; · __ i 
· · Re•·establislunent: ot ··glucose b!"eak4o1ni U{ e1 ther 
. ' . 
th·e diabetic or ·the· tasted animal restores to normal the 
·. ' ~ ... 
abil1 tr to $yntheslse both. fatty ~o·i·cle·: (Uld e~oles.ter~;l 
)' ~ ' I • 
and ketosis is abolished (S:iperste~n 1958') ~· · : I:. '·. · 
' •,' •' 
lt l.tr assumed, from this and othei' eVtden~~·· •.. 
tn.at in these tileta~olie ~.tates' the ·aefocta in ·:tiptd 
,, '' ' ~ ; ~· l ' ( 
Acet,yl . c.o A ocoupies· e. cen~l\al position ·in the 
metabolism of.· ca:rbo-rdrat~ att4 . fat.; Dot only aer a common 
oxi.d~tion .intermecU.ate J:r!l.t aleo· as .au ;fntermed1ate in the 
eynth~s!s of, .;tatty .ao1·as trom carbohydrate (.Oc~oa· 195·4)-.• 
l 
fhe toll.owi.ng reaction also deserves special 
mentionc 
Alpha ketoglutarate+. NK~ + DPD *Hi+~· ) L .... glutamate+ J.)PNt~ 
~his !'eaction may be o:e great biolog1ca.1 
eigriificance since it pro-rides a l'iak in the s;Vnthcinu.s 
ot an· animQ•acid frOm. a substance which can be teriwd 
t~om oar\ohydrate or· ·eonversely, it demonstrates h~w 
energy may be derived from protein by converting the 




DIAGRAM SHOWING THE IMPORTANCE OF THE 
THE NICOTINAMIDE-CONTAINING COENZYMES: DPN AND TPN 
IN INTERMEDIARY METABOLISM. 
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·u DPN (TPN) 
GLUTAMIC ACID 
CITRATE + COENZYME A 
.~ ... · .. 
From the diagram (Jig.IV), it may appear that 
only the coenzymes DPN and !PN are operat1Ye at the 
various points indicated with the enzymes of which the7 
form the. enzyme system. 
fhe diagram doea not represent the complete 
picture but itaer.es to ahow the universality of action 
of the nicotinamide-containing coenzymes. 
Thus the reaction which may be ahown in ita 
simplest form as follows 1 
Pyruvic acid +H2o ~ .. Acetic Acid + co2 + 2H 
appears to be quite complex • ~he p7ruvate oxidation 
system involves not only the participation of at leaet 
two enzymee, Co-A and DPN, but also that of 
diphosphothiamine, mapeaium iona and alpha-lipoic 
acid (Ochoa 1954). 
Jurther amplification is requiredat another 
point in glycolysis as this may have an important 
bearing on the problem to be digoussed in this thesis. 
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It now .appears that the tr1osepbosphate 
dehJdrogenase S.tselt h$.s glutathione as a prosthetic 
gJtoup thl'ough the •SH group ot vhlch tt l;Uiltes wlth 
ita substrate .• 
H 
~· ENzn.S] ~· R .... 9 '.. S -t E;llzn:tE f 
OH··. 
a - ; • s -!I ENZM I .,. nt>N~B - c~ ---cl EliZYME l + nJ>NJia 
OH 
'!'he aldehrde group ot glyceralde~yde - a -
p)losphate tlrst condenses w.lth the sulphydryl group or 
the enzyme bound glutathione. 'l'he condensat.1on product 
ts then dehJdrOgenatecl to an acyl mercap~de or thioester 
type of compound, the pair of hydrogen atoms being . 
accepted by DPN. 
32 
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ZBE INAO!IVATION OF DPB AND ITS PREVENTION BY NICOTINAMIDE• 
'the ensymat1c inactivation of DPN has been known 
from the early stu.d.ies of von Euler et al (1937). 
It 1p'BI!t noted that nicotinamide prevented the 
1nact:t·vat1on of .DPN in brain preparations (Mann et al 
1941). 
Other workers also demonstrated in animal tissues 
a splitting of the DPN molecule at the nicotinamide ribose 
linkage and that this S];)litting was·~.inhibited by 
nicotinamide (Handler et al 1942). 
The ability of the diphosph.opyridine 
nucleotidinase (DPN ae.e) of beef spleen to catalyee 
an exchange reaction between the nicotinamide moiety 
of DPli and added nicotinamide has been reported (Zatman 
et al 1953) and it has been suggested that this 
phenomenon serves to explaill the well known inhi of:tory 
·effect of nicotinam.ide on animal DPB ases. 
It seems that nicotinamide can increase the . 
concentration of DP.N in the animal and also prevent 
inactivation. 
NICOfilfAMIDE IN ALLOXAN .INDUCED DIABETES·• 
·: ; · ·. ·. ·. 'Alloxan has been ·reported to. oompet.e with DPli 
ln a yeast ·apc:a~,mase enzyme ··sy,etem) (lensl.er et al l.942). 
Lazarow •t al ( 1950 );. decided to test the component's ot 
'. ' 
·nPN :tor their pl:'Otective effect against alloxan-induced 
j, 't t t \ • • '. • 
! 
~hus they foun.d that rats were protected 
' ' ' ' I " .. ' 
' ' 
against alloxan diabetes by ;erior inlection of 
; \':' . . ; . . ' . ; . : 
· nt·cotinamtde. Banerjee ('1947), reported that ntcottnamide 
:;- ' ) ·; 
had the same protective effect against alloxan diabete:e 
L . 
. in .rabbits~ 
McDaniel et al (:1955) reported that conversion 
. . . 
ot tr7ptopha.n to ttioot1tuunide appears to be disturbed 
,) '!·I • • ' 
' ' ... 
in elloxan diabetic rats, ·but alloxan treated animals 
• • • ' ' • ' > 0 ' ' 4: : I ' ' • • ' ' ' ' ' • < -~ '~' o 
which failed to become diabetic ·converted tryptophan 
'. . 
to nicotinic acid as did normals·. 
l,; 
.; ' . . , .. :i : 
. , .. 
' . 
tRYPTOPHAN AND NICOTINAMIDE. 
In man, nicotinamide can be formed from 
tryptophan. It is therefore important to consider 
the metabolism of tryptophan (Garfield Duncan 1959). 
Likely pathways are: 
Trntopba.n 
Quinolinic •cid ~ 
' 
~ 'B,;rdroxJ'&Dthrinilic acid·~ Kynurenine 
~~ 
Nicotinic acid xanthurenic acid KJDureDio aoicl 
In pyridoxine deficiency xanthurenic acid 
is formed ae an end product instead ot nicotenio acid. 
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ANti-JIEfA.iOLITES OF.:NICOTINAriliDE 
bPN ·col!aist.s of a combination of one u1cot11la.tn14e 
gxooup with one adenine., two pentQse .e.n4 two ph,ospllol!'ic .. · 
acid groupe (See Fig •. II))., .TPN contains ~-n adcU.tional 
phosphorio a.cd.d group (Warburl,l et a.l 1935). 
Substal'Ace.s similar in .structure ( bu.t not in .·. 
their. t>btsiological ettect) can replace n1oot1:ne.m1de ill 
the molecule .DP.N. 
' ' !hue :Lt .has be~n rep~~ted (Kapla.tl et-al 1954l. 
. tha~ .a.D:J.mai t1esue DPN ases ca,n ea:~alyse .an ex<?~~nge 
, .· reactiiota b~tween the »1cotbamidti .moiety ot DFlf and 
compounds related to nicotinamide according to the 
equation : 
('N. is r.iootinam:tde,· It :ita ribose, P ts phosphate,, A is 
adenine, X is pyridine compound related to ratcotinamide}.,. 
. . . ' 
!J!he pyridine compotmds that have been found to 
W:ldergo exchange :wJith J:&icotlnamide are .ison1cot1namide, ID1t. 
\ . 
:J~:ac~tyl Ptrid1ne (Woolley 1945).~ and ethyl nicotinate; · the 
reaultiil$ D~N analogues have ~ow all been isolated. 
fbe structural formulae of eome of the 
Dicottalc acid antagoaiata are hereomlpared •1th 
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: ~he niootuami~de portion of coenzymes. apart .· 
. txoom 1 te importtmce in ee,rbohydrate metabolism;· is ·. 
probably then the most vulnerable portiora of the coe1u:jme 
moiety - a disturbance at this point may ca.u.ee a 
Widespread disruption of cell\llar metabolism. 
Nicotinamide is the moet activo part ·Of the 
coen_zlltleS DPN and TPE. ilhesc co~n,z;vmes pla;w El.. vi t4]. 
.role in the intermediary metaboi1sm Of carbohydrate and 
fat. 
Anti--metabolites have been ·shown to replace 
· nicotinamide in ·the molecule of DFN.. !he nicotinamide . - ,· 
portio:n mar be the most vulnerable portion of the coenzyme 
\· 
moiety. 
J'icotiJJamid.e has b,een reported to pre?..ent 
alloxan ihdu.ced diabetes. 
!fhe next .section will deal with; 
fHE ACfiON OF NICO!I!IIAMIDE IN DIABETES. I - • •• ·- • 
THE EFFECT OF NICOTINAMIDE ADMINISTRATION IN DIABETES 
NICMIHAMIDE IN DIABE'l'ES MELLITUS 41 
MATERIALS AND METHODS 45 
The Cases Studied 43 
Methods ot Inveatlgatlon 43 
Sow fhls Study Developed 46 
The Safety of the Proceduree used ln thts Stud,- 48 
1U.cot1nam1de 48 
Glucose Tolerance Teate 4B 
~~s ~ 
ILLUSTRATIVE CASES 55 
DISCUSSION of the EFFECT of NICOTINAMIDE IN DIABErES 70 
DISCUSS! ON of ltEStll/rS 7'5 
REMISSIONS ln DIABE!ES 74. 
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/j./ 
NICOTIN4MIDE IN DIABETES MELLITUS 
Pharmacological agents like the sulphonylurees 
have revolutionised the treatment of diabetes; their 
impact on research and thinking in diabetes has yet to 
be completely assessed. 
Phyeiologioal agents however, may prove to be 
of even greater significance than the pharmacological 
agents in throwing light on the aetiology and pathogenesis 
of diabetes mellitus. 
As early ae 1914, Punk demonstrated that 
vi tamine in ;yeast exerted a favourable influence on the 
carbohydrate metabolism of p1Beone (Funk et al 1914). 
Collip (1923, 1925) and Gaebler and Ciszewski (1945) 
confirmed this action of yeast on other species. 
Beckert (1938) reported a favourable influence in diabetes 
in man in one third of the oases to whom yeast was given. 
Although it had not been determined which 
component of the vitamin B group was responsible for this 
effect on carbohydrate metabolism, nicotinamide appeared 
to be the most likely for the following reasons:-
Nicotinamide is an important constituent of 
the ooens~ee diphoephopyridine nucleotide and 
tripb.osphopJridine nucleotide (Warburg et al 1955), 
which are of vital importaqoe in carbohydrate 
metabolism (.ae was pointed. out in Section III). ID 
man the concentration of the latter ooenzJmeS can be 
increased by the ingestion of larse amounts of nicotinic 
acid or nicotinamide (Axelrod et al 1940; KohD et al 
19,9; Handler et al 194'S). Moreover, nicotiua.mide 
has been shown to prevent alloxan induced diabetes 
(Lasarow et al 1950; Baner3ee 1947). 
What is the influence of nicotinamide on 
human diabetes? 
!he results of investigations of the effect of 
nicotinamide in diabetes have been inconclusive and 
conflicting. Some investigators have reported 
improvement (G6bell 1940; Marche 1943J Neuwahl 194'; 
Uhger 1957) 1 but this improvement has not been confirmed 
by others (Banerjee 1949; Cumings 1947; Wade 1947J 
Haller 1957). These investigations were carried out 
over a short period onl7. 
I have therefore thought it im.portant to repeat 
these investigations for longer periods as it seemed 
useful information might be gained from a prolonged 
comprehensive studr of the effect of nicotinamide 
administration to diabetics. 
MA2ERIALS ABD METHODS z 
THE OASES STUDIEDt 
In this study the patients were limited to 
those under my PBRSOBAL SUPERVISIOn for some length of 
time at the Diabetic Clinic. They were selected after 
I had established that there was no precipitating cause 
for their diabetes, such as infection or injury. 
46 patients were given nicotinamide and 
investigated for a sufficiently long period to enable me 
to draw conclusions as to its effect. 
~HODS OF INVESTIGATION& 
lasting blood sugar estimations and glucose 
tolerance teste were the chief methods of investigation 
in the majority of oases. 
Prior to the administration of nicotinamide there 
' ; ' ' 
!he tast1ng })loo4 !Sugar e·stuatio~·s and 
.glueo.s• tole:ra:noe tes.ta, w~~lre repeat~d ,!~ing tiie 
Jlerlol,,p:t n3-.,.c<>t1ne.micie admin~st;ration· ·(usually 500 mg. 
d.aily·in divided·<losea;, i:n $Ome ·cases much larger 
.. ' ' . . . .· 
doses ~ere.· g1 veli, . e .~.g .•. · .. 1.000 mg. ~ally· ol:-ally. ·pius· 
· pax-enteral uicottnamiie as :well). 
!tu~se . ~·~te . ~ex-e centlnu.ed tft(f~ nicotinamide 
had been etopped ~ 
; \ <. '· ;· 
An ad:Cli tional :metho:a. of &Sees sing the value 
·Of treatment Was by estitnati:Og 24 hC"Clr quanti tat1 ve 
uri.ale aqa:r · excretion in · :theee patients befGre, 
. . . 
· during ud after n1cotina.mi4e. · 
11') pa~1ente 1~ ·"hom d1$tary reettt1ctiGli al(')J'lfi 
was considered to be the treatment of' choice, a 
I ' : ,' ........ 
. Groote Schaul!" Hospital ,Step 2 41et was prescribed 
us the stano.ard· commet1c1ag 4te.t at the cl:iabet:lc 
~.' -.. 
' ' ~ I 
clinic. .This is e. 1150 ·calorie d1et ·&ltd is 
calculated "to btr comp.osed t>f .carbohydrate 9? & •. , 
Protein 55 'G~ •. and Fat 61 ~~· · 
• ', ' 
0 0 
' , :1 I •, '- • , 
0 
' _ ' f ·-· ' · 
wtre placed on e. diet which had be~n 1ndiV1duali$$d· 
fer· the patient eoDc'ernea. ... · · <tep$n(11ng on · th~ 
se.,erf'ty of' tb.e' diabetes . anti' 'with :regard also to'' . 
the .. paticmt•·a .oalor:t.o· ·~equii"emeilts·~ 
': •• I' 
', ·' > 
Tb.ue to eliminate the · intlu.ence ·Of di•t · 
on carbohytl3:'a.te toltranee these patients were as· 
a rule .~llowed a taii-ly lib~ra.l cariu~hydrate ·&iet 
of moder:ate cel.orio ·value . (~ubchrirate 150 ·1.;, 
protein 75 fl-:·• MD. £$t 1q e~ • approx111atel~ 1600 
calories). 
The.prepara.ticm.for 'th~ gluooae tcle~ance 
t$ete and the ·~onditiOn$ observed atte described in the 
' 
1 
. · Thill. atu4y ota td.ootiruimide. 011mm~nced in · 
1947.• ~e in1 ttal period Cotlsi.sted $( U i·ntettaive 
.. study o.t pati~~ts by frequen~ glttocee to1eranee tests., 
,, 
.· tn those who. were mimi t·ted to boa pi tal., 24 hour uritle 
g:lucoee estima:tiona were. done ae well. ~he ,glucose 
· ·tolerance test~ ·and '·24 hou.r urine .gluct:Hse · e~t.tmation~ · 
·· we)je carried out by ·me .in. the firat year of· ·thiis 
stU:n:v (1947). 
4fter the 1nttial perii,o4s the•e patie-nts. 
were again s$en b;y ·me at .. the diabetic elird.o. ot · 
·Groote ~lehuur Hosp~ ta.l where l wa$ abl·~ to <iont:t!l:u.e 
observe. tions .• 
tn the l)epartment of Chemical Ja:thology (Prof .• Q..Q.; 
Linder}. which enabled me to .he.ve a double check a.ncl 
mo~e ~r.equent tests on changes. in blood glucose 
levels ooourrtng at thia important ·stage in tb.e 
1nvestigat1·ons. 
these patients who we;oe placed on · 
nicot1aatn~4e c~natitute the nucleus of the iDvestigaticne 
in. this thcud.s. 
Thus the patients who were first eeen 
in 1947 were followed up for a variable period 
and some are etill being eeen at the time of 
writing in 1960 {e.g. D.R. oa.ae 127, G.s. case 
136). 
Subsequently more patients were included 
in this study (e.g. J ,.F. case 47l and these patients 
too, are still the subjects of study. 
A further long term mtudz was embarked 
upon parti.cularly in those patients who ha.d shown 
an interesting response to nicotinamide. The object 
of this was twofold: 
1. To provide a further control period. 
2. !ro assess the subsequent response to 
hypoglyoaemic agents in relation to the 
response to nicotinamide. 
!fhe effect ot prior administTat:Jton of 
nicotinamide on cortisone enhancement of the glucose 
tolerance test was also investigated in a few cases, 
and wil1 be discussed under the section on 
OOR!ISONE ENHABOEDRT, page 
!he Satetz ot the Procedures. uspd ip,this studra 
Nicotinamide was used 1~ this study 
because it does not produce the unpleasant 
side-effects of nicotinic acid. However, the 
physiolos1cal effect of both these su'bstBDces is 
identical and therefore in the discussion no 
distinction will be drawn between them. 
In spite of the unpleasan·t side-effects 
of larce doses of nicotinic acid there are now 
severalreports on the safety of its use in large 
doses. e.g. 3000 mg. (and more) over long periods 
in man (Altschul etaL 1958; Parsons et al 1956). 
These doses are much larger than those ~sed in 
this study. 
Can sluc,ose tolerance testg harm tbe diabetic 
patient? 
The administration of glucose in diabetess 
There is no evidence to show that Blucose administration 
as in the glucose tolerance test harms a patient with 
I 
matu~.ity•cn~Jet type of di.abeterh :ttl tact it 
. would 'be a.s .incorr~ct. as sa.Jing that oatme~~ narm.s 
the dia~e.ti-c p·atient, ~d yet th~ oatmeal ·-d~et was 
~. emit¥ent,lt .successful :f'ol"ltl of treatment of 
diabetes in the pre .... tnsulin days (·vou Noo:rdeR 190'). 
' •, 
te oatmeal atter its dlgeetion ti.r!d absorption. 
the aamii!istration ot gluco.ee tor glucose toiera.nce 
test$·: in ttita · type of dli.abettc ts probabl;y harmless. · 
l have :seen :no singl~ instane• ot ·hal~ tn a:ll · ·tae 
. ' ' ·, /. ' ' . ' . ' 
;caf:res in ·_who¥D ·glucose to.leriu1ce te.at$ were ·done • . 
. , ' 
I ' , ~ . '' i: 
. . ~}ii~ st~43:' however,1 ~as .el\. t~e fl1&tu.rit;y.;;. 
·. qn;e~ t;rp~ pt.: Uabetil.cs... . In . ~ne case where the 
·. patient was considel'ed tcf belong to the 3uvenile 
, , I 
type c'or t*<ntth..:.onset ty~ ot',diabeti$),: the: stUd,-
. •as' dtill'l'ilucte'd' l1114er observa1i1on , in hospi t'al: aa , a 
• I ' 
·.· : : · pre:o~ utttolu1rt, m;$asut'e ~· · · ·· · 
· .... ··· .. 
\ '. 
•; I . ' 
·The reaul ta tn tba Nicotinamide study 
C$!1 be o'lasaified 1nto·2 groups: 
20 pa.tien~.@ who ehowe4 improvement 
after treat.ment w:i. th niootine.mido ha~ 
·GRotTP 8: 2.8 ;ea~t.~ts who showed no im~:roveme-nt 
after comme:n.ct.ng treatment with 
td.cet~na.mide. (2 of these patients 
(J,.Ifi 74; w .. ;a.,.. 126.) are t1lso ineludeC:f · 
. in GROUP A· beeause ot their alfbeequent: 
marked . Ji'8$p0tl&$. With the addtti~:ll of : '·. 
1nsu1tn ·to l11cotiDami4e}., • 
Sl 
GROUP A. (Total go s G.! .lf. • s in l;:Z) 
( 
'~ I. 
the following cases showed improvement in blood 
glucose estimations after Nicotinamide had been 
commenced: 
Duration D.M. See 
Age yre. before control Graph 
Case. lame. let seen. period. G.T.!. Pages -
' J • A. 15 3/12 lio bl 2 M. A. 68 4/12 Yes IO'l 31 J. c. 65 11/12 Yes /12 
32 lV. c. 55 1/12 Yes /06 
41 T. B. '2 1 yra. uo 
47 J. r. 47 l yr. Yes /07,/0'$ 
80 M.La. 46 1 p. Yes flO 
82 m. L. 53 6/)2 Yes bS a, L. L. 58 l/12 Yes /03 
66 J. L. 6·7 2/12 Yes 
95 o • •• 51 18/12 Yes Ill 
112 S. B. 55 2 rs· Yes 127 D. R. 43 4 12 Yes 551 (tot), to2 
130 K. R. 67 ,/12 Yes 64-
136 G. s. 53 3/12 Yes 1041 IDS 
161 G. w .• 50 1/12 Yee b3, /Cf1, 20b 
5 J .Al. 50 1 P• IJo 
81 My.L. 48 3712 Yes It/ 
74 P. K. 37 2/12 Yes II 3 
126 w. a. 51 3/12 Yes "it-' 115, 20b 
!he type of response seen in 
GROUP A can be further classified as follows•-
(1) Improvement to a normal glucose to~erance 
test or practically normal glucose tolerance test: 
total 6. 
Comments 
Oaee Name · (Lowest fasting and 2 hr. 
figures of G.~.~·a) 
\7e1ght 
52. 
127 D.R. Normal G.T.T's after Gains 10 lbe. 
r;oaely abnormal G.T.~•s. 
87mg.a 2 hr. lllmg.) 
161 G.w. Normal G.t.T. Constant 
(F llOmg.; 2 hr. 107mg) 
83 L.L. (:r 12ems. a 2 hr. 142 mg. Loss 2-4 lbs. 
1t hr. l2lmg.) 
32 u.o. (P 124 mg.; 2 hr. 147ms.). Loss 3 lbs. 
2 M.A. Normal G.T.T. + Constant 
(F ll8mg.J 2 hr. l20mg.) """' 
82 M.L. (J ll9mg.; 2 hr. 142mg.l Loss 2 lbs. 
53,. 
·(ll) I•ovemc&t abovlq. •••., tova.Se ao••1 
glu.coae tolceMna• teat, t»u' &topp~ att~t et 
cqptet• nmbalon t 'iotal J• 
Ca.•• lfllttal.s 
'" •. ,. 
Ia:? ,,,~. 
eo LLa: .• · 
(lll) &~l P'aatlft8 blood ll••• lo'fela atte&¥ 
pe.l'f.ott of eataltlldhed a\laoJtiJI\1ltr:e 'total 6 .• 
Q.l,l::!- iHHWIW.S&all.if.i · nl!ii . 'l>i® £1,t.}ill8! .• -.;..r m11· ·.· f!t~~~~~ 
'1 I,Q. • laok to .,.:at f = tiONJal 
(Loll n~l*) 2 ~~· = Be•• d112l'U1· 
.. 112 s, ••• 
~ N~o ,. llS\\8 , .) 
l.L., 
(No S.tlu ·• ) 
P=-llntal 
2 u •. = abnortltll 
P= GOJ'mtil 
a '·br. ~ :a'OJloftf!(ll 
.P= a'*'..-:&. 
I u .• = t.baOJi>Ml . 
r = aormal (110 •s•) 
2 br. = atmormal · 
(195 mg .•. ) 
p·= a.ol'tS-1 
it tw.=-~1 
(tv) tlom&··. tXliP!'o1fel!fDat ,_actn~o\1 'titbit• 
"~et.wbg tt~lo;cttuml4ot 1..\,ot.l·J* 
J•Al, 
t.E. 
tuven,,1• tJJ& .. - · 4tabet,o. · 
8•4uotlcm: Ia 14 ~ urtae alucoee 
eacl'•tl.-n.; -tt<tuottu loa I.Dmult.n 
"'"u••»' • 
Reduotlon. ta lasuUA H4tllnm&nt .. 
.ltnpl'O'Vemtmt ltt :ib&ll11t1 cont.rol. 
(y) ftt*d t..,•••unt •• uo•t••m.ta + Uie•ll• •. 
' 
•• ,eaet.tett~-1 a:tlc-.tlau.ne~ «.tt' £•14m~ Ctb••• 
patiata thwott n• laltiltl ·••*»>n••. :to tllltott•.et•• 
~fllOM Ui.t •N thttl'etOl'O taeld'$4 l·n GROUP 8 e• ••ll ). 
?J•· 
126 
A "tll)&J> tl.t •'* Gab ' lbt• 
A tMtter t.f£'.:f:v Gala J4 1ba. 
i'~rtd.etaiae Of lAw taatlQ& 
tu•l•· . 
DIABETOGENIC AND ANTI-DIABETOGENIC SUBSTANCES. 
SUMMARY: 
This is a long term study o~ the influence 
of various substances, diabetogenic and anti-diabetogenic, 
on the glucose tolerance o~ diabetic patients. 
The effect of nicotinamide in diabetic 
patients is investigated. These patients were 
studied over a period o~ years and formed the nucleus 
of the patients who were further investigated with 
other agents, i.e. the pharmacological hypoglycaemic 
agents: the sulphonylureas and the biguanides. 
Carbohydrate tolerance was investigated in 
a :group of gouty patients. Gouty patients with 
a diabetic or abnormal glucose tolerance curve 
were followed up. 
Cortisone/glucose tolerance tests were 
per~ormed on patients from the various groups studied. 
In the discussion o~ the thesis as a whole, 
the interrelationship of the various aspects of 




























NICOTINAMIDE 500 MG. 
26-9-47- 7·11·47'· 'NIL 
100 
NIL 
ii iii . iv v vi 
D.R. CASEI27 
WEIGHT! 173 I 202 I LBS. 190 180 I 166 I I 162 174 I 
400' 






• •F' 300- •F 
25·6·53 p 
200----;/\_:-----r- 10·7·56 / """:0"- .,,., .......... --------------.---------------- -~-- -----.-- .. __ ,_:_- ... ----
100-- . F • 5·4·51 
13·12-51- 25-9·52 







Olwsoae tol•HDoe teat (wS.l) on 2o.6.so oould •tt.ll 
be coa:al4ei'M •S.tlli.D tbe MOst ot o.orul lA aplt• 
ot tM taott uaat her v•t.sbt aow wu 17J lba. 
A nlap•• to a ''*"''• ,,,. ot alu.oo•• 
toleraaoe OUJ'V. bU OOOtll"Nd Oft 1,.2.51 ('fllt.). At 
tbt.l t1• bUt ••llht •• 202 1bl• Dlabet•• la tranklr 
£11ftlt .. t lo Boveaber 1951 (&) wlth • relapa• to tb.• 
pn•t.oulf hlp t•••t.ns sluco•• 1•n1• •••n t.n (l). 
fhS.• la u• lnt1G•cecS bJ • ••ooad co••• ot deotl.uad.4e. 
J'lw .... patlcu ••" fOWld to ahott tbl• 
tJpt ot •••JlOIW•• ¥ta. t.L •• G,..w., I.e •• M.A., M.L • 
• --· toval'da a ....... allloo•• tol•raaoe 
our,w•t, but •toppt.na abOrt ot • ooeplete ••.S. aat.oa •• 
... n ill o.s., z.v. w M,&.a. 
'l'bla ••• ••aea.4 •• • •lpStlout Mapcmae • 
•• u lJip»o'fed our•• ••• •••a to pPeoete a ftOJI'.•l 
atuooa• tOlU'&Doe tJe•t J.a OROOf A (S.) • 
(iii ) POUP of ttw 6 o•••• cu. lov taetS.q blood 
glaoo•• 1•••1•• (••S• 90 118•) ••• :recorded •16bt 
ba'le ao• n•pOilae alld.lal' to tho•• ln (1) or 
(ll), ba4 auttloleat sluooae tol•..noe t•••• 
l»t•n avallable • 
.................................. 
POR !HS ILUJS.THA'l'lOIS OP !BE VOLLOWIIG PATimrl'S 1K 
OROtJl A, SEE PAGE UUJIBBRS XIDlOATED • TBESB PA'.rlBftS 
FORMED PART OJ' A LONG TERM SfUM' AID ARB liiOLUDEP XB 
SECTIOI V. (in some cases) 
•••• c ••• Pap 
t.t. a, 103 
o.w. 1,1 63, 197, 206 
B.c. 32 106 
M.At 2 109 
M.L. 82 65 
o.s. 1,6 104, 105 
J.P. 47 107, 108 
K.La. eo 110 
J).R •. (Cont. 1d) 127 55, (101), 102 
GROUP B. (Total 28 ! G.T.T.'s in 13). 
The follow1ng patients showed po 1mprovemenj; 1n blood 
glucose est1mat1ons after Nloot1nam1de had been aommencedz 
Dura tlon D .1-1. See 
Age yrs. betox-e control Graph 
Case. Name. 1st seen. period. G.T.T. Page {Fc.c:ir..~). 
4 s.A. 55 i yrs. No 
~a R.B. ~ yr•· No t.c. 1 '/'1:'· No 
29 E.o. 55 1 yr. Yes 11<!,12.0 ,o T.c. il 6 yrs. Yes '9 K.D. 18712 Yes b"a lg5 E.F. l~ urs. No 6b R.J. 12 Yes b~ A.J. ii ... Ho 7a I.K. 5 '1_1'8. No 
~9 D.L. 61 15712 Yes t4.t:L ~ - No 8; H.L. 2 Jrs. No 
102 p .r-t. l~ 1 J't'• 
l Yes E:to 
.94 S.M. VJt,. No 97 a.r-w. '5 Yes 131 101 F.r4.B. 
'g 
3/l2 No 
114 w.N. 1 yr. No 
·123 E.Pa. ~~ ·10 yrs. No 
.62.. 
119 E.P. a/12 Yes 
121 A.P. 57 .,rs. No 
1,51 H.R. 21 ~J~s. No 156 I.u. Yes /:LI 
158 c.v. 
Po 
1/12 Yes 5CJ,Ilb 
15~ s.v. i/12 Yes bl 1; a.s. 5 yra. No 
Ji P.K. 31 2712 Yes 113 w.R. 51 ;'/12 Yes 114-, 115) 2.0~ 
P.n:. (74> and M .n. (126) o.lco S.o.cluded in 
CROUP A. 
C.V. CASE 158 




~roo~ 0 ---~--- 0. -/).- ----~"-" __ :~7·6·56 •• ·-
o I 3·2 ·SS .\-:-:. 3·3·55 I 14•4.55 \ 26-1-56 
9 m . . ·" . . . ~ - I 
100 
sot-~~~---.--------~--------~~~~~----------------~ 
DIET I !'NICOTINAMIDE I I TREATIIIEN FROM 13+SS D I E T 600 MG. RIBOFLAVINE 4SMG. 
FROM 8-9·55 FROM 5·4·56 
ii iii iv v vi 
C.V. CASE IS 8 






VII VIII IX X XI XII XIII 
~------~--~------------------------------------------------~---
io thl.s 8ftllP theM __.. aattlcleat data 
a'fdlttile oa 28 dl.ahtto s-tleat& wtso baa neeS.vetJ,, 
.&.cotlo.ull4e •• eta•• "'•' ••• ·••• 'ftot beD•flt.ett. 
1ftlf;p tuJle was b.tP"U¥fimeat la IMUq 1ovelt thU 
ooda aot iM. *'tt-1lmt~ut to •t•o~~"••••· , ·~ 
oalibe~a qJMI SAI:tl.-ls of tb•e pe,tleita eo 11ated. 
~ost et ·-•e•o 'P&tlete ,.., •• , ae• 0'9tW 
~ .. ,, 
a period of .Je,uu. Jo 1J pat:lOllta .s1aoo&•· tolorenoe 
tet·te (.cme osw ae,eel) ••e ctca. · 
tutod of th.a ·setilaoti ot t•w•tLaa'tt.on 
eaf nspoae• lD tbie SM•P '-• o.:v • (Oa~t~ 15f.H • . , 













P.M. CASE 102 24 HOUR QUANTITATIVE URINE GLUCOSE ESTIMATIONS 
--
·~ 























P.M. CASE 102 
G.T.T."S: 30·4·47: CONTROL .. · 
17·5·47: NICOTINAMIDE IOOOMG. 
ORALLY+ 300MG PAR EN 
FROM _1·5·47. 
9·6·47: INSULIN 100 UNITS DAILY 
0 
4 HOURS AFTER 
SO G. GLUCOSE 
HOURS 
18·5·4 7 -7·6·47. . 







., --~~e ·ee.ae or .r.M. ( 1Q2J, a sever.e dlabet·~e.; 
1:$ al~o 'Of ~sp;oial in·tet*~t&t• This O_ololll"-ed iuQ 
a.g•c:l: .39 7~a~s wa$ .·n ~ass ()f. tgf.owth.~nset• trp~ 
·Oi'. t;it.a.b&tec and l'llustrat:ea ,co~plet$ 1aet ot 
re&pOta!Je·to ftl.cottl'iaUllae • 
. fh-. patt&nt ~tall~d to HPOVt back to th$ 
. . . . . . . . . 
I>iabet!c Olltllo at~er hts f.lrst ~~•:t.t and remained . 
for 4 montb.a ·on en ~contrwol1elt diet~ ·w~tb.out .~. 
·t:r~atmen.t. .An i.nveattgats.-.:q., ~tlett oborvatt6p. 
tn bospltai, ·prlor to. sta.t-~1n:s lt.Miu1in tu3ecn~tol)•• 
·Sh&t'~ed ~hAt .glueoae 'Qletrance. \fa$ not ln.tlu~oEuJ bf 
the athrd.n.lstrat,l.on o.t nlcotlruu.nlele; ft.O;t" lfQ·I the Sllloose 
tol"f!!t\\ne$ te&~ lntlu.ence-'· by t. ·¢cuz.ae of tru:uailn .•. · · 
24 b,QUJ? · :qt.taatltat11f1t: \U'~t1~ · gl~c<)ee ~s tttta.ttons 
SQ.o•~" no appeo1ab1e 4t.ttelience l~ the q~n;~it7l ot 
gltto9s• &xoretea. ~~!'ore o~ attit.Jii ·<a:ioot:;1aamide 
a4~~strat1on,. s.-.m11arlJ.•' wh~l<t f;Dl S.nauit.n~ nlootbl&.rniclht 
a4mlnJ,stl'atS.t>n Qrallg (ltJt pa;reu.te,.allJ mt.de •• ttppreolable 
• t, ' • ' I' '• '' 1 
. -~ . 
. ~·· 
• .• _'f' 
'0 
The patients described on pages 61 - 68 apply 
chiefly to SECTION IV and illustrate the 
different methods of investigation. 
Illustrations of long term cases are included 
in other Sections of the thesis. 

















J.A. Case 3, a Colpured boz aaed 15 zeara. 
Th1a was a case ot severe diabetes in a young 
boy • an acute onset w1~h Ketosis and blood 
glucose est1mat1ona otten over ZOO mg. He was 
a&nitted to b>.ap1tal tor control. 
With the diet and insulin dosage being kept 
61 
constant, there was a ~eduotion 1n the amount ot 
gluooso excreted dally 1n the urine - after commencing 
n1oot1nam1de orally and bJ intramuscular injection. 
His subsequent course continued to be tba t ot the 
growth•onset type • although his 1nsul1n requirement 
was lower. 
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, .B .• Pa. . , {Case d11;5l• 
!rbls patient was an. eltex-ly European wGman. 
No s1gn1f1ca.~t reduction is shown in 24 hout-
quantltattve glucose escl'etlon ln urine afte~ 
nicotinamide orall7 and })J 1nject1on. 
J ' 
b.2. 
G.W. CASE 161 
WEIGHT 















0 F• ...J ID 
100 
-_--_---~---.--------- --· ---- ;-- --- --_·----
. • 10·2·55 0. ~ 
. _/l7-3·
55 
"- ~ 21'4·55 '"'\ 
B-12-55-16·2·56 -P-_ _ __ _ 
15·3·56 
. , F• 
13·1·55 
- . • 
5o+---------r--------------.----N-I_C_O~T-I_N_A_M--ID~E-------------------,---=R~IBO~F~LA7~~1~N=E~3~0~M~G-.--, 
TREATMENT CONTROL DIET 900MG: 14-1-55 ~ 450 MG. 11·2-55-16·6·55 25·11·55-1·3·56 
ii iii 
.,_ 
























. .... , ... 
, .. 25·6-59-5·11·59 
/ 15-10·58 .. ____ ---- ------- --·--
J '-. F•.;F 
VI vii 
-~ ~ .. 
., 
o.w.. . Ca$$ ,1611 .. Eur!)pean man ased 50 rea:r~i· 
Tbia ~t ~~n•. -~l.eo .~d ~so~t. _ ·&ne_rslJ.fl&emlo _ 
. levels ·were estab11(!hed ove.r a 6 weeka' per.iocl • 
. A. Sl~~~ae.toie:ra~o~,t.,$~. ~tte~•belng tmdt!r: .. :::., · · 
abS$l*"'at1o1'l .tor e. months .waa al)nomal :C.11) •.. . .... . ' . . . ' . . ' 
Glucose' toleranoe. te .. sta. whtie :·on ntcotinam1d.e' .: 
. (i1l), ttv)· ~a· Cv1.beo~me.:e.o.l'fl;pletfilJ:rid~l' .• : ·· · 
. •. : • . . : ; . . i . • . ' .. ' i ~ ' . ' ' ~ . : ' '' . ' ' ' . ' . . _:r • ' ' • > ' .· _.-_,. . . .· . I '· • • ·• •. ' 
~l$ :ta~ing'l~ge :d()S"$ Of·r1b.otlay1ne til$·. '. 
-taat1l'lg glucose levels were elevatetl (vi). and 
63 
a· gluCQiile. t()l..erance .. te~t sh<>we~ susptc«ous1j· high . 
one b.otir (224· •a·J .~~d e hol:l.? (~56 :n!S.J, ·levels •. · .. · 
A cort1sone/gl~coE)~. toleran~e .. teat wh1le· on : · ' 
.·.;ttt~ofi~~n~ .· ~·~.:t~J. · ~powecl no .. f!isnlt~oant .·change: ·, .. 
from the gly.~ose. t~lera.nfJe .teat on 1&.3 .• 56 (v11}•;· . · 
· Glucose · ilolerance tests pe:rt·o~ed . subsequently ( t&) 
anct··:_'(.x) ahoW(td ·comp$rable t1gurei -although ~h9se 
or l& .• lo •. fSS, ('x) oould be 'ona14ered to be within · 
the diabetio ~auQi:t.·. A tollow up ln 1959 show~.4 . 
• t endeno7 towards a r.lse 1n te.sting glucose · 
levela •. 
..·.·. 
















ii iii iv 
.· .... : 
. l . 
,. 
' .. 
.. ,- . ; . 
. K·.K. . ( OQ.fle_ 1&0. )_ .. : ... 
. . ,..,....b -
.. . \ ,', ', •. : .: . p; . . .I' ' •. ~~ ... 
'fhilii, patient wal an eld.erly European woman. 
_·· '·,.<;\!,,;,·::·,, ··~-:; :.~-. ,;·,,_·~.;···~.-- ~~ . .l''''t•'. ·: , .•. •. 
so.me, r,~~-~~ol1 ~n .the e.bnormal_levels ·'of'~the stucose 
tolel'a.nc~ test l$'Shown. arter tb& pre:vlou.a . · 
tntr~ve~chtiS:. tn3•¢tlon: Of,·nicotli'ls.ml~e; ~.< il ~· ::.· · 
. ' '•' ' ' .': i . . • . f, •. ;, 
No turther Smpro1'ement ls· showr.:' in 'siucose tolerance 
tests (11) • (tv} • 



















TREATMEN~T1:~~N~I!C~O~T:IN~A~M~ID~E~~~~-,~~~~~~~~~~~~r-~~[JG~r.----r--------------.. FR~ 02~ SS 2MG. NIC~;~~ .IDE METHIONINE 6G. CORT./G.T.T. 5·2·55 TO 7.6.55 + CHOLINE FROM8·6-55 NIL TREATMENT NIL 
II v vi 
M ...... · . .. ~.~. 
'!'his p$.t1ent was tou.nct to have an hepatomogalJ 
·and glJCoaurta. There was a family b1story . .. ot 
d1abetea. .. 
While on n1cot1nam1de h1a glucose tolerance test 
evolved from abnoromal (1) to a practically normal 
slue. oae tolerance teat on 21•4 .65 ( 11) and '1.6 .56 
( 111). . ' 
On l1potrop1o agents the glucose tolerance teat 
again showed a det1n1tel7 abnormal 2 hour level.and 
a ooJ-t:lsone enhanced glucose tolerance test Ghowed 
considerable impairment ot tolerance. A glucose 


























a • .r. .. . .. lea .... !S'Ill 
. ' ' 
Th1s pa~t:ent .wa$ .aJ'l ~l.der)-7 ;European man~ 
0 • • ' ' ' ' • ' ' I : •' • • • • ; < i I ' I : ~ I 
Glucose' tol.eranc• teerta '{1}, (11), (1.11). ahow 
a te,nden~y .towar-4a remission but a. relapse. to 
hRerslycaemio :levels · t,·a ~.ho.wn. shortli afterwardS 
(:Y~• ::;;·', ' .. · ·.'.;:. ,: ..... , ···~ ·.· ~ :. ·: .::·· .. 
Fastlng levels· are ·no·t !l;ower·ed bJ nteotlb&rnide. 
' 
·' 
K.D. CASE 39 .. 
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TREATMENT CONTROL 400MG. i.M.i. 
DIET 
BEFORE G.T.T. ONLY 
[I Ill iv 
\ 
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f, 
' > ;. ( ~ I ' ' ' ' ' ' . 
! .. ::Y.· .·· ~ fC~'' .19Yl #, , , ':: 
T~tl': pa;t1e.11. vas A !lit4(11e•ageci ·.Oolouretl :woma~;.· 
' • • I • ~ ' l , \, , • ' . ; ' • ' ' ! ' 
~ez': gi~_cc>se.· t~ie~$.ncc :test$ r.Enoatlm4'comtlete1'~t' :;; abnormal. . ' ' ·, . ' .... ' ; . '.: ' ' ' ' .; : : i ' i . • . . ·. '• ' ,·' 
''I '·,· 
; ' '' l 
. . . · . :.' '.· !'.1 \ 1·, • • 
' 
' \ ' .~ ~ . : 
··. ,···.:· 
x.n.. tease .. 89 l t 
I 
fhts patient wae aa el.4ez-lJ Buropeaa woman 
wltb ,eetabl.1ehe4 d1abetea. 
A alight re4uct1on l.n the level·G ot the. aluoose 
toleraace ;toat ( 111.) ::was shoWn when a ai111gle 
tn.tramuacnd.ar 1n3eot1on of atcot1111Jli14e preee4o4. 
the al114'08e tolerance teet. ' 
the following 2 c•••• (w.a. 12,, ua 
P.K. '14) were 1nclude4 bOth ln GROUP A &D4 GROUP 8 1 
nlllaaf.oDa occ.srr•t after the .concurrent admf.Dlat:ratlon 
ot tnaul~ ~d nlcotlnaalde. 
MJ-•. V .. a., -.s•c1 51 r•u• • ahowed an ln1 tlal 
detettS.ontlon or sJ.ucoae · tolerano.- uat ulle on 
olcotlnud.4e. Inau111'1 ••• glve in addltlon to 
l'11cotlaua16• 1 u.4 a ••pld MduotS.oa tn lnaulln 
requtNMnt ooourre4. Inau.1ln coula b• 41aoontlnue4 
4 montha lat.r. Olu.ooa• tolereo• te•t• done at 
tb.S.a tl•• •hewed 1mpro•e•nt oft~ preYloua alllCoae 
tolerance tut. A saJ.o 1n wtp' ••• coupled wltb 
an lmp•o•••et ln gene:ral concSlt1on. 
After stopping nlootl.natalde, tbS.a pat1en.t 
behaved 11k• a ••tt.U'ltJ-ouet• tJpe or 4labetlo and 
later r•aponde4 well to tbe a~tftlatratlon ot the 
uw hJpoglJo•••to aaeta. (See pages 114, 115). 
P.lt. (Ca•·• 74), • Ml1 aged 37 , •• ,.., ta1ltt4 to 
.. apond to d1•t and nlcot1Da.td•• Inau11n vas stven 
tor oon.tro1 and vlth nlcotlualllde, a rap1d reduotlon 
·:f.n ltt.sulin was posslbl$., untll tt coald lif& oJd.ttea • 
. 0.1ucoae tol.e~ance after.. 1nsu:1tn had.boen atop,.a tor 
' weeks showctd cons14e!'able .laprovement. Ills 
aub~aequtrli; ·OOl.U'se was more .. $uggetu~-.ve ot the 
3uven11eiillitJp& ot ~iabttes and .l11St11tn was ~eqtd.r.eci 
· ag-.ln f·or control. (See page 113). 
1" 
·~be acti.on o~ nl<h,tl~mtde in ·t:U.abetes has been the 
subJect of _paf;lt tllvfts·t1gat1cns. 
Go*be11 (1940·) toi.Uid that· a1cotln$mide . 
~amtnlstrat1on eause<l a i"ewctton ln blood sugar ln. 18811 
of 20 • 4.5 .mg.-. An lnjeot1on ·"f n1($otlnamlde p~oduoed 
a. &l.licose tolerance t~st ~1tb. lowe~ 'bi.ooa g1uose leve1a. 
Ma~che .et al. (.l.94J) •nd ,fowneM·•D~).lll.e et .al (194J> . . - . . 
eont1Pmed ~ht.e hgpog1ycaemt.c actto11 ~· nottmsl buman 
f.du.l~s. ••"wahl .(194-J) ale~ ttecos-4ed ·a. tall in blood 
glu.eo.se a.ttf)~ act~1rd:.stta.t.1o:n ot nl'cctlnlc a,t~ .to 
1,,. 
••••Sl.abetlo llub3~cta and· an lllfH9eat;tAU l,t.: cor.JJObJ4Patt 
.d;,_., ,,..... . . 
tiole•ano$ S.n d.la~•tlcth · Ua1er (itS·?) note'd a 
OO:ti$ldet-!tl>l• t$11 111 ·title.· ttl* gl:t~ooee of cllabet:loc t:a 
a 4 hou J$l'l0ti a.f~~ a•ml.nlt!Jtpatlo¥' of eo41'*lb IU.ootina~eJ 
' ' 
but no etf·•ct ttta.e· .aemons-.ateil 1ft. ·••••1 h•~Mm atu.J.ts .• · 
'thtu blooct· gl."ceae,,·.lova~:~N :·&tt•et, bow ever • 
watt not ooll.fumea bJ ·Othe:r- ·wop·Jt•~ '(;.BanerJee at al . ' ' 
hM.f' J$e tJt al ( 1949) ~~l1tl that tb.e bloOd 
stucoae of dlabetSc .&M. noN!Jll.su:bjocts •s ,pttaotl()allf 
·W'lti:ttect;et 'bJ the '··•. !nJ&~ctlcn of ;oo m&• atc.otlrulmt<Je. 
c.b.Jiataga (191t7l .shoved that nS.ootb.amtae 1e withota' 
ett•ot ou 'b19o4 eupr 113 no~1 su'bJeota. :Wa_,t (1947) 
tou.~ no ~'"t<Seac• · that 6oo mg.. ateottttel4e t .~e ·•·• f()l' 
Jh. 'oars lot1uenoet th• r;lt.looee tol,e.ttanoe teats · tn 6 .. 
41$'betlos. Hore reo&JltlJ.t Hall•• et al (195?) ola1me4 
that tb.e fall la b1oo4 sl·~c-oae- nota<! l>J Vrtptt could be 
:t"Gpl'Qd"oed to 1\la eofttfOl ee..ts# 'W.beD . nleotlaet8lde wa:tJ 
emttte4. · 
~be l"t&Glts of these t.hv~ust.t.aatl•hl have _.. 
laeoncili&S.ve and o•i\tt•luU .. otoP.I• 
?/ 
It I.e to bt not(ut tba' •i.moat al'l these 
obae••••l• were made "-· :ahoJ-t•t••• atu.dS.ea of 
tile aott.oa ot at.oot'J.Damlde. 
llcotlmlldCJe I.e a pht,tolast.oal qe~t of 
p.-tme Importance 11"4 tho nol'-.1 pl:ijrtd.·o10·Sf of 
(U1~0hJdt'att •tallcllem (.s.e SOO~~IOB 111).. lt l.t 
1\ae· u aoi;f;ca on ._ c&rt>ohyira-. ,.,.tt.bOllem, 
'h• btt:netlt pNfll\ti~d ur be·eapeote4 to b• a lODSJ 
1ai!tl.ng one. ShoP' tie.rtfl atutllae wotdA not 4emonttta~ate 
oz.· slve ltdot~t1on on tbta pol.nt. . A lcm.s term etll4J 
1s also mo_.e lll«tl' ·to 111atdn• the t'ol• of nlcotlnemlte 
ln 41abe;t•.$ by glvt.n& .tnt·o..-t$.olt •bot.t' the ltQbGequ;&At 
proar••• of dl.abeu~. 
As the etu4J •~lvea t.t we.s •eall.$64 tb.at the 
81 b!UJ.(lUGtlt Pl'Ogreas maJ be ·Of ane.' atp~.n.oace .•. 
ll1~eontiJlu.eacc. Of ,Qf.eOtl.,t\~14& 4S.4 aoi; 1~1J 
tha\ ·tbt. 'benertt wht.• 1t .S.Sb' b.~v• ln~os6 wo"'1a 
not pel'si'lt• rn.cotJ.namldo MJ bi;lv& •or"&te4 sorae 
:tGtlaruential eno• of ataboll.sm. 
~ -, . ' . . 
72.. 
[', ··-· ........ 
Ot)ti14 we expoo.t to •• a e:oDecticm •t ·the 
meet tUJ1dam.n,al.·4letsa-baa® ~r 4trb6'bf<l'rau 
metabcl·lsm vlss. ttw st.uoou, toleraace tea' reve•'ltC . 
to no~l ·t 
·tne ·ftr.et ~ mQtJt dra.mi,J.c resptuuM• seen ta 
tb£& fJtu.«s Ca. oleottn~mlda ~an that ·ot the. ~•mlaat.on :s.n 
4lGbe·tes to a llO.l'tiltil aluo~• . t»l&l'attee te$t ln. Mr& •. D. I. 
(Oaae 127)• 
. ·till.! oaett1 n.n.,. wa$ ot .~eat .lo.t&~ee1l * en 
· es~ablS.abe4 ·case of llDdtu.'tatc 1J a.e\i't·H . alabetes lfip1'ovod 
/3 
to tn.u)b tm $~tent· o,tt~~ stat!'tlng ·nt.eo,S.ca~$.4~ admt.nistWtttem.: 
th&t cOl"' moet •fleturt tt. •• te;at: to~ 1!l$bettu;, :~ 1i'i~ • .slueoao 
·to1e-~anoe t~t, t;s.i'let to "1\<m tn• .pi"~C't.m.:o& ct d1·$b.-tea. 
'.t'b,tte: the" was an a;ppBtt~nt c~Jt• O't • est$b1l;sltea ca.•• 
tib.ere wee an aocompan,tne ~~~revemt>nt l.n wsllbellla ana e. 
gaift ta we·lght. 
,. ,.,.,. later whtQ el\t bad eaee4td ber 
pn•dlantlo heaviest vel&b' t~re wae a No\lfteneo 
of •rmPto• of aS.abetee. !he t\U~a)etea aow waa qot 
tatl.ueo.ed bJ tb.e edmiftlstrattt.on •t rd.ootlnemt.a•• 
tsletatr •efJtrlo,loa •• ••lt§bt lot.•• 
Tblm treft4 towa~ds lr~Pf09emant followed 'bJ 
relapse woe aeen ttt p'a~tloa&lr ai~ the caaea who bt:4 
·lnl.tlallf t'~ttdt.t.e4 tmd who were to11o•-t u:p over a 
'Per.loct ot rea••· n.a. (121)• r,,r,, (8J); x.c. (,a}, 
M.A. (.2) 1 M.t. (82), t.s. (l") Jl,.f. (lJ.?)• 
The lllOGt lt~J¥ottt.ut outo;oiue of tble at\147 was 
\he oocoronoe ot Jteud.,Gilons M t1 .-:mal glucca• 
toleJI'anee teat 1n 6 of the ;cases ~Jttldlea w1th 
ateotlumlde .• 
It became 1liPOrtant to peeea the PfU't plaJed 
b$ at.eott.namlde in pl'04~&otfl& tb.e pemlS$ tou •••• ·fb.e 
.PNb1em was a.pproacbeG tn te W&JI; 
1,. . aemualc:mit ot d~a'betes lD the wo:r14 
1l:ctratu,• were revi.•wod. 
:a, An attempt ·wu ma4e to tlnd ot.be.r oaeea ot 
relf4;ea1ou in Ot&t- laqe 4lAb$tlo oit.nle (elld.las- to 
thono tfl1Q weat S.~tt:o r.-~mteslon ® nt.oott.namlde). 
1. Ia t'he 11teratU.e t a-. to Oti l"emJ.selona Wfii'G 
found to 'bl lftadeq,u.ate. tor tb.e .tellovtag rreasons.t 
(a) 
af.itbora eons.l4e.r•d .,a welimattked ,t.mprtntmn•at ll\ the 
41abetea a• a l'emlatd.on, 
(bJ !ot?Jtt t'eporta of :t.'emte•or.w ••• 'baeed on the 
pt-e"ioua .tlod~n.s ot s1Joos~Utia lttee .J • oa• abnoPma1 
b1ooa glu.cose test o.nll• 
(c) 'l'hc. pel'loci of establlell&4 dlabetea waa otte11 
ebol't, e.g. oxae week ~~. 
(e) Gluoc.se tole.-oe tests were aot done to 
d&mtn8tJ-at• tho oomp1eteneae ~ot the J'ellls sltWh 
(t,) Wh&Jte glucose tolehltoe teate we" acme tb••• 
w&J'e often tt:l'l1 poaa1J abnormal (f}laglor 1960), 
75 
. ~. " .,. ,.... . 
RemlteJ.ono b my stlldi •e meant to lmpJ:r 
an lm,prcnYemMt't. aot o•tr .to a u~al taattJls. blood 
· 11ucose level, but elao 1G tba g1ttootu• tol&J!'anct te~Jt 
to .a #O'l'tual ton fl& OefU!i noz.,mll to&-m att&r a pe!'iod of · 
eetablllbed almoXtmalltJ. Tb:e~Je -.ere, the c&tttel'la · 
apl)11ecl to th• 6 oaf)ee ln OROUP A of the 11l,eotllUU2lde. 
:atua,. 
. . 
. 1ft a 4actton tn the Heatoa1 Annaal 1959,· 
remleat.or.t$ ot ·dlabete.a 81'8 stated to b• t'&l'J l*'Are • 
nthere are l•se th&a 20 caeec ·tm. fi\OOI'dll (!b.e Meelloal 
AtlD.Ull1 1959) • 
ln .a a.-ev.s.ow ot thf) ll 'el'Atu.l'e ot t*eported 
r•ls~lonc or atebe,ee the:re -~ ·taome remarka'b1e 
iaaee (Huwooct 195? ;f. Peete et al 19'8• Cbeq e' al 
19f,, del Greoo et al 19SJ, JOlmaoh 195EH. th7We•er. 
·s.n noae ot theae oaaet was the period of eatab1lt:Jb.ed 
" ' 
dl.ebet·ta .« 2-eaatb.J one (loell.• (l952) atlplllatee 
eettlb1lsbf.l4 tS.abo•a of at- 1eatt · ~ae month's dU~"atlon) • 
The to110W•QP wea ·Usua2.1J ••' lOftS en&Q&b.• Harwooa•e 
oaee petbape 'b&et t'ult11s tn.e ottlte'l'la delDahtlec,t bf 
3oa'l1rh ·rbe .PGrS.o4 of ·•stabllsbed ata:betea 1tas brlot 
76 
T.h~ .onse ot D.a. "WQUd th .. ,- almo~t~-wd<tue• 
T:he•e S.a -. e.d(llquat• c-;cntrol petlo4 ot on Ul'U'et~l,tms 
eatablt.~a d'labet&a to.llowed bJ n p:roven ·re$1s11on 
cottflrmed aot 4tllJ bg Q.Ot-lUl ta·sttq blood gl~&coae 
tet~te., b\tt tiOl"Ul Sltlooao tOl$t'arlOtt teote as •ell ln e 
patlent. WhO yp,. Sf!Drti ... !JlSb.\·• 
&tUAs&&!Tlt! .,,.9l}OJAI\J..,}19&sb!;. lotJs .u-e .knt>,urn 
to occ... lewbnrp and Conn (1959) t"epottttl~ that thie 
oecu~t~ed Nb&n the patt.ente bai lost a tonsl4erabl& 
propo .. ttoa of the eaeeG wtU•Sil~:• 
fhtlS .2 ot the pe,tl<m'a l:n ~b.el.- eer1&e who 
Sb0wt4 •u ~:Lto•t retu,n ot • aoru1 ••a~nse bad 
lost JS lb:a,. Gad 3$ lbe. l"'«UJpe.otl-..lr• some G.t theee 
patl$llt& 1ate» alla.lldonea the ·dl&t. •4 asaln beclUQIJ 
obese; 'lt ·was llOtiotd tbat tbt;l,.. ,ea,bO-.Jdrate to.l-.oe 
· •u event\\QU, 1o&t a~4 that tb(]t tllabeti.·e apptoma 
JtrlltCt.Uti'a4,. 
" 
Xu a atibs•tuont pape..,, Bewb•ab. (1,4;2) ttepol'ted 







C. G. CASE 51 
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who ~o-o~rate4 t~llJ and •uoceeded .tft redaoloa 
thet.,. .. tght to normal. tfJ.1a4 to achteve normal 
glu.ooae tole.ranc• ot.WVea ... • fladlq that oaat ao•• 
doubt on bl• tMOrJ tb.a\ tbAt 4J.ab•t·•• ot Qbea1t7 
wu • dltterent cJt••••• troll oxrdln&PJ t!1abete•, 
2. Would • ••arch at • laPs• dlabetlo cltaic 
reveal •••1aa1ona al•llar to tbo•• •••a la ~·•• 
patlenta vblle em aloot laallllde t 
(1} C•••• vbo ahcMad a sood -hJposlrcaelllo Hapou• 
judglq t.oa tu tlna glt.too•• t••ta ad tNated bJ diet 
alone vere ••l•ct.4 tPODI 'the 4lab•tlc cllt.tto. flh•-
ob~eot vaa to ••• ~~•r l could ftnd •eaponaea to 
matoh tho•• •••n 1n th• oaaea WbO had ahown • rea1aa1oa 
•ltb n1oottnamldt. 
Ia ou ataoh oaae whlob ••••d to tult11 the1e 
orltv1a beat (C .a. Oa•• 51)~ a s1~oo•• tolAt~tano• wat 
atll1 ab.owed a tJpical dlahtlo cur••• (S" taol.fts page) .. 
( 11) ~ba onlf 'Jtealaalon • recordet! 1n 210 patlant• 
••l•ct•d at I'Ail40JI hell th• 4lab•tto oll.nlo tor a a~olal 
E.S. CASE 135 
























FOR 3 MONTHS : 
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RIBOFLAVINE 30 MG. 
23·12·55-309·56 
:G.T. T. & CORT./G. T. T. 
v VI 
ol.m~oal i .. ,, (Marltl'lln. et a'1. l959}, was .a· Pitt~ 
I ~ ' ' 0 / : 
of d.· (;c.!t, .¢aee .14,) •· 
( t.S:.t ,) Remt.·a~lotM~ acoo~~1•4 'bf veleb;\ lo•• f . lA 
' ' f ' 
. 1 ,. ' ' 
. ·•1 $~1'"1e.s fit~ o•:oe• (t~~.t~. tretlt~ ~t.th .Aleoti~amf.ae.), 
tb.e ,to11o'lt1ng ••• tl'W best. eMtUt>» l. coul.a flti41t 
• ' c ·, • ' • • • • : 
,8ft' ··ohese.•man. cs.s,.·ceee IJSl wb,o. had t.eea •• 1oau1ln 
=; . . ' .. - /. 
eh~ed a •emltls£ou :ltl .(Jtabo~ea· tittett S.su1b w•• CJtoppea. 
' • ' - - 0 ~ ; I , - - - ' • • • , 0 , • , , • • t' • ~ 0 I - , - ; 
f~s waa aca~~·tt bJ ll.&*~.~all!i.•&al• Bowtver. tho 
ortgtnal S].u.coae •~leraaoe tttt · •a• not eOilvi•otoglJ 
·.· abfto,_l aacS 1B moatha 1~t•• ·~~~~.· aeamed ·to.be a 
- . . . '. ~ - '~ . ' : . . .. ' ' .. . ' 
HYtralon to an llft~ftlal 2 ho~ tlgutt&, ltt .spit. ·Ot the 
.ta•t.. tba' tht .. P4~Lent. had. al.fttalaed ·~e~ ve·lpt lo·ea.· 
' • ,' • • ' ' • ...~ ~- -~ i" ~ ; ' • 
Acute . ditib&tu a.t.el·Dt trom ouabie oauae.at 
·. . ,. ' . .. : 
1-.e t•llovi111J eaa, wht• wa,a PJl&C:1pttate4 bt. t•auma 
. ' . .·;' . ·.,·' ... ' . 
. · eta.o:W.a • reialeslol\ 1n tU.ab•t••·~· 
·,' ' 
MtD~ (Case ~)~ a ·b.ael.thJ loatng m$n aged 
.4$ .rea.ra, ws.s. •eon b1 me •t the tttabe·tt" ~li.atc When :be 
was· tald.tag ~0 ttolts · ot Le~te laflulb. nla.betef:~ bad tl»'st 
manlt$iit•«~ tteeu etcet-. an Qcot~eutal NpQiro ~t the 
tonao AC'b111ea~ t.t tte.o poeea:ttle. ·to nctuce 1:nel11'ln. ua . . . . ~ ' 
to omtt t.t alto.aetmtlr' 2 JJXmtbS lat·e•• Pot- 12 moo~ 
·.' . . ' ' . . . 




-· _- ... ~./' 
1. 1flcotlaam14e wae fo-d to have ,a beD&t.leS.ai 
e1'feot; Oft tb.e carbcbJ4ttate tol&rcmoe ln 18 patlente 
of the ;•*•1\J onaet trpe ot dla'Hte& ot recent 
2. !be l~npttO-verent could •' be aloi'S.beei to ·wei.Pt 
1osa vtd.,ch l.a .mang et tbeae oase& wae nes1lglb1e .• 
tala. tmpl'OVemtmt vas uauaUr moe t •nlttat ~h11e the 
patlet:J.t 11tU!J Jtegalntq tlelgh't .• 
J• WD•n tb.••• •• a re~ps~ ot tb.e b,gpe•alrcaemla 
~L• ta:L-le4 ·to .re.,poad to 4t•t .OJ! nleottna·ml4e •. 
lj ' 
4,. ln 2. po.tteats of tbe ''growth•oae·et•· trpe ot 
Cil.a:'betea c:;n·• 8hfted ,aomf) t.•mpM"ftme¥itJ the other eb.OtUU.i 
ao ft&ponee. 
S• ·:ro 2 ;pa•·tents ot • later·tae41a·te tJpe ot 
dta:bms, tb:ere waa a l'4P14 •e4ta:o.tlon. 1ft ·s.uulb 
requt.reaat when slvea c.umc:nu'Jl•ttr w.t. tb nlootl•emlde. 
·. x.• '.~1.1mm w .m.~·wumB. ,, •• -., t .~P. J @, • -· i 7. I .. I F . 
Wll.tle · the obeerva,lo-. on. the aott·on ot 
l'ilcotinam!ae in dlat;aetea wen belq made • other 
lu&.den,tal poS.ate beea•' evident• 
some ot the patlm&'ra wb.o b.aCS been taklna 
ntcaoti4ut4• top pJtoloft884 pej.S.otto 4ev~loped an easalar 
eto01atJ.tl.s. Ji. 'Wae tboqbt that tl\la phea(>IQ$'10D 
oo\114 be due te ~ trlta114n lda:taAc• pro4~ooa elth•r bJ 
the 1.\lcothlarialde .aamud.etl'littion Oll' elae oc•u.rrlng S.n 
\ 
Htbotlavl:ne' '111· ler,ge d.osea (e •E• 15. • 45 mg. 
dat.lJ) vas ppeecrS.'bed. ln the •e:nt1met !observ&,1ons 
on the JJlood s1llooae lev•l• la these patlmts were 
ettll b81q J"OOOi'ded .• 
. ' 
On examl.nlag .. eae 11eeult• rotJtoapeot1velr, 
/ 
1ft vas toaad tbat lo so~~e ca.••• the.-e bad taeea a Cb.aase 
b blood &lllOoae 1eve1e • usaal)f .a eteadr rlee • otter 
r1botlav.lne adml.Dlet•atton bad ·eommenoea. 
8/ 
'":· 
J·t· WGO· taoNI&J.'.e 4heltef to 1!'8001'4 
oba••vatlena made on ~~·· U1 't.J:1ood .. @).•o•~ .. 1ava1a 
- • • l . ' i ~ ; ~ ' . • ' • 
tollowt.ns J4bof1a'f1ae admlatak'a,..t.oa. 
. . ' ' . . ' 
. ' ,, .
~ . .'. 
. ... \,• same .• · .I .. . .ce-.ta 
162 , ••.• 
99 .o.s. 
126 -·. w.a. 
15!).. z.s. 
1'1 ·e.w· .• 
at .a.c •. 
51. J.C. 
l.JB a,a. 
~ : . 
s:&.e-.atloa lo !CGlbiaa ttlood ~vela ·af-tfll' 
a ·eo••• ol' r&:t;or&evl.ne• · · 
.Aaara'it:ati• ot· · stucoae tohl'm'loe teata. 
Eltl'fattoa ot tatttr;g blood $1llooa• levele, 
'·. ' . . . 
ao ot.m:Uloat ott.•a• 1ft .g1QOos\l tole•aao• 
teato. · · 
· &llab' ele·vatlon ln faetlng bloott .. alaoue 
. ~ l.evele. · · ' · · · ·. · · · . . 
. ,Al>J'J.OI'mll p.uoo•e tolenac• •••t developed. . · .. · 
.llevatlcn ot tutlaa blOOd. sluooae 1evo1e 
tU&tt 4evelOPJI*lt ot ebaoJM::'i&l .akooa& . · . 
tole.•mce •••• 
Glucose tole..-. teata ('ll Blevatln ot 
e1l 1•·••1•, CS') Sle'f'atltm· of lt ADd a tw. 
levela OUlJ• . · 
Ele.qt;S.oo to taet1.01 blood alaooa• lnela. 
Ol~ose toJ.e.:noe eeau -.cb.Gasef• 
·:t•onclu~lvt• 
~ftALt 'll potlate t elovatitn ot 'blood aoaer levele t 8. 
co ohftaS') ,,.., lBeoaeluelve c .3• 
t 
.--lntlo• ot tbo Nt»lta, Gllo\fet ~tut. 
to11~ftl •~etret!en •t f'i.l'Jtfl•v,l• ·M• · 
eleW~tlcm ttae suwJ> ·f.n. tuttos '''~ ·glucoee leeols . 
or f;1UOSO t01Daee tu,t/111 ~· •tb lla: 8 Of tbe 11 
pctleAtt. 
'.tbe n1u~lte or tbtt l-.veeclptt• eott:W 
e.asse•t ttu\t ~tlMI'led:o.e bat a d&•betoaat.o ·effect, 
lo ~ pati.ente •toit.ed• 'lMa la • pot.at ·Of great 
&At•Nat~ 
It •• beea aoue•·tet .a elM• ellosea 
3•• .,,.., '• a • aS..tbrl 4 • •tao • t (4 • 1 »lbltJlam&ao) 
• bettaeno to fofim t'J.botle·ri.M the· ClUoatton baa be&ll ztaued 
aa ·to cwfle\l'Mtt '"' ••"•••• rKO·tift .=f ooov .UJlde~t eenaL~a 
co~ltltmt (Da:nel'~•• •• ol l~'J• 
•e et~4le8 of ttien$C)tl e·b al (1959) u~ a1eo 
ot pu' l.atentt S.n tihla oo_.etl•-"l·• In enldl\1 ••41.ee 
tUJ ba•• ••~a~ated that a. ttleta" laok ot .t»atotheD.lo 
aol<J • pi'Otf»ift. o!' t'lllotlatfi.ftiJ (h!J,t; ao' tb.lcaao) leads 
to o 41.u4ala•d actt.•t.tr ot tl$po.ttc t.uulloa••• 
.;A . . . . ' '. , . , , , 
fb&e if:to:ar ·as,{Jb,e · :belp to oap'lftla a.· tirl411)8 ·o.t 
~ l•9.:1t .., b~ .• ~~· 4lft4 ~~& glp~f&ll 
., 
lu rtbOtlavioe' fette·teat ~imalo (l?orb:er et al 
19,..)~ 
Jo i.e poeet.blo tblt .r1iboftaviM in, •a•s 
•J b&vo tbe nverae ettett 1 
'late 'blAtt ·l)~ea a ~ubedt..,··,at~~a;r· an~ m&J 'be 
,a ~Giat Wblo~ llled~ b6 el~•14at_.d JJ:t •. tv:rttt,el' ••alee. 
~lle•• £a. nttltleat t\Vlfeno.e avallabl·o · 
f~'li ·tltGS'(It irf.~GB\tglitl- im·f!it.bOtlevtu .•• 81Nio't 
· appeal" tlttit l,lbo.tla•1ns Ia. bu.1'1se .tJoeeo: :rr&·i b~v• e ... 
dlt\betose.~e ettect.,, . ~tl'M'J~. t~Q"fotstlp~ton. mt~: · 
ttlh a.apeot t1 "l<lflhe<l~ , 
. . .. ' (. 
It ••• J."eport•4 t•t potu.ta -., ba'te a 
tlefteflelttl •ttoet ·Oft ca•bOb.Jd.,__, utabOll•m .sa atft'ol4 
·dl:atiet·•• (ltiueU ·et a1 195Jl*. Jt •• aeot.aea to hat 
tbe etteet ·Ot ;potatel·am onll.r tft.4oa·ta ot JOO. •• Bq., 
ts.liJ 0!1 the bloOd gluoote··a.a 4Salecea.- (Poteaalwa 
aoetaw 8lld eblorlde tosatherl ·. • pota••·&um aol4 PttoapU.te 
was aea.) .• 
s.o. ·c.oaae 19); a .• a. (oee.e l!HJ Oil• tcue SJ,); t..c.coaae IIJ; 
141?. c~ •••• lt.?»:t o.s. (oue· '") •• l.ae. (.caee 196), 
x~a. ' patlenta' ·-e -- ..... aot.t.oed ••• a 
t&&IM 1&8 tA blood sluoot• ot.O!' • abOJ'l ten ata4J, 
(Stt:e tlluatx.ttOD. past If o••• ·:Oaae ,S.).. the oatue 
Of l'88pcm8e ttae. bOt tat1ueace4 bf ebanglDg tO pb.oaphele 
t"m , ... acetate a.a4 Oblol"lde •. 
:zt •e••<~ •4tt••ttt.GJ)It to coa'lltlu. tu 
o4-'A&a·cratt01l ol pota1af.w1s. fb• .Jte~t.~lt·• D·tt ncordtsd ~•••• 
•• ttlte to. blood gluooae wa1 twlr attONlr •••aet.-atea • 
. . ;
(~t) J)'i':Att•tt•d 
[;I 1 •= n~Dr 111.& 
Tile oomtMement ot .,. , •• ,, m 191•? 
aatetatea ·the mt•oauotloa of ·tlle hDOsl:JOGea'to a;.ate 
l.ti o.apr•t •••·• 
Oae of \U.ae p.-•puatlons, Dl·abetoe'~• 
wb.loh wae •~e tll'llt to beoom• •vat,.leble waa tl''led t.a 
• t•• pe;tsee~a. 
5 ·• lfae>al • entba-lftlllc &ott 
Vltt1d.a H 
Vt'amiA 0 
'DL • Motbtoaioe 





Aa· tbe ftN.t 2 tr.pedleats ot tble. tablet 
an oloaelt related to tPJ~ metabo1le• (and 
fd.ootlumlilflt oaa b• 4el'lw4 I'Nm ·e.JPtophf.m) lt aeeraod 
t'ba't Ol!ei'V4tlOM OB tble Sf 'be Ot lft.tell81t f.A P81t\l1ft 
to a atuda of ld.oo\lmldfJe ta f~Abe,ee. 
tbel"e ·••• to· be eo .loaloa1 'baala t• t-.e 
laoluelo.D Of tu oMte~ J subataaee• l.a thh tablet aa 
'lba obaorvat1ous on tha ~Gulta of · 
adminietrat!on of thS.s tablet nro 1nelu.ded tn tb.la 
atudJ• 
Th.& results ln 4 patients at-e available* 
(1) M.A.. (Case 2) showed pr~eael ve improvement 
towards a normal glu.oo&e tolerance teat. 
(11) M.La. (Oase 80) showed improvement 1n tlrst 
glucose tolerance test 2 we&ks after commencement 
of DlabetOnJ but after a fllrtb.er 2 weeks the 
glucoee tolerauce test Ub.OW(u.1 oome rogresslon 
ago.tn and was abnormal in all rospeo ta • 
(111.) E.o. (Oaae 29) showed no improvement in tasting 
blood gl~coae levols (Note the iaaulln doaea had 
been 1n.oreaae4 .) • 
(iv) D.R. (Caae 127) shOwed a deterloration 111 glucose 
tolerance test. 
Dl8CU8!10n& 
Since one ot the components of Dlabeton•R, 
vlz.~ V1 tam1n B6 (pJl'1dox1ne ) la lnvolved ln the normal 
~7 
aaltlPmi1lo eo14 t.e .krlG'Iftl to ·.bft· a :ded vatt. te ot 
tfJPtopl'dA1 1• le 11k,e1J th&\ .t'h~ ~~~~ ot act1oa 
of Dt.abetoa-"1 ., be o1onelr ttohhd ~· ttt.at ot 
ftlCOti.Mai4o, 
:A,e abo\~' tate tlme tbo o~1 tqpoaloaeue 
as6At, ea•w•emt.de., beoane evallettl•• hooaae of 
St& ·UGtl14\tLo hJIMPI&~oaemlc ert.eo' tu.ttter observatlOIUl 
oa Dt..-eton ••e C.tlllcatet• 
. ·I v. 
THS ACTION OF tHE PIARMACOtOGtOA'L HnOGLYGAEMIO AGEN'T$., 
t#IA_t_,~-,·_'-~m···- -·-::'·-!._!!_: .. __ ; Lib/i -·~-~1u'l::·r -·r-;rn··-·-r .. _, -- ·· · .. 12 r - ·. --·---~- --("t 
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m: .AcTION •oF. m E!0Rf!APOLOOICAL H~~GL'f~Ef.i2 
. :~G-~ I I! Ql~BEJES,. 
, The ,·aea~¢h t()r ()rally effeotlve hypog1rcaem1o 
agents b.as ·pl'OCe$<3ed for mUJ J$&r.a. 
. ' ~ . ' . 
f~1or. to the ad\'ent of i.nsul1n 11 Watanabe (191~) 
demonstr.atea that gll811l<U.ne. l.~wE),.e4 b:locd glucose 
le"Vela •.. A suanld1ne 4er1vat1 ve » deoam&thJl&ne 
•.U.gu.anid1ne., was used tn the tr6atment of diabetes ·tn 
man: (Frank et al 1926), b11t. tell: ·mto .disuse becaaae 
' 
ot~ta toxtcltJ, ob.tetlr 1111er .aamase (Granatn lUl.d· 
.LI.nder 1928) • 
. Xn the ·meantllllt the .suooesaful use of ·lnsulin 
had. become flrmlr establS.shect~.· lt was natural that: thi.s 
great discovery by Banting and Best ln 1921 weald dlvert 
resea:reh in the t~est'lltent of diabetes towarcls the new 
tc0cal po1nt. tnsU:lln. 
It now seemed that thE! t1nal an·swer ·to dlabetlo 
tr~atment was at hand,, but ·e.s. ~lrne wtnt on lt became 
cl<tatt that lnsul~ was neces$ar~r onlJ 1n a pl'Oportlon 
ot. diabetics. . .In tho acute•on,et tU.ab19tes ot the 
·. juvenlle. tJ'pG;I ;Otten associated td.th. ketotd.!i, .. lnsulln 
would eorttect .. tb,e phgstolosl,c.e.J.; abnormal f. ty. 'rbe 
maturity •cnset t;vpe cf at.abetle. ·"' who had been sb.own 
to have available pltUJma•insultn (Bomstein ·an.d L-.vl'ence 
19.51 {a) and (b):·) • was ,not fundamenta11j ben~'t$.tGcJcj' 
·as tara ~• we' know • by. "exog•nou.s $.nsu1lth 
Att.empts to coi'~ect· th¢ h.yperglJc.em.ta· ·in·, 
cU.abet·es ·by· •ans · oth~l' :than, l.1tsu1~ ·pt'oved · unsu.ooesaful 
. ' .... 
. Tb.S.s .new era in the t~&atnu~nt of diabetes 
' . .· . .' . . . ~ . ·. . -. . '. ~. - ' ·, . . ; . '· . 
tollowtt4 ·Ol'i· tfu,.e lnctd~~tal ob$~fvatr1o~ bJ .Janboll at al 
u.942}. hlu,rlng '~n i~v-~ttge.~1o~· ·Qn . the ~etten ot drugs 
l >It • ' • 
ln typhoi~l' tha-t th.e -su1phonJ1urea I.P.~.th ha4 a . . 
hypog1Jeaem1o aetlo:n·. · toabat·s.eres · p~bt~laah·ed the 
re·sulte of his •xterud:ve ln'V&$tlgatt·ons en t:~P.T•J?'4. 
(1955l• · . 
. A group of' wo:vkere (Franke et a1 195;,. .Aeh&.lis 
et a·l 1955,· Bertram &t al '19S5) reported on the 
;Qllnioal u.e~ ·.or· anotb.e~ · &ulpl'lon;lurea• cattbu.t;amt.'d& • · ·· . ·. 
Carbutamide (8~.55>. ls ,now genera.11r be~levea 
to be . t9o toxle tor ttoutS.ne use. :W1 t}l the .~•placement 
r· 
. -·. -· -·~------------- ------.. 
THE SULPHONYLUREAS 
. . T-J-CH--<CH~ 
H~-C>-~NH-,N)J 
P-AMINOBENZENESULPHONAMIDOISOPROPVLlHIODIAZOLE 
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. . ~ ~ :' ' 
. ' 
. I 
ot iine ~ group b:r the OE:J tn ·tclbuta:GtcJe tb.e 
toxlc ef'feots we:fe . greatly cilmbd.ehod, bJ!t ... 
, I ' ' 
I ' ' , 
· · .::iomeriiha t deot.'eas ed • 
l 
: · , · · ·tn chlDvp~cpfim.lt1e 'tb¢ ~b1or'tn& riAdieal has 
replacea. the ' Jm ~ ,~ CB3' grollp~ .· ·• 
\ 
Anotho• hypoalrcaoli1tc .agent also 1neludl•d ln 
tliis s~gd:J is :tsobuzole wh.lch :ahows an l.nt·eres;t1ng 
re1at1onsb.i~ to the 'tlrsti. .a\i).ph~ntlurea ecmpouna 
· I .i-.t.t •D ~- ~· walcb. w:as · .sb.own to· 'b~: a powe~.ful: ·ntl)oglrcaemS.c 
. ,)·. I 
: .. _the, att1ph1on~f1q:reaff 1s · evideri.t,.,trom .the1f'· formulae. 
-' 
''I,' 
" . 'Xh~ dem~~et~a,tton of ~b.~ :eu.eq~:uulful \l&e of the 
suil;pnon,-lurea.s 11,'1. the . ttt,ea .. <tm•nt;, ()1" .. ~.la,•t•s <l~eated .a 
I • ' ; ' ' • ' . ' ' ~ • ' 
. .0 
resurgence ot interest S.n tb.ei .. <Staer compo~da whi.ch had . . ,.· : 
.· ··~·.·· ~· . ·· .. ,\~.~ ~~· .... ; .·.\ .. ·.;·; .. ,' : .. •'' 
b6en abandon•id ... the _gl;;UlD1.dlrut-Ater1vatlvea •· . · . 
~ ' I . I • 
. . . !.J!h~ 41guan1d~n~_s, :.e~·g.-. ''ntb.alln,. wer,e too 
toxic. tor uset 1n .the t:reatEnent 6t d iabet•& .• : . :fhe 
.. , ' ' . . . : . ' . ' ; ,' ' . ' ' . - ,- : ·' ~ : - •. ; • • . - ' . ~ . '. ' ! . : 
., . 
. diguan.ldes, )ihezte 2 s·~~~d~e .mo1ee~l.s_ ... l"e ~~J,).kea w1 th 
th~ eltminatton ot .filn 'NH group~_ sttll·. rete.tnea .the 
. '•' 
. :'; 
-- -· ---- -----.. 
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hfpoglJoaemic ettect of IJnthal1n (Slotta et al 
1929) 1 but the tox1c1tJ had been largely eliminated. 
A natural outcome ot thla latter 
obaervat1on was the re-appraisal or the action in 
man ot diguanlde derivatives, the precursors or 
which bad fallen into disrepute after the advent 
or S.naul1n. 
Phenethyl dlguanlde (DBI ) was ahown to be 
an effective hypoglJcaemlc agent (Ungar 1957) 6 and 
tree ot any aeriou.a toxlc etreota. The htgh· 
incidence of gaatro-lnteatinal alde erteota, however, 
hal precluded ita wldeapread uae ln diabetes. Becauae 
ot the aide ettecta ot DBI, another dlguanlde, 
dlmethyl-d1guan1de (LA 6023) has alao been lnveatlgated. 
(See facing page tor the Guanld1ne Derivat1vea). 
The mechanlam or action ot both these groupa 
ot druga remains obscure. Several auggeationa have 
been made aa to their mode of action (Loubatlerea 1946), 
Mlraky et al 1956), but none baa proved entirely 
aatlatactOrJ• Loubatlerea auggested that the 
hypoglJcae.S.c a.c tlon or the aulphonylureaa waa due to 
stlaulatlon ot the beta cella ot the pancreas to greater 
tnsultn produ.ct1on. Mirsky et al shoved that 
there vas lnhlbltton or insulin de8tructton b' 
the sulphonylureaa. Beringer et al (1956) 
demonstrated an increase of liver glJcogen content 
ln starving rabbits receiving carbutam1de. 
Recent work has anow.n that the suggested 
concepts on the mode ot action of the aulpbonylureas 
have to be re-evaluated (Weaver et al 1958). 
The aulphonylurea drugs and the blguanides 
may prove to be a stepping atone towards the search 
tor the bloohemloal lesion ln diabetes and its 
correction. The hypoglJoaemlc action ot these 4ruga 
ls undisputed but it ls problemat1ca1l whethttr the 
other biochemical abnormalities ot diabetes mellltt.ls 
are corrected by ~••• pharmacological agents. 
In this age ot great therapeutic advances we 
are w1tneaaing the apparent paradox ot pharmacological 
substances (e.g. the sulphonylurea drugs) being t.lse4 
tor the correction of a phJaiolog1cal aberration suCh 
as diabetes, on the one hand, and on the other hand ot 
a phJe1olog1cal agent, cortisone, be1ng uaed tor 
lta pharmacolog1cal action ln the treatment or •cure' 
ot a varletJ of 1nflameatOrJ and allergic conditions. 
There are man, puzcltng teaturea connected 
~1th the cl1n1oal applications of tneae drugs. It we 
conalder the maturitJ-onaet type of diabetea only -
why do son. patients in this aroup respond to the 
aulJbonJlureaa and others not t A proportion ot the 
diabetlca who respond aatlatactorllJ to tolbutamide 
tall to respond atter continued treatment. Wb7 should 
thla aecondary tallure occur f Wb.y may patlcta 
respond to chlorpropamide when tolbutamide has tailed 
e1tber inlt1ally or later t Ia there a difference 1n 
thelr action (or la the apparent difference merel7 one 
ot abaorptlon and blood lewel) t 
Why do patlenta respond to the dlguanidea 
when the7 have fa11ed to respond to all the 
qs 
sulphonJlureaa or, alternat1velJ respond to a 
aulphonrlurea drug and tall to reapond to the d1guan1dea t 
These phenomena tbat are atlll obscure and that 
are poorly understood were a1ngled out tor atUdJ. 
MATERIAlS AND METHODS a 
THE PATIENTS IN THIS STUDt were aa followa a 
1. Patients who were aeen 1n tbe lnltlal atudJ 
of the aotlon of n1cot1nam1de ln dlabetea and the 
associated atudlea. Spectal emphaata was placed 
on thls group tor the tollowlng reasonas 
(a) Theae pattenta bad been observed over a long 
period of time; the course of the diabetes 
waa alreadJ well known. 
(b) Tbe blood glucose eat1mat1ona and the 
glucose tolerance teats of prev1oua 
1n•eat1gat1ana were available. 
(o) The reaponae to hJpOglrcaealo agents could 
be compared w1th the prevlows reaponae to 
nlco t1namlde • 
2. Pat1enta of the maturity-onset tJpe 1n whom 
dlet alone tailed to control the glJcoaurla and 
hJpe t-glJoaem1a. 
,. Some patlenta on 1nsul1n who were probably of 
96 
maturitJ•onset tJpe, and eager to change to treatment 
wlth tablets. 
4.. A few patients of gl")wth-onset t7pe who were 
(a} either taking large doses o.r .1Mulln or (b) showing 
poox- control on insulln, were gt:ven additional 
adm1n1strat1on of th*' b.ypoglycaemlc agent to, evalWlte 
ito etrect. 
(1) Patients from prlor studies who tound their 
previous diet adequate were maf.ntained on 
that diet. 
(11) New patlents • or patlents who were already 
(111) 
on .lns\illn were allowed a tatrl:r liberal 
calorie diet (depending on the1r requ.tremen~s) 
e.g. 2000 calories or more (end conta1n1ng 
200 G. carbohJdrate or more). 
Once the patient was on a trial ot the 
h)'poglyoaemlo agents. no f'urther dietary 
adjustments were made. 
'l'HE .METHODS OF INVESTIGATXOlU 
. These remalrmcl the same as in the preced1n& 
study vi·a. Fastly blood slucoae estlmatioll!l and 
glucose tolerance tests under tbe conditions previously 
stated. A glucose tolerance test was alwars 
preceded bJ a generous 800 G;. carbohydrate intake tor 
one week before. 
The results ot these investigations 
are presented graphically in the following pages. 
The oonunenta on the illustrations in th1s 
section deal chiefly with the intluence ot the 
pbarmacolog1cal agents on the blood glucose levels. 
and glucose tolerance tests. 
Other features ot the investigation are 
also shown in the illustrations to give a better 
profile ot the course ot the case as a whole. 
Cortisone enhancement ot the glucose tolerance 
test 1s discussed in SECTION VII. 
qq ' 
PRESENTATION OF RESUDI'S; 
Po1nta to be noted perta1nlng to all parts 
ot the preaentat1ona 






Gluooae tolerance teata uaually show 
flgurea plotted at i hourlJ intervale. 
Where onlJ 3 po1nta are plotted, th•ae 
are Fasting 1 1 hour and 2 hour levela. 
Where a glucoae tolerance teat cont1nuea 
beyond 2 hour a, the 2 hO!!£ level; haa 
been grked bJ 1 b.eaYJ: do,t. 
The acale tor the gluooae tolerance teata 
reaalna conatant tnrou~out both tor t~ 
blood glucoae level and tor the period ot 
ts. .. over vhicn lt 1a performed. 
Cortlaane/Glucoae tolerance teata are 
4lat{ngulabed bJ broken ltnea. 
2) PASTIHG GLVCOSE LEV§LS (denoted bJ F), are given 
oonaeoutl'felJ, i.e. rn ohronologlcal order but the 
apan ot t1me between the plotted taatlng levela 1a 
not to scale. 
3} DOSAGE atated in 1lluatrat1ons retera to the 
daily-doae, e.g. 111cotlnaJJd.de 500 mg. ahould be 
read aa 'llicotinamlde 500 mg. dallz'• 
4) Each column 1n the graph S.a marked with a Roman 
nu.aePal. 
5) !he AGE atated rete.Pa to the age at date when the 

























21·8·47 - 21-9-47 
NICOTINAMIDE 500 MG. 
26-9-47 - 7·11·47 
ii iii 
NIL NIL 
iv v vi 
-;. 
CASEI27 WEIGHTIC::J~~~~~== 








Viii ix • X xiii 
. ' . 
The mat'ked hti>erg1y~aet~ie fasttng 1ov&1~J Qn.<J 
., ' ' 
. . ' . . . -
.abnormal glu~ose tole.ranctt. tests ar~ $een in (1 ),. 
• . 
. A reu.ftiss1on in gl.t.~cose to'leJiian·~e · tosts to normai: 
(1~~) • (vf.t). 
Tn; relapse ot 'by'pe~gl}fcafmta (.::) 1 (Xi<) • (x11) 1 
·ana markedly abnormal glueo~:e tolerance t&s1;$ 
are shown :tn (xti-1.) .and. (~1v). 
IOI , 
D.R. CASE 127 
WEIGHT I LBS. 174 152-157 I 160 
400· 















' 1 TOLBUTAMIDE 
\ : STOPPED 
,' 25·6·57 ~, J· DECEMBER 
\ ---------C~---·--~' 1958 
... I 























F. • • 
LBUTAMIDE IG. 
xvii xviii 











·' ~ ' 
1.' 
., . 
An excellent response to tolbut$1i11de 1s shown 
w1tb. low tasting levels (.x.v) and a cemlstlon 
tb a poel slucose tclerantt te!!, while on 
tolbutamide (xvl). 
Relapse without tolbutallllde tx.vl11). 
Del&Je4 failure to tolbu.tamlae (xtx), 
bu.t an excellent response to chlorpropamide (:a). 
Another rem1se1.on to near normal glucose tolerance 
teat is seen with chlorpropam14e (us.). 
The reaponae to chlorpropamide 1s .malntained (n11) 
(Note no tabs. to'/.' 4. days ) • 
(It ls to be noted tb.at an improvement S.n control 






















L.L. CASE 83 
123- 119 118 114 116 
25·11· 54- 6·1·55 
F• 
Fe F• -£-13-1-SS 
~r-----~~--------.-~~----------------------------~ 








Fe eF eF 
F!eFeF• eF 
FROM 14-1-55 . 450 MG. I 4~ .... 600 li.4G. 
FROM 1·4·55 TO DEC. 56 
fll iv vi 
· .. 
122 125 129 127 














FROM 17+57 FROM 15+60 
vii v'1'i1 IX X xi XII 
/ 
L,L. (Case. 8;), a European worgan aged 58 ;rears. 
A remission vas recorded with no~ma6 fastLBs and 
2 hour level (1v) and. (v). 
Than a rolapoe to an abnormal glucose tolerance test 
(v1). 
Although the tastlns blood glucose levels we•e 
lowered b7 tolbutamide, a glucose tolerance test 
ls still grossly abnormal: (v11) and (v111). 
Later tasting levels show a tendencJ to rlse on 
tolbutamide (lx) and are lowered by chlorpropamide (x). 
Reversion to tolbutamide agaln causes a rise (xi). 
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1947 FEB. MARCH 









TREATMENT DIET 1-3-47, CONTROL 
5·3·47 '+ NICOTINAMIDE450MG.. 
ii 
NICOTINAMIDE 500-tiOOO M 
FROM 7·3-47 
NICOTINAMIDE 1000 MG. NIL 
FROM 12-3-47 
iv v 
The rednot1on 1n the amot.1.nt of glu.ooso _,xor_e~ed 
dally 1n the 1nlt1al part ot the studJ la 
charted on tbe facing page-. 
An 1mprovement in slt..toose tolerance testa 18 
snowns (1S.) • (v). 
Note: Gl:ilco.ae tolerance teste 1n. (11). (111) ana 
(lv) are charted over a 4 hour pttrio4. 
As usual, b.eavJ dot marks the 2 hOW:' tlgure·. 
/04-
------------ - --- -
G.S. CASE 136 









160- e e F 

















eF ... ;. 
F 
X 
-- --- -- ·-- --~~------------'~--~---..,.......---



















SO Q-ILORPROAIWIDE CHLORPROFIII.MIDE 0-75G. + 
TOLBUTAMIDE O·SG. FROM 19-6-59 
G.T. T. & CORT/G.T.T. 
TREATME O·SG-
FROM 13'3-59 




G.T.T. & CORT./G.T.T. 





Maintenance ot low tasting levels ana a rolap~e ln 
the aeveZ"1t1 ot dlabetea aM ·Ot .the ahno:ltmalttJ of 
glu.eoee toleran~e tests arfJ shown 1n {v1). 
A. good hNP.__ogl,-oae:m1c .reapo~e ~o . ca:rbu.taJI14e .is 
shown (vlttl. 
A neat .llorJ!!l . s*!:'coee . itelereeotJ!e& ~ wbile on. 
· to1butam._d. (1&) ~ 
A moderate :tastlng re$pOfl;&~. to ~hlor~J'ope.mla.~ i (x~) · 
is fi:nhanced by tb.e a.ddl'blon of tolbutamlde bu.t the 
glucose tolerance tests (~1i ) ·&..n.tl httiJ.) show a 
seveJ;"elJ $.bnorma1 .form• 
Elevatien ·O.t ra~t1ng ~evels was'~ noted on tll.e 
st.llphonylurea;,· ~.•obuzole (xtv) • .. 
·The gll.loe.se tolera,nc•. test (xv) t,m dimetb.ylblgu.ard.d~ 
appears sllgbtl;# o~tte.r tb~n. ·~n .th$ sa1pnon,-1areas. 






















































' RIBOFLAVINE • .' NICOTINAMIDE 
; 30MG. SOOMG. 





N.c. (Case 32), a Europef9 man aged 35 xear•• 
A £§m1ae19D tn glucose tolerance test to por~l 
1s shown: (v). 
The relapee 1n sevettltJ of d1abetee ls seen 1n 
the next glucose tolerance test (vi). 
A tailure or response to a hypoglycaemic agent, 
1sobuzolo 1 is rooorded 1n glucose tolerance 
test (v11). 
An excellent response to chlorpropamide and 
dlmethylblguanlde was noted (v11i). 
(Subsequently the urine rema~ed eugar free on 
IA 6023 1.5 G. dally alonet chlorpropamlde alone 
had tailed to do eo). 
lOb 
J.F. gs;; ~z 
WEIGHT 




. ;- ., 
300 








Dl ET AP:1fX 
TREATMENT BEFORE Tt. FROM 20·2·52 
NIL 3oo o.k. TOLBUTAMIDE 
18·6·54 -a ·7·54 I G. 
ii iii iv v vi VII 
J.F. CASE 47 







--- -. -.- -- -- --- -- -.-. -- - - - •F 
l'e eF • 
• • • • •• 
too-• • 
• 
• • • 













TOLBUTAMIDE IG. (G. 1·5G. 





J.F. (Case h;Z), a Eul"opean 5 ag4 4.7 xea,p,. 
l:Dlprovement ln glucose tolerance tests (1) • (111). 
Glucose tolera.nee teats complet&1J abn.or:mal oa 
tolbutamide (v1) and (v1t) althoqgn satlsfacto:r7 
taat1ng le~els are reco.tt4ed (v1l) ana (v11l). 
Moderate·reaponae onlJ to chlorpropamide (t.x). 
Further elevation ot ta.etlng level on taobu.tole (xi). 
A good response to phenethJl41guan1de enhancea bJ 
tbe add 1 tlon of eb.lorpl'Opamlde (xU.). 
A,;ormal gluceSf,ttole£ance jest on ·the oombtnatlon 




















OBI ONLY NIL SINCE 
TREATMENT FROM 3·3·60 5•5·60 
xiv XV xvi 
· z .~.--·.• .• 'e£uut '1,71 .: · · · 'oo:nt···•a:\·~-
-· - ··· ·~, ..... a,... •1-f:tci , l ~ • Jlin_, ./:.·.~ 
Hot SUch a gooa'. glucose toieraztctt 'test on DBI alone 
(xtv). or 1.olb.en ~h'-s ts di~oontib.ue~ {ltv:) .• · 
!he reapoD.ee to anotlie~ :4igua?;i.d6 · ,4fb1'.1 vat!.:ve 1~ 





M.A. ·CASE 2 
P A ---A------A--· ----A--- ---· ------------ --- ------ .27·7·56 10·9·56 .· 24·9·56 '-~·10·56 
ii iii iv v vi VII 










§ J 28·10·56\ I 19·11·56 \ . . 
~ 100- . 





: TOLBUTAMIDE : 
: IG-I·SG ·' 






(A patlont with gout end dlabetes). 
'the evolution ot a £em1as&on 1n glucose tolerance 
test ja,watrdm norma~ ts .a een : ( 1 ) .. ( v) • 
The tasting and 2 hour levels are further 
dopres•Gd with hypoglJcaem1c ag$nts oarbutamlde 
e.nd tolbu.tU11de ~hil.e in remission (v1) • (lx). 
Relapee in aeverlt;v after being oft tolbutam14e 
tor mor·e than 6 monthS (x1l ) .• 
DelaJed failure ot reeponse to tolbutamide occurred 
(x111). 
Persistent glycosuria and blood glucose 323 mg. 























13·6·56 ..... 13·7·56 
iv v 
(A oue of put and dlabftea) • 
After a tccleoJ to r•ld.llaloa ••• aoted, tbeN l• 
a t.anb.•• lowert.Da ot tbe taaUq U.d 2 b.ou flauea 
~lYlftl rl.ae to an llaR!J~ &1&181 gl110oae tot.r•M 
t .. t (wl) oa oarlNataat.cJe. 
1/0 
'. 

































< .. , 1, .. 
Normal fastS.ng level& are reoot-4ed dur1ng a 
phase of :remission (11), (111) 1 (S.v), 
A glucose tolerance teet, thou.gh, &howe a b.lgh 2 hou.za 
level (111). 
Pasting levels on carbutatll1de (v1) atte s1mllazt to 








J.C. CASE 31 











~---;.~! ~,;------~,;.-~~---- · 
~ Fe Fe Fe eF , . 26·9-57·24·10·57 
F.• 
Fe •. --.- __ _ 
Fe 




DIET TREATMENT . 600 MG. 
2·12·54-13·10·55 FROM 













NICOTINAMIDE RIBOFLAVINE TOLBUTAMIDE 45MG. 600 MG. 
600 MG. 17·5·56-30·8·56 FROM 28·2·57 I G. 




--Fe. eF • --. -~9~~59-2i-s-s9--
















NICOTINIC ACID ISOBUZOLE 
600MG. IG. 
FROM 22·10-59 FROM 4·2·60 




An improvement to low aor.mal tasting gl\tocse le'fela 
ls recorded ( 1 ) • ( S. v) • 
~hen a gradual el,evat1on in tasttng levels 1s noted 
not influenced bJ tolbutamide (vl1). 
Ohlo~tpropamlde hal lowered the tasttng level& (lx) 
bu.t a glucose tolerance teat (x). ln eplte ot the 
hypt.o··glJcaemlc agent • show a a hlgber rS.ae and a 
hl·gb.er 2 hour level than 1n ( 11) and (lv). 
11'2. 
Later tasting glaacoae levels show a rtae btl) and (xil) .. 
It is of 1nterelt to note that the taetS.ng levels wltb. 










P.K. CASE 74 
156. 156-168 162 161 160 157 
~ 24·3·55-8·9·55. I 5·12· 55-19·7·56 
~ roo_ -- ---:~:=--A -~~.~G~, 
0 • • • • 
2~8~5_6_~---P--- p 
_.-23·8·56 . . 
. . . -
9 • • 
m 100 • • 
• 
• • • ... • • • 
sot----------.--~~~~~~~~~.-~~~~~~~~--~~--~~--~--------~ 
TREATMENT 0 I E T NIL INSULIN 
ii iii iv v 
I 







200- • • • 
•• 
• • 


























ix x xi xii 
ALL BLOOD GLUCOSE LEVELS AAE APPROX 3 HOURS P.C. 
vi VII 









A remla11on occ~red after 1naul1n admtnlatratlon 
had atopped on 15.10.55 and glucose tolerance 
te•t (111) 11 much better tban (1). However, in 
(v) a groaaly abnormal gluooae tolerance teat 1a 
recorded aga1n 1n spite ot a law taating level. 
Glucose tolerance teata on oarbutamlde (v1) and 
(v11) are atlll abnormal. 
While taking 1naul1n a trial of tolbutam1de, 
met&hexam14e, chlorpropamide and laobuzole tailed 
to lntluence ~e tnau11n requirement (v111) - (&11). 
However,~ wlth the addition ot DBI or IA 6023 
( + chlorpropulde) the hyperglyoaem1a waa not ao 
marked. 
113 



















- ··:;' - --- - ------ -------- ~~~· ---- -~-:-~ ... 0 ... ~-
1.:) 
0 






DI£T DIET AND NICOTIN- NIL 600 MG. TREATMENT 
AMIDE 600 MG. FROM 26-12-55 FROM 29·3·56 
Ill iV V Vi> VII 
1 . 
.... .,: 
W.R. CASE 126 





RIBOFLAVINE 30 MG. 




F• F•' • eP.C. 
F• P.C. 
X XI 
I\ , \ 
I \ 
,' \ 
~ \ , \ 




w.a. (Case 126), a ES£Opean woman aged 51 1eare. 
The severity ot the diabetes le eatabl1abed by 
hlgb taetlng levels and glucose tolerance testa 
(1) - (111). 
Then after the termination or a course of lnaulln, 
low taatlng levels are recorded, b~t tne glucose 
tolerance testa remain grossly abnormal (v) • (1x). 
On hypoglyoaem1o agents low tasting glucose 
levels are demonstrated (x) • (x11)J the gl~cose 
tolerance curves vary sllgbtly; low tasting levela 
and near normal 2 hour levels while on carbutam1de 
(x) and tolb~tam1de (x11) but the peak 1a raised with 
tolbutamide. 



















A " \ 
l \ ... ,, 
so~~=--~~~~~b~~~T.~,-c~.OR~~~G~T~.t~ 
XI 'It 






lt•ft•·· .,,.,12!1!! .. 126!; . · lPon~~!i>• 
., , - , ' - , ' . ' • • . . - (_ .. • '. 'r • ' -. : ~ ) • • . ' 
.. 
~ .. ,;~ 
r , 1\ • I 
tAw te.stlns .levels: per-sist (x.t;v) .- btUt)·,· b1tt ... 
ln spite of ·the low fast1•ng l-evel on chlorprop~l4.e • 
a g:rossl»' (Abn.ormal:gl:u.eoao .tol.eranee test. (g:\f1'11) 
lu recorded. 
Aftet' ·•toppJ.ng .:to1butamtde·' (~V.l.) o1"· chlo.tipropamlae .· 
htf.x) the .g1uoC>et tol&J~ta&ce tests show f'u.rth.et" 
' ' ' . ' 
elevatS.on. of ~}le .. 2 .. hOY£ le;y.el.! when. compa~ed wlth 
the correspoa41ng Cut'ves oa tbi,bu.tamtde (xii) aD.a 
1 • ' , ,oc,; \• ., 
clilorpropamid. ,(xv.111,l ~ ' :. ' '' ,., 
' '. ~ ' : :, ' . 
~· ·g1ucos·e.to1e.rance· 'testi le~ .• abnormal ·s.tt ·all .. 





C.V. CASE 158 





~ /12-4·56 • 














TREAThiENl FROM 13.1-55 D I E T 600 MG. RIBOFLAVINE 45MG .• 
DIET . I fNICOTINAMIDE I J 
FROM 8-9-55 FROM 5·4·56 











iii iv v vi 
. ..,, 
·, 
148 151 ISO 
X XI XII 
ISO 
XIII 
A brief rem1ss1on to near normnl tn glucose 
tolernnce test (11) ls not mlnte.lned (111). 
Abnormal glucose tolerance tests wltb·a return to 
prevtousl.J abnormal level U.v) - (v11). 
Rom1ss1on to ~ormal slucose tolerance test soon 
after starting oarbutam1de (vi11). 
Gradual aggravation or glucose tolerance test atter 
stopping carbutemlde (ix) and (lc). 
Response to second course of oarbuta.m1dtu this time 
glucose tolerance teat htl) 1s not as good a.a glucose 
tolerance test (viii) ln spit& or low tasting levels. 
The response to chlorpropamide is more or less equal 
to that of earbutam1de. Glucose tolerance teet (xl1), 
3 months atter commencing chlorpropamide, and glucose 
tolerance teat (x111) one year attar commencing 
cblorpropam1de, shows a normal tasttag and near normal 
2 hour level. 
"" 
-·---· -··· -·- ~-··-~--·--~---~ ~--~---~ 
Mv. L. CASE 81 
WEIGHT 144 140 
LB~ L-~~--JL--~~_j--------+-------~--------L-------~ 











FEB56"0EC 56 I 
~z.r.. 
There· vas some redu.otto.n 1n the fasting g~ucose 
level while taking n1oot11UUJ114e bat slu~ose 
tolerano~ teats Jt1) .and ( 111.) wer& .atm.ormal. , 
'here waa no apneo le. ble d1tterenoe in glucose 




H.M. CASE 98 
WEIGHT 




I 2G. t 
-· ~= . : JULY. AUGUST 1958 I 0 
F 
I I 
~ , -FAILURE~ 
LA 6023 1·5 G. 0 
/ 0 + 
~ 300 : NICOTINAMIDE CHLORPROPAM 
~ I 900MG. I O·SG. 
UJ : AUG.58-APR.59: MAY 1960 
IJJ ;-NO RESPONSE-: 0 
-FAILURE-u 
::;) 






100 8·4·59-JAN 60 
50 
BEFORE DIET I OBI 200MG. 
TREATMENT TREATMENT FROM 26.7.56 FROM 2().1.60 
ii iii iv v 
~' 
I If 
'.,' ' 1 . '.1 .. ~.-~;· .. ·:; ::. 
fhbl jjOUhg EultO~~an··man wa·a. ag&~f-&7 tears· 8:\; ... ·. 
o~et of. cll&;bet .. a ~.... . . . . . · 
.if . .. ' • \ . .• ., . ~ ' • ' ~ • • ' • ' : : . . • ( : : • . ' .. ·. ; . 
Fail'lJ:Pe :i~t r•sporise. to. a11 'oral 'tn&41cat1ort~ ~$' \ ailolrh.: · · : . · · • · · · • · · · · · · · · ' · · · · · · ' · . 
. . ' ' ~ ' 
. ' ·' ' (0:n: nm: a:in4-l*A.-.. 6028,·:tb.ere· •as ;a:~edu.etlon.!n ' .. 
lz).th.tlf.n req\l1tement); 
<' > ' ' ' I ' ~ • : ' ' 
E.C. CASE 29 
WEIGHT 
LBS. 168-172 171-165 170 170--'167 165 166-160 
400 ' ·J 
eF 21·7·5S -9·2·56 
.:j 
Fe Fe eF ::E 1·7·54-10·2'S5 Fe 0 eF eF eF Q 
0 DIET eF NLY 
Fe Fe ::E Fe Fe eF •F· 
w 3+52 Fe FeeF Fe •F eF 
"' •F eF Fe ee 0 200 e F u Fe Fe 29·4·54 -17·6·54 
3 Fe Fe 3·3·55- 23·6·S5 
\.? Fe 






so DIET + DIET ONLY AP~ NIL RIBOFLAVINE 
TREATMENT NICOTINAMIDE 300M .. K. FROM 17·6·s+- IS MG. 300 MGAa< 14·2-52 FROM 21·9-S2 FROM 15·4·S4 FROM 1o-a.s5 
II iii iv v vi 
E.C. CASE 2Q 
WEIGHT 






23·2·56-7·6 ·56 eF 
eF Fe FeeF e· 
Fe e Fe eF Fe 
200-
F .. ~ Fe eF Fe Fe eF Fe 
Fe· 11·10·56-8·11·S6 e 
•F 14·6·56-27·7·56 e Fe 
Fe eFeF 





CARBUTAMIOE IG. TOLBUTAMIDE 3 .. 1 
20--30 +NICOTINAMIDE 
FROM 23·2·56 6oOMG. ,.,,,. 13i256 
vii VIII IX X XI XII · XIII 
B.C. {Case 29}. ! E\aropean woman f8ed 55 zeara. 
H1gn taatlng glucose levels are shown througnout 
(1) - (vi11) until carbutaaide 18 atarted u.x), but 
a glucose tolerance teat Oft earbutam1de is abnormal 
1n all respect• (x). 
l'o response to tolbutamlde 1e seen in (xi) and a 
aat1efactorJ reaponee to carbutamide 1a agatn 
shown in (:r.11). 
On tolbutamide there 11 a gradual elevation 1n 
taating lev•ls (x111). 













172-165 165 16 7 
eF 











. · .. 
~4·4·58-9·7·59 . 
XV XVI 








.. . •: 




,.... .. ..,, 
\ 
I \ 













A ,- --,, 
/ ... lit 
' ' I ', : . 
' ~ 
50.-------------~~~~~~~~~~~~-,~~~~~~~ 
TREATMENT ISOBUZOLE I·SG. 







Hyperalfoaem1c levela are cgain shown (x1v), (xv), 
(xvi) until a moderately good rosponse 1n tasting . -
levels is seen w1 tb. cblorpz-opamide (xv11) which 
was not s1gn1t1cantly enhanced bJ tolbutamide (xv111) 
or DBI (xlx). 
Severely hJperglycaem1o levels tasting and in 
glucose tolerance test were recorded Gn 1sobuaole (xx) 
and .xx1 ). 
/l.O 
On DBI + ohlorpropa.m1d e (xx111) and IA 6023 + chlorpropamide 




















FeeF ~ , .. , 
Fe - --- FeeF FeeF 
Fe 






10"4'58-3'7"58 Fe e.F 8-10-59-31·3·60 






v VI vii viii 
'\ 
/2.{ 
(A case or gout ana atabetes). 
There WGS no response to tolbutamide: glucose 
tolero.noe test (111) or tasting blood glucose levela (v). 
Chlorpropam1c1e (vit) stm1lal"'lY pt"oducea no response. 
Thls pattent however, did show a reduction 1n tasting 




















M.D. CASE 38 
SO RELAPSE AFTER 
TREATMENT INSULIN SiOPPED 
ONE YEAR AGO 
176 
23·7·59 





















A progressive imp~ovement 1s shown in 2 glucose 
tolerance teste (11) and (111) following the 
commencement of chlorpropamide (ln a man who bad 
pz-~vioasly been reos1 vlns 6~ un1to of insulin and 
bad gone into a spontaneous remission followed 
by a relapee of diabetes) • 
/11 
E.N. CASE 113 
WEIGHTF~===~r==---~---,-----~ 
















CARBUTAMIDE IG. NIL 








Gtl!-,ue toleNiloo teat (l) ••• ;fOu .aftol1' q .. period 
ot eeublil.e~tef ,41&\tetea (lS ~•atU ,. 
OltiGcOt• ·tole~&t\01 -.at (il) &t· ~lillb lmpHVCtl 011 
•••t~utami.fe thoup t>f tbt. ••• t•~ •• (l). 
A tetter.;~-, to l!te.lapa-e attt11 e;t<$ppf.ng -cal'thltaldt~e 
t.c •hottrl ln (11. t). 
I, 
I.W. CASE 162 
WEIGHT l 1 163 J 166 I 162 I 170 _] LBS. 181 
400 
21-4·55 




















2·8·55 28-6·56 11 ; 1. • 
100 ' 
50+-------r--------,,--------.----~~~~~~~~~------l 
!REDUCING DIETl I R I B 0 F L A v I N E. 30 MG. 
TREATMENT coNTROL I FROM 22·4·55 DIET FROMI2·1·S6 !coRi:/G.T.T. 
ii iii iv v VI 
/· • 
I.W. CASE 162 
WEIGHT 169-183 178-158 158-164 166 168 168 
LBS. 




...i 24·9·59 ::; 
4·11·591~ 0 300-
I' 0 
'" F• I 0 ::; 
18·6·59-10.9·59 Ul 
"' 18·10·56- 9·10·58 0 u 
200- f• : :::> 
..J 
•F 0 
25·9·59 • 0 . § • I • • F• " ' m •F Fe ' • • F ••• •• too-• •• •• 
so 
NO G.T.T. & COR't/G.T.T. G.T. T. & CORT./G.T.T. ISOBUZOLE IG. 
TREATMENT TREATMENT NIL NO lOLBUTAMIDE TOLBUTAMIDE IG. FROM 8+60 FROM OCT. 56 19·9·59-26·9·S9 
vii viii IX X xi xii 
/l'f 
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FiJ,v.ctuatt.ons in glucose· t-o1ext$n'ee :teats '(1tlr-~ '(:v;tJ. 
(, .• _l ·:. • •• : • ' • • ': ; ·: .·' ,• •• '.' .: •• ' •• • ._ ) ,'.: ,, 
_, l_. t ' 
ii~l:~P,s~ ·1a aiabe:toe ~(vtll) att~t' 1o~ nol'MAl .·tasttng 
I -. -~· ' . ~ •· . ' ' ' . '•' ' • ' :'. I • t ' •'' :· 
. . . -. ' .. " 
l~v~la :(v.ttl·• .. ,i_. ~ .. ' ' ··.' 
'···. 
A __ n .. !mQ~~~.c]· · :s~ac2ae tol~argc'~:·:;:.t•u :·-on tolbutamc4e (1'~ --~ --~~---·-:"'. :~-._1 ~- :l'"q(.---7-.- .. ·- _fL ··-
.. (note low taa~tn ·. ·1eve1 ~ct n~~r ttorsl 2 hoW.:. ·1&v61:. ··· :. · :, · .... :''··· :.; ... ',:,_·;·; ,8:. '.• ';; .:·•. :·.'· •!·.,., 
. ' . '/ ; . 
' ' 
b.JpOglJoaemic ageat ian')b\tlao).e. '(x.tl). Note the lew.· 
taat1ns le't'el. has been .matn.tat.ne.a but the .~)1o!l£ 
level t.e b.l~Qi,,;lr aaormalt 
4:·. 
• :.·;; __ ,·j 
.·,, 
. 
R. L CASE 79 
WEIGHT 
LBS. 170-163-148 1 153 .j 152 -I I 52 ; : .. 
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ICARBUTAMIDE IG1 N I L II TOLBUTAMIDE IG. DIET 
FROM IJ.7.56 FROM 23·8·56 FROM 12·1().56 T CORT./G.T.T. TREATMENT 
ii Ill iv v 
lormal tasting levels are not 'achieved with dlet 
and. weight loss (1). 
On oarb~atamS.cJe thel'e la a •l'ked reduction ot the 
.tasting glucoee level (S.l}. 
TJae glucose tolerance teats on carbl1tamtcle (11) ana 
tolbutamide (S.v.) are almost 1d$it1oal: a low 
t'astlng level but an elevated 2 hour level. 
Ott carbutaJDtde the glucose tolerance test (111) 
la more abnormal. 
J.G. CASE 52 





18·2-60-28·4-60 . Q 
~ DIET ONLY 
3·6·60 w •F 
~---------
r-,, "' 3'4'58 0 Fe 
I ' u 200 2 ·7· 59·30·7·59 3 F• 
C) 
Fe - . F.••F 0 Fe 27· 8·59-7·1-60 . F• •F § •F Fe•F 





ISOBUZOLE I G. TOI..IIUTAMIDE 
TREATME':lf 1-1·5G. 8·1·60 - 28·4·60 FROM 4-4·58 
i. ii m iv· v vi vi'! 
~.g. . (Oase 5g), ! ~uropea~.man aged 54 years. 
Bo respouse was eeen to tolbuta.m1cJe ( 1), but a .sgd 
£&Spo:ye was recorded leO chlor:pl'OJ?!lJPlda: glu.cose 
tolerance test (11) and taatlng levela 1n (111} and 
(1v ). 
On 1eobuzole the glu.coae tolerance teet response (v) 
was l'ee.sonably good but tb.ere was an elevation of 
tasting levels (vl). 
An excellent response ln glucooo tolerance test (v11} 
waa reco~ded to dimethylbiguanide. 
l.2.b 
•' 
J. R. CASE 128 
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Ill iv v 
... -~-· 
. ! 
Glucose tolerance curves (ii) on oarbutamido and 
(1~1) on tolbutamide are praottcally normal apart 
fro~ the h1gn i hour figure in both instances. 
(This period maJ cor•espond with a pam1ss1on ln 
diabetes due to weight loss). 
Glucose tolerance test (1v) 1s completely abnormal 
aga1n (after weight has boon ge1ned). 











Thls patient. showed a· sooa hJP<>SlJcaolblo rtn1p9nse 
to tolbutam1d$ and .cb.l6rprop~ae •. 
'the glacos~ ·to1,tance teet ·Ol,l eb.l.o~px-opamlde (1v) 
was bette» than that on toloutamlde ... ( ii). - . . . . ·. . I 
I • 
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SO G.T.T. & CORTJG.T. T. G.T. T. & CORTJG.T. T. 
TREATMENT OBI IOOMG. LA 6023 1·5-t3G. 










'1 ~ --· •••• 
A g:OO~ l"esponse .t() tolbutU.D!i;.de is followed bi .. 
.. • ,;;... •,, ' • • ' • ' • ·~ ' < 
de1aJ-e4 .ta11Utt~ ( 11). 
An ~xc•ll~nt ,fuspon.s~· , ln ·. tas t tng levels to 
chlo.z-propam1ct• ls a~utn (lU.) bu.t the g'1u.cose 
.. 
tolel!'ano' test SJJ gPOEHtt:ty abnol"mal (1v ). 
l?astS.ng levels ·on ·Qb.lottpropamS.Ci& .;Later ( 'fl) ue· 
not ql\tte a.s gooa .• 
On ·tsobuzole thel."e 1s the asvelopmeut of gro~u~l;, 
al;)nomal taattng blood gl.uq®~ levels (vl) ana 
glucose to.1ezt:8l'lo& test, (vit)' 
o.o. DBI (v111) atta ttimethrll>tg~aalde (~t the · 
l'&eponse in glucose to1e_.aa¢e testfli was a1mtlu t·o ••t 
seen wt~h chlorpropamta~. O.v h 
11'l . 
\. \ 
Glucose tolerance testa on tolbutamtde and 
after d1scontS.nu1ng tolbutamf.de are almost 
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I 9 0 
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previous r~na1 · ·gl.J~6•~rt8.. . 
j··. . ' ' . 
. '\ ·. '' . 
On · 1$ob·t.t~olt the glilch~e' · t:o1~rano- teet ( 1.11} ts 
pra~ti.ealllJ unchanged.-
I?J I .... 
G.SA. CASE 134 
WEIGHTr---~----~-----,--------. 





TREATMENT CONTROL CARBUTAMIDE IG. TOLBUTAMIDE IG 
FROM 29-6-56 FROM 13-9-56 
II Ill iv 
---- -- ---- ----- -------
G. sa. , JOase.,lJkla 1 qoloured ~1i2!AA tsod 44 lH~*l• 
• • • •• .' ' J. ••• • \• .- • : ,, ,, ' 
The response as Dleasured bJ gluo,os e tolerance 

























Q.p. CASE 120 ... ;~"·'"··. 
138-147 14 4 
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G :r. T. & CORT/G.T.1: 
ii Ill 
o.p ~ • (Case 120.), a Eurosey .j9J!!!n as~<l 65 .U•£•.· 
There was failure ot response to tolbutud.tle U.) 1 
but an excellent reaponae ~n tasting levela to 
chlorpropamide (11). 
















' . 1950-1951. : 
: INTERMITTENTLY: 
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12-5-60 ' 
' FAILURE ' 













frogresa1ve wor.sentng of gl~t'n>ae. tol.e~an~~ . t•ats 
.. . i , ' '¥ ·'I '' , , . •• , 
azte she-w~ (11. U.til» (·tv)-•. 
l . . . ' ~ 
t , < • I ~~ 
or I>BI .• · 
,. 'I 
I,' ', ••',' ,< 




(Th1a man, prev1otas1:r on insul1n1 tailed to respond 
· to a trial o.f all the sulphonrlu.reas .: tolbutamide, 
chlorpropam1de 41 metahexam1de, 1aobuzole). 
His control wl th chlorpropamtde+. dim.ethJlblguanlde 
was good and the glucose toleXtance test aa well was 
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SO G.T.T. & CORT./G.T.T. 
LA 6023 3G. t 



















A.o.S. CASE 140 
400 
300 
'7·6·60 ,' ...... _~ 
I ' 




TREATMENT LA 6023 3G. t 
CHL.ORPR~IOE •SG 
o.v.M. _;{Case 160),a Egopeg. man. aged 6~ xeara. 
(There was a tat1lll"e of ¥-eponse to a trial ot all 
the sulph.onjlut'eaa t tolb11tamide •. ch1crpropani1ae·~~ 
.metahex.amide and S..sobuzole 1n tb.S.s pat.1ent who was·' 
tiaklng lnsulln · 45 ual te daily. Insull.n could 
be d1scont1nued atter starting th~.conc11~rent 
adrn1n1strat1on ot :tA .602; and chlorpropamtde), 
Glucose tolerance test showed an excellent response 
to dS.meth,Jlbihg11anS.de + cb.lorproptm14e. 
On w1th.cSrawa1 ot ohlorpropamtde he remained a\lgar 
free. 
-"·'· 
I;~ .... · 
P.L. CASE 88 
WEIGH 
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:OBI ISO MG. 
I FROM 3·3·60 
G.T:r.'s & CORT. G.T. T.·s. 
OBI ISO MG. + LA 6023 3G. + 
CHLORPROPAMIDE 0·2SG. 
FROM 7·4·60 
II iii IV 
(There had been poor control on 1nst~l1n 60 - SO 
un1 tn. On DBI or dlm$th:rlb1guanlde better blood 
glucose levels were recorded). 
Glucose tolerance tests on DBI alone (S.j) or 
DBI +chlorpropamide (111) or d1methJ'lb1guan1de + 
ehlorpropamt.de U:t) were all almost 1dentS.cal and 
equally abnormal. 
131 
A F. CASE 46 G :ns & CORT/G:n·s ... . . . . 
.. 
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OBI ISO MG. i 
TREATMENT 17·3·60-,2·6-60 ·r FROM 14·6·60 AND ! ON ~YS OF TESTS. 
j 
Tllls patientlj wtth diabete·s or 2 1ears!. · dU):ia.ti$n, 
we.$ preylou.s.ly on tnstJ.lln • • 
She showed an .excellent ·respoWJ~r to DB:l # tastlng 
and gl\\00$$ t&ler@ee te$t ).$•·6,60• 
(TW.s was ~'lone wh.en. th~ pat1$nt o~1t~d· Dil f.f'om · 
the. prev1,ous · day ) • 
On.. 2a.6.6th tl't& gluoo:se tole.Z"ana-e teat bas been 
lower$d bf ta1d.ns; 011 50 mg. bet<>re glu.coae· ()I'J. 
1;he dny~ o.t glu.coes tolerance t&sts. 
' ~, ' 
13~ 
·he :pnoe~bg t.llust""''ou . cl.eal'l.J 
~••••ate the :Jlla!&U<u~s~~~~•t&tl o.f the vulou 
ag•t• ·used. 'bea• pa'llmte ·ut -I. ••prea.-tati.V'e 
1-&fleotltn ot \be,- total po·up ·$ba4&ea, ad be.ve b<ten 
,. . ' . . . . 
aele~eoa tot~ })J'eatmtatteo A·es f.b._, · t11usttate the 
tollowlng .teatuee ot p.,.tlotllV ·in,••••t b . , atuctr #. 
:13'f 
1. . aeepOll,tt -.a fat1•·• ot NG;pcmt• to PhU'.Uolostoal 
e*taes. ,· . ,.... . j 
J• Oepa•att.ve erte~t ot.- tbe·:\tu1ou .,poalrcaemlo 
' . ~~ ,. 
'lbe hfpoalrea.emto aott•· :t:;t p.,_colo&~oa1 
' . .. ~ 
aa.Uta ue betn ttl'ialr aaua•U•h.4 tA •• ll,eratutte 
" ' 
anct t¥•• otutlos a191r eoutlrJn t,b.h pof,n•; 
lifO 
The Value ot Long Term Studies in assessing Byposlycaemio 
Asent~a 
The value ·or the method of investigation 
which I have uaed here in assessing tbe response or 
failure of responae ot a diabetic patient to 
pharmacological agents over a long period haa been 
demonstrated in my publication on chlorpropamide in 
diabetes with apecial reference to tolbutamide• 
tailed cases (Herman et al 1960). 
Patient• in whom primary or secondary 
tolbutamide failure bad been demonatrated were 
treated with chlorpropamide. Ot 51 patients who 
had previously bad tolbutamide, 4:5 tailed to respond 
to this drug. In this latter group there were 18 
primary tolbutamide failures and 26 secondary 
failure a. The test imposed on chlorpropamide in 
this trial was therefore a 'f/ery str 1ngent one. An 
excellent response to chlorpropa~de was obtained in 
SO ot the 43 tolbutamide failures and a partial response 
' in a t"Urtber 14. Chlorpropamide vas often found to 
be ettective where thexae vas primary or secondary 
tolbutamide failure. 
·~he report'S on the·aot'1oii of carbu.tamid&. 
and t·~lbutatttl::d.e in diaoates bJ'-' Jaokson e·t al (195'6 
.and 191'1) U~o·lude· .oofrl$ Cit the pat~ierit-s;:~ had 
studied OV;er· .. poi'*1od. ot. J;ea~s:. The "alue ·i;t 
. ~ . . ' . ' 
·,lo-ng te....m as'Sessment' ot hypoglyc~a)raio a<it-~oh ·is . · · 
. ... ' - . 
'') 
. i41 f 
' ·the a:oov$ Jr~·p~:c•1ra aea.J. with .thO ~t:fe¢t!"Vs 
'}lJpoglreaem:lo aoti·on c~f'' tlla ~,tl1.P;hl.ll1Jlwt~~s·, .• l1Jibutami'da' . 
. ·tol butamJ:de and· ·chlorpropara14a .•. 
. ~ \ 
l)111obuzole; a. th1-.d:tazole .der;11$-t'!,v~,. 
·•7athes.~sea bJ _Chubb et al. ·(.1~59) a:na re.sernbling_ ~a~ 
' ' .· '. . ' . . . ,, . . . ·" , 
orlginal :Product used ·by Jan'bon· .:(1942) 1nhi->~- o:J.o~e~r· • 
. . ' ' ' ., '. l' ' ' ' • • '.' I • ' 
tban tU'i)" other ~c.glJC~em!o agent. at present in~us&, . ·, . ., . 
wac not to~d to be . an: ettective. hypo.~t·,,-ce.em1c asent: 
in tho· ·b>atie:nts in who~. it w"G.s ue~cl (li(3rD~..Elr.\ ~9Go). 
!!'he guanidine 4er1v~t·tvas mtght be. et~e·ctive 
wherei the sUl.1phonflUl'ea.s have railed to .produce ~ 
· sa.ttstactGFJ r$aponse ~· · This ·was well de:mon.tra:tec:r 
1n ·c.-~.M •. (Case leO) an ei-de~ly man -on f.nsultri who 
tailed to respond to ·all ·the available aulphOnJl~ee.s. 
lila l"&Spons e to both phenethyl'b~guan1de and later to 
41lnethylbiguanlde we.s excellent and his control waa 
._;:,-.' 
I: ,' I'\ ! ., . • ; '' . ' ~~ :_ ,· • ! .. ·~ : ~ : (,. ' 
bett6l' than' tthen be was taking 46 Untttf or 1,..$ulln~ : 
• : , I' •' '• 0 ' · ! ! 
• l ' ' ~ ' ' I 
· · '''l'ht:> ttol.:lowtns patients, :too• ... wbo had 
tailed 'to rsspc.nd t·o the s~pho~yl~eas, ·snowed.· 
' ' 
sQ t1sto.$t,;ol':r· 4ontrel . on the dtguantct~.i!l 1 
P.x,. (.Qas~ 9$;); •~<=·- (Case ;32). A·:F• -tease ·Ge.). 
A ·few other patle:nts .~ an L!lt&rmed.l$te., · .. 
gtJoup. ot ·d1abat!ce. aged. 5() to 40 years :a.t··onset. · · ·'. 
of Gliabete·s • whO .t'JB.d tailed ·to .. &bow a hypoglycaemic 
. response· t() t~e au.lphonylureas, showed thie 
Ul'i8attstaotc.ry · res·ponse to the b1guani.des also,· 
e.g~ :P_~i. (Case '14), ll.M. · (.Cas~ 98), HiM!- i( C~se ·97) ·• 
fhese patlel\ta bad been observed ovep 'a long period . 
' - ; . . 
·Of t1J)le and. lt'e·s•mblf/18 N.Of (Case 82) tn· age ot ·on$et 
' . . . . . . . 
and t,P~ ot .d·l<e.~etes,. but not ln the1l' tJpe of 
re•ponse to the guan14es. 
/ 
/4-2. 
1pe Value of Glucoae Tolerance Teate 1n aaaeaaing 
HJPoslzcaemio Act1ont 
The action ot the pbarmacolog1cal 
hypoglJcaem1c agents was put to the most stringent 
test, the st ucoae ~olerance tes1?. *ny ot the 
oases who were on the pharmacological agents had 
glucose tolerance teats done betore treatment aa 
well aa when receiving treatment. Fluctuations 
in glucoae tolerance testa had already been noted 
1n many or these patients over a period of years. 
The slucoae tolerance testa portrayed 1n 
th16 8 tUdf baVe been a better index Of tbe extent 
ot improvement tban the tasting blood glucose levels. 
Thus when a patient was thought to show a 'partial 
response' to a hJPoglJcaemic agent aa judged bJ tasting 
glucose eattmations the glucose tolerance test often 
revealed the srosa abnormalitJ. 
Where patients had shown a return or the 
tasting glucose levels to normal or near normal 
(e.g. a feature often demonstrated in the 1lluatrat1ons 
vas a dramatic tall in tbe tasting levels trom 
300 mg. to 100 mg. unde.r the influence ot the 
hnoglyeaemto agent) the glucos.e tolerance teat• 
showed • types of.r$sponse: 
1. A w e1l•marke4 lowering of ·tb.e tasting 
blood glucose level but the rest ot the ou.r•e 
J-ema1ne4 elevated an4 otten grossly .abDomal. 
e.·. Marked tmprovement or remtss!on to a 
normal glucose tolerance ourve • 
W.he patients sbowtns these Stesponses are 
l1Sted. 
14-4- . 
1. A well•marke4 lowtd.ng ot the tasting:. . 
glucose level but the t•eat ot the curve , remained 
elevated and often goaa~J abnormal a 8 patients. 
' . ' 
Column no. 
Caae Haid S.n graph 
83 · L.L. ('f11) 
(xtl) 
























·x eobu.zole · 
Chlorpropam14e + tolbutam!.de 
Cblorpropamtde + tolbutamide 






DBI + Chlorpropamide 





. a. :Glucose tolerance tests Showing !Qai'keA 
·tmprov.ement. ()r:.t~miss1c,ns·t() .. no~l wb11e. o_elag · 
ire~E~a. w1~h ·hypo.sJ$'o$ernic .aeen£tu· :14 pa.~;ents. 
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t,rolbutaml:d~ .... : ::: . Co~pletelr n<>rmal 
• · • ,I , GeT.t'l. · 
. (Jhl()rp~opamtae · Near · normat·~:a. T. m. 
• '• \I' ,! J • 
• o \• ·,: :1 • •I ·, 
!fear normal G. T .'l • . : · 
£A ¢011···· · .. ; ; " ·; .. ) :: ,. ' . \ .. 
~o:rp~l)pam.tde · , , .Bea~. ,~~~1 ·<J.i~. T. 
J)BI ·~ , .. : . . CQtnpletely ~~l 
. ohtorpropaml:de G .T •f. . ·, 
., 
.OaJlbutarn14e . '· · . ~ :, Normal G •T .t • 
tolbutand:iie · .Normal & .• ~.T • 
' ' )'' -~- -'· :(·; 
• ' : I I • l \ .. ~ 
Carbutamtc.ie Near normal.Ge'T.'T.' · 
'folbu:tamtd&· ,, Near normal ~.·w.·t. 
Carbute.m1de· ,_. · Improvea, G.T.T. 
(Form ot G.T.T. re• 
·· · : ·'' sembles previous , 
G.T.c,r.·) ·· · . 










Ne.ar normal G.T.T•·. ·' 
Near normal G.!l'.T. 
(Fot"m ot G.T.~ ... r&• 
eemblea prevloue · 
G.T.'l'. '~ 
G.t.'l'. with normAl 
p an4 e .hr. level• 
ltlgh peakJ . but 
good 2 hr·. level. ·· 
Low Fast1ng and 
2 llr. level.. · 
Mildly abnormal dy . 
Much lmpi'o'f$.4 G•'l'.T ... 
Examination ot Groupe 1 and 2 indlcatee 
tbat 4 patlenta bad at one tlme shown a 
remtaalon in gluooae tolerance test to normal 
or near normal while being treated.w1th e. 
bJpoglycaemic agent, and at another time had shown 
severe tmpair.ment 1n glucose tolerance test 1n spite 
or a good response judged b7 tasting levels onlJ. 
·These 4 patients weret 
G.s. Case 136 
·I .F. Case 4'1 
W .·R.· Case 126 
M.P. Oaee 122 
DISCUSSION OF THE RESULTS: 
'l'he most interesting outcome ot the results 
111 that patients have shown lmprovement in ~hf 
s+uoose toleran?,e teat to near normal, or normal. 
It has been generally accepted that the 
glucose tolerance teat does not tmprove with the 
hJPOSl)'oaem1c agent J that there 1e merelJ lowering 
ot the blood glucose level. 
1'1-1 
The f patient• who ahowed both tJPel 
ot reaponae 1n gluoose tolerance teata clearlJ 
demonatrate that a change 1n the torm or tbe gluooae 
tolerance curve doea ocour, and 1n 1everal or the 
patients 11ated 1n Group 2, the raating and I hour 
levela were ahown to be within normal l1m1ts. 
It turther eY1d.enoe tor rem1aa1on to • 
P,L normal sluooee tolerance t!J~~. on a hJPoalyoaemlo 
agent 1a requlred, Mrs. D.R. (Caae 12'7) (See page 102) 
demo~trates thta phenomenon pertectly. t 
On 11.4.57 a completely normal gluooae 
tolerance teat (xv1) val aeen atter tolbutamide 
had been given tor one month. Her~attng blood 
glucoae befor• that waa over 300 mg., and abnormal 
glucoae tolerance testa, (e.g. on ~3.'7.68 (x1v) where 
the a hour level waa near 300 mg.), bad been 
eatabl1ehed over a period. When tolbutamide wae 
omitted tor 3 weeka, a glucose tolerance test 
(XY111) on 22.4.58 with a e hoUP lev$1 in the v1c1DitJ 
ot 400 mg. waa noted. Atter tb11, another much 
improved glucoae tolerance teet on chlorpropamide 
(xxl) vaa aeen e.t a time when she had developed 
eeoondary tolbutamide failure with tasting glucose 
levels again at 300 mg. 
Thus fluctuations tram grossly abnormal 
to normal curves have been demonstrated ln this 
case. 
It seems that we ma7 have to alter our 
previously held concept that an 1mprovement in 
glucose tolerance test does not occur. 
It a normal glucose tol~ranee curve bad 
been recorda d in pa t1ents who showed only a m114 
aberration ot the glucose tolerance test lt might 
bo argued tbat thiS phenomenon was merely a 
man1testat1on ot tbe blood glucose lowering ettect 
of the drugJ but the most striking rssJonaes 
were seen in patients with sross abnormalities ot 
tbs glucose tolerance_teat. 
It is possible that the reports 1n the 
11 te:rature of the type of changes seen 1n the 
glucose tolerance tosts bave been m1elead1ng. In 
a report on the results nf a joint investigation 
lll-'f 
ot the oral anti•diabetogeuic preparation, tolbutatrd.de, 
(D.eeo), held at F.rankturt/M on 8.12.55 and 8.1.66, 
aeyeral vorkera (G. St8tter, G. Mobnike, w. Creuts-
teldt, R. Seua, .St. Schlag1ntveit and B. UlriCh) 
contributed their experienc~a o~ the reaulta ot 
gluoo~e tolerance teata in patient• with tolbutamide. 
It vaa atated that with the Staub-Traugott tolerance 
teat the trend ot the blood gluooae ourYe waa 
practicallJ identical ln diabetes with and without 
tolbutamideJ only the level varied. 
Granville-Groaaman et al (1Q59) reported 
their experience on aluooae tolerance testa in 
11 patienta vbo had been treatet with chlorpropamide 
tor 6 weeki. The tirat gluooae tolerance teat 
waa done betore tbe oourae ot chlorpropamide and 
the aeoond aame weeka or mont~ after completion 
ot tbe courae, when the patient• were well 
controlled on diet. 1'he7 reported that all the 
blood sugar level• ot the sluooae tolerance teat 
had fallen after cblorpropam1de, but that the curve 
vaa atill abnormal. 
Duncan et al (1956) carried out oral 
slucoae toleranc• testa betore and during treatment 
ISO 
with oarbutamide (BZ 56) in 10 suooesstully treated 
oases. They reported that oarbutam!de was without 
etteot either on glucose tolerance or on the rate ot 
its absorption. Thus, the mean ot the oral glucose 
tolerance curves obtained in 10 responsive patients 
before and during treatment with oarbutamide show 2 
parallel ourveo throughout their tthole extent. 
It is difficult to reoonotle m7 findings 
on changes 1n the glucose tolerance test with the 
reports of the German workers on tolbutamide, and 
the work at EdlnbUl'gh on BZ 56 (Duncan et al 1956), 
and of others, (Granville-Grossman 1959) and also 
with the generally accepted view. 
Some co~nts can be madea-
In this stud7 a long·!!£! observation ot 
individual diabetics was undertaken and the course of 
fluctuations in glucose tolerance teat ot each 
diabetic was well-known. It was therefore not 
necessary to give an average of results obtained 
in a group of patients. Inclusion ot all 
diabetics with varying reeponses and giving the 
result in the average ma7 be misleading. 
lSI 
IS:Z. 
Was 1t possible that the inclusion of 
patients showins 2 contrasting tJ,Pel ot responaea 
in glucose tolerance test (like those seem in tbia 
lnYeatigation) would obscure the results seen, i.e. 
it Groups 1 and 2 were averaged would this not obscure 
the result seen in the group with rem!aalona in diabetes ? 
The report or changes ln glucose tolerance teats 
obaerYed before and during BZ 5& therapJ bJ Duncan et al 
(1956) vaa baaed on the changes produced 1n glucose 
tolerance testa after a 5 to 10 da7 period ot treatment. 
In the report bJ Granvllle•Groeaan (1959) the eecond 
aeries of glucose tolerance tests vaa done after the 
CO!!J?letion ot a 6 week course ot treatment and la thus 
not comparable to •7 sroup where patlente were still 
being treated at the ttme of the glucose tolerance testa. 
It 1a possible that the preaentl7 held concept 
that there 1s no im,provement in glucose tolerance 1a 
baaed on short term studies such as the ooe bJ Duncan 
et al (1956). It eeeu that this •J ~ the verz 
sisn1tlcant po1Dt ot difference between •J atud7 and 
those ot others. Whereas moat report• ot this nature 
were made on ahort term atudlea onl7, m7 atudJ was 
·. 
conducted on pat1enta, many ot whom bad had 
1nveatigat1ona on tluotuat1ons 1n glucose tolerance 
te•ta over a period ot 7eara (e.g. In the group 
showing remlaatona 1n glucose tolerance teats t~re 
were 6 patients whose course bad been observed bJ 
me tor 5- 19 ye~e), 
The :ttltl uence ot n COTIIAMIDE on the Fl. STING blood 
GLUCOSE level ot Ratienta on Pharmacoloslgal asehtat 
The adm1D1atrat1on ot n1cot1nam14e ooncurrentlJ 
with a hJPOglyoaem1c agent was not found to enhance 
lta hJPOg1ycaemic.action; on tbe contrary, an examination 
ot the result• •••med to auggeat that an elevat1ol1 ln 
tasting glucose level might have been tnduoed wben 
n1cot1nam1de was admlntaterect aa well as a aulphonylurea 
drug. 
: 
The. ·§1c()tlnamld~ .lie_~;u.~M,e , 1!1-l,te~ati<tp _tq, t~!J, Response 
to ·Bm_ otQx_ ·caem_··te_ asen_t!u 
'U , I f Jl' : --· '· . ;7 - ~ . t ··_ - · 
~u.cot~!ia~ttl4• _ ~pa . B:zeoatzcaemtc A'sentaa 
I . ; 
· To1~u~4e 
I 
' 1 _andar7 Ohlo:rp!'op• 
lfame C_a.ae i · Res onae Failure ~ amtde Re$ _Of!$~ 
D.ft. iev 
o •. $. 116 
M.A. .e 
t.·Iu 81 
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. ..., 
.... ' 
:' .. _': 
- ' .. '' Garb'l1tamide .. 1retponae aoo4 
... -C~buta.Jbi4e 
.re•p~i'Ule good 
. . '; . . : ~ . 
agents l~ 9 .oases who had ahown a satisfactorr remtssS.oJ:l 
• ·.- ... ,, •• - •• ' - '· < f . • • -. -
w.U~h llS.<Sotlnamde Jt-evealed ·tnat 6 ot t~eee ea~es lla.w. 
Bh<»W1i an lrdtlal rcua~poaae to ·tolbutaalde aad a to 'carbut..-4e. 
. . 
-B.c., (Caae aa) had ta11e4 to show an, respoase to tim 
· su1ph0il7111X'tas, but aubsequentlJ sbtmed. a goo4 i'e&potwe ,.o 
411 of the 6 cases whO showed an lnltltll 
1'-0&ponae to, to:lbu.tamtcle and were t~·11ow e4 up to_r a I · 
pertod of gears shoved a aeeontiat"-g .fa1lve ot 
response to tolbutamlao. 
Taus ~ patlents Who ite.<l $ho\$ a :N)Jllaud.on 
followed by a relapse 1n .alab·e·t&ti' (bet<>re tb.e 
pb.armaoo1og1oal as•'' bad beel\ preacrloed) showed 
.a sa·ttafaoto~y or excellent respcn$e to tolbutamlde 
tnlt!i.all.J• !'his rosponae grad.u.ally gave wa.y to 
complete ta11u.re -ot ..-oapons• w1~h a propea1sS.ve l'.1se 
ln fasting glucose levels,~eometl.rae$ to JOO llg•. Oi' mo~e. 
'lbls .flnCJ1ng may be s.:t.gnS.f'1cant: · a !"em1·ss1on 
a,.nd a rela.pae ·Of diabetes has been noted twlce in t.lle 
s'!'me patl·ents• .Has the ata.bet'$ changed tn. some waJ.• 
1.e. ·towards the severe ttpe OJ* Juvenile trpe 'I 
' ' 
This does not app&(lt' to.be the lS.kelJ' . 
explanation 'beoa~e ; ot thea~ p.e.ttenta who vre:ve trted . 
lSS 
on anothel" .sulphcmrlur.ea cJp.ug,. ~bl.ol'pl'Of'amlde,. snowe.a a 
reiPOJIS«t wl11Ch oo\ild be olasstd ·il&tlstactory or ex.oel'lent. 
SUMJ&ARY: 
1. In this section the hypoglyoaemtc action 
ot the various agents has been demonstrated. The 





Isobuzole was not found to be an effective 
hypoglycaemio ngent in the patients in whom it was 
used. 
2. The guanidine derivatives may be effective 
where the s~lpbonylureas have failed. 
'· Chlorpropamide may be effective where there 
was primary or secondary tolbutamide failure. 
4• The tasting glucose level, although n 
very good index of ?Jhether a patient showed response 
or not to a hypoglycaem1c agent, was not as~good an 
index as the glucose tolerance test of the extent 
of improvement. 
[si, 
s. In the glucose tolerance tests it was 
seen that the hypoglycaemio agents produced a 
change w.hen compared w1 th glucose tolerance teats 
IS1 
done previously• Where a good response in ~asting level 
was seen : 
(1) In 9 patients there was merely a lowering ot 
the fasting blood glucose levels. the later 
figures of tbe glucose tolerance test remaining 
elevated. 
(11) In 14 patients a marked improvement in glucose 
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A STUDY OF 2A~~BYIRl'1'E TOLEBANCE 111 I OOU'l'. 
thes-e ex.lata a lara• sro"p ot dlabetlo. ln 
whoa tbe dlaturbance ot oarbobJdrate metabollam 
la not dependent on loaulln lack (BornatelD et al 
1951 (a) and (b) ) • Recent advance a 111 our 
know·ledge b&Ye talled to tbrow oucb. llght on tbla 
aroup, and the .. tabollo leelon 1o cllabetea-..llltua-
wlthout•iD•ulln-deflclenoJ atlll reaalna Qftkoovn. 
T~ dlacoYerJ of alloxan•lndaced dlabetea 
(Dwm et al 194J) opened l.lp a new field tor 
lDveat1gat1on and acted aa a atlmulua to reaearcb 
worker• 1n tbelr attempt to dteoover eo .. naturallJ 
occurring cllabetogelllo agent el ther ln the dlet or 
aa a reault ot a dlat~bance of lGteroal .. tabo11••• 
The formula ot allosan reaeablea the pJrlmldlne 
part ot the ulo acid molect1le and lt la poaalble that 
a aubatanoe aucb •• allos.D or one oloaelJ related to 
lt oocQra ln man as a rea.alt ot nucleo-protein 
breakdo.n (Loubatleree 1954). 
It •••• reucmabl• to •~peot that auob. a 
prOduct •J occur to •xo••• S.n a dermp•nt of 
nuoleo•protelll ••tabollam, ••8• •• ln gout. 
AooordlnglJ' the tollovlng lnveatlgatS.on 
11 conoerDed vlth tbe ••adJ of carbohr4rate 
tolerance ln gout. 
~TBRIAJ'B AWD f:!UIOJ?§ 1 
Patleata Who v•r• known to have gout were 
••k•d to report tor a bloOd augar teat after a 
12 bour taat. At t1rat a aodltled slucoae tol•ranoe 
teat, U .••• taltlng, 1 and 2 hOllr levela) vaa abo 
done on all the patlente-. Sube•quentlr cmlJ tho•• 
Vltb a auaplolou.lJ blab r.attns blood ausar leYel 
we.. ..ked to report baok tor a aodlfl•d gluooae 
toleranc• t•t• 
82 patluta wo weN ubulant repo•t•d tor 
a faatlDg bloOd augar teat, tmd 46 or the1e bad a 
modltled alucoee tol•rance teat done aa well. 
the ocmtl'Ol group vaa •4• up ot 27 allbulant 
DOD•gOUtJ &Ptbrltlo patl~tl att•ndlQS to• 
160 
• 
Groote BobQ\ltt -lostltal ~out•patlents! 'Deputment. 
Tli._e •ttenta weM tJlld.1u11,.&1kt4 ~o Jtepoi-t toJi 
tastlas' blood alucoae- ea-timal(otw.- -
The,,. • .., t•o'tullolu 41d tb.e testa oa 'h• 
soatJ- ucl ooatnl SI'OtAJB. · 
Tat M'tllo\1 Ultd ~t11bi.JU.t\ W&l the 
laa•doa.aeoeera. aie~aoa 11e&ca blooO ob•u•et trou. 
·tb.t ntss••tt.p. 
· (iJ'bte iftYeett.satlon of rea,.~drate _ __ 
to1eJ-anoe -Ill {tOGt ue· oon<Jutt<l fu&tll •• ~noa 
Oe\Ober 1955 to luae l9S6 ~ - - ~ 
ltoUstla Wl'iO w•~• toQl'lt to bGv• 4iahtea 
wer• rete.,nd to ttte tla.betle .p11a•o wb••• th•J 
ve.a atMd'lttd ta~D.e• and .·were ·•tl:ll •-~ Jab.$&otl 
of tut})e• Oltlel!'vattou whlob taave ooa~lfti14Sd to 
tb• ••• •t wt.tins). 
tao gen.erallJ -accepted tlau.ea t• tbe 
llPP*l' 1trd.t ot aormalltr t.n tll& etuco.• to:leNAoe teat 
bi the hs,edoM-Ieuen melbod Cuellle .oept.1 ... J blood) 
are (KoaeatbGl •• al 19,0. £aveoe 1941) s• 
. . 
:Peetlq bl.ooo c1•ooee 
1 bOiltt J..vel 





To allow to• the pOsa.lbh .Preseo.c• ot 
l'ttthacln.a eu\uate.ncea other than· gl~oae i.A eoutp 
patleota ('flOe Dl$CU:SSI.OB page /7o ). 1 bav .. :ws .. 4 
even •··· ttlgld o»iter.ta ot abn<ttt~lltr then 
. lndLcated abOve, vlz .. :J 
1. .hoar 1e9e1a 
2 bO~ le'f.lt 
g"ater tbaa 2,0. mg. 
g,eater tau ~so 1111• 
tb•r• ...... 10 ••ttftt.t• 4lab6tS.oe u.~·· taJC) 
tn the e;rowp ot 82 · goutr patlqp.to (bJ,~! al'l the 
stttlftgent erl·tel'ta) • 
· Aft. e1evatect ta.tlAS b10C4 glucose level i.e 
probablJ t.be most ccmelblve test tor 6labttea 
.melUttl$ (Hosent\\al et al 19;0 ). 
1'.1.\flt.lq blOOd g1·1AC0~8 1eve18 o.t 120 • .·150 fl11• 
b.ave to ·be oOlUiliered preauDJP,l'felr •ba._.mal .md lt ' . . 
t.• S.ateM-ttlng to ''r.GGora tbat tbe .taats.Qg 'bloOd a~ 
. ' 
vaa o-ve• 120 Bll• in J2 patlmtt ~$9 It) ot tlW .sout; 
gf!Ollp• 
. -- '• 











~11•. to11ows. .. a 1• .. an .aaalJcia or· tbe 
Hltllttor the testa ln these .32 l)atl.eatl ·tJb.o, 
acoordllag to ov u.ewtllf $0cepte4 4r.LteJt1a, bave 
to be e.ouldet'ed dlabetlc u ,.. .... U.abet1o .: 
Ot the rema·t.nt.~~& :22 ,tJ,tl•fttfJ •tth .tal:tlas , 
· blo~ sluoo••· valu~t oftr 1.20 t1B~• ·' pl\tlentt ·~lltl4 
e :blgll one b.Ou 'letei (appMXlmatelf 220 tn:B•) •aa . . 
a tul'th\\r 2 b.tl4 a h~gb 2 bo~ 'le'\181 u.e; mg •. ad 
1.46 mg .• ). 
Ttto :nore r.m•ltl\'& wlt;b. taetlag blood 
1'1UJ'l~$$ $Uap1ctoa.s1J ~d.gb, (l,f:f~ ·mg., and 13fl tnl•) 
failed to ... cpoz.t lNlck .tor· a &ill.OOP8 to1e.raace teet .• 
'lbWI bJ .leae r·~gCd orl.teJ'la,. there mal o. 
u •44ltl.ou1 1 ctt.abetloa, sktq a total tf 1,1 
dlabetloa (2~ ~.) out ot f2 gOl.\t)l patf.e&tc J the . . 
reatatnS.a.s 1$ goutr pa t;lenta •r ht to a pre•4labetlo 
pbate • . 
See faclne page tor giuooee tole.r•o.e tests 
. . 










·· ... -· 
... . .... 
A COMPARISON BETWEEN FASTING BLOOD GLUCOSE LEVELS ~OF .AUTHOR'S GOUTY 
AND CONTROL ARTHRITIC GROUP OF' PATIENTS .. 
<90 91-100 101-110. 11'1·-120" • 121:-130 131-140 >140 
FAST I N G BLOOO GLUCOSE (MGMS. %) 
... 
f • 
· .. ~-'" ·.• 
Itt the ooatPol gro.ap ot arthrltlo pat,leata 
(eacfladlng go.atJ patl•Ats:), onlr one patient _otat 
of :~1 had :a tastlfts b1ooa augu val\18 ove• 1.10 •ID8• 
- tb.le patleat waa tot.tnd to be dlabett.c. 
A oo~pe.rlaoa between the taet1ng blood 
elliJU" values ,of bOtb sroupa ibowe cl•arlg that tb.e 
soutr. gpov.p has hlgh&l' t.aetlns. blood eu.aar ·v_aluea 
·ttto.tt the artult1c ·lf'OllP (8ee t~lg.. taclf18 page}. 
'!'here ue J poaelb1e eJtplen·atlone tor _tbla 
bt.Sb laoldenoe ot abnormal oe.Pb0~4rate tolettariCe 
.la· sou,:• 
.1· ... 
2. tlu\t aft LQ.termecU.al'J prodt.tc' ot nuoleo•pntelb 
brealt4owo naultlq .from tib.t dletU!'l:taace or metabOllem 
tra. gout acto ae a dlabotogenlo agent 01' that the 
''q. 
118tabolt.o abeHat1on raapGnalbl• tor gout la alao 
raaponalble for a aubaldlarr abno..a1ltJ in 
carbohJdnte •tab011••• 
In dlaou•aS.ag tb• ttrat o.r the•• poaalbl• 
axplanatlona tor the high lncldenoe ot abnormal 
oarbObJdrate toleraace 1a gout, vla. that lt la 
pvelJ co1ncldenta1, the atteot of Yoloua factor• 
lofluenclng glucoaa toleran .. .uat be lh•eatlgatea. 














lnclualon ot non•gluooae reduolQs aubatano••• 
Tr•tment wltb. o.oJttlaone. 
U.) !otlvlg; 
1 t baa been ahovn bJ Blotner ( 1945) tb.at 
p»olonged oontlne .. nt to bed ta reaponalbl• to• an 
abnor•l oarbohfdrate tol••anoe arld that Mauaaptlon 
FIG. 3. 
A COMPARISON OF F.B.S. LEVELS OF 
A ·GROUP OF AMBULANT GOUTY PATIENTS AND 
A GROUP OF AMBULANT ARTHRITIS PATIENTS AND 
A GROUP OF BED- RIDDEN PAnENTS. 
70-105MGMS. 106-1241>1GMS. 125-140MGMS. 141TMGMS. 
(±130) 
FASTING BLOOD SUGAR LEVELS. 




. . ~·"' .... 
. ln fll, e .. tu4J, tn• 1)1006 ~~-_. · testa we .. 
·mac1c oa MbQl!Q$ tst·•IJ!jlf!l)tl• 
. . 
lt la lbtet-eotlng to ooiopare the taetlng 
'blood au.gu 'V&1Ue8 ln BlotnePla bed•rldden pa.tleQtS 
wlth those ot «9. 2 .grou.pa ot paid .• ts · (See l.'lg. 
. . . 
. taot.ag page). 41~b.O. 'ttl' ma.,orltr t>t Bl.otner •a 
.. :pa:tler~.ts bad • abt\oJtal e&i'bObfdrat:e. tol6rMOtt tb.e 
. tu:*£ag \llood *'USar teat$ :w.ro aorJJal. 
It le sene;rallJ'_&coepte4 that e aeve.-elr 
•. ·! 
l'eat,loted dlet oen i.m:stalr glttto•• tolettanoe (Cou 
1940, Blmswol'tb 19J5) • 
the da11J earbob.f\1J.'ate tntaJte .aeed not be 
ae blab ·&W auq•s~etl bJ Cono. £,•fit 300 G• Cru.Cl$1 
tlgQIJet tor d~11i caatbObJ4rate toteke "" pPObabJ.r 
be\tteeD so e. ' 12S •~ (Mosenthal. et a11950~ lrvtna 
•t &1 '1954). 
It aeams Jj.kelJ _that ·tb;e ~~mal at.et of u 
aa-.quatelr ftoarla-ed pettl•nt (auob as those ln. tlill 
, .at•ar>. n.eea not be a~smen••• batoN· ,aolas a: &ltJooae 
I 
... 
gl"co•• tolel'anoe teat uae -obtatned, the. pcatlent 
wae &$k:td a"bout J;.ts diet• tb.& oe'botqdrate intake 
we.e foun4 to b& .. we.ll abov~ 125 <'~• end "sua11J .in · 
tbe a-eglon of JOO Q • 
(GOUtJ patsienta WhO WOJ'I toun~ .to bave 
o. cU.a"bt·tlo .g111coee tole...-• ·t•t were Jteferred ·to 
tile atabetl<J ollalf> tor to·l.lov•u.f.t• Dlabetea waa 
contlrmed and ae'veral ot thea$ ·Plltieato· 'bad gluoao 
toltraftoe teste ••peated (one c.r moJ'e) • OD6 week attel' 
betns on a diet c"'talnto.s JOO G·• oa~bObJdt'a.t~· dellJ)• 
group •. 
lb1 
Ike maJo.t-1'' ot Al't'Al'ltlca ln. 'be cont;,rol sroup 
wette ot tho· obeae tJpe alao.- · 
.. ~ . ~ 
%t ·i.e a wo11kno..m. ta.ct tbat tnt> malo.-ttr flf 
. - ' '· :: , .. ·; . ' . 
dlaHtlo patJ.•ilts of the •tv.ntr~nset. ~~,. are (or 
have· bee a) obese (.los1ta 1952 .) ·• 
. . . 
· Hospital . -epot-ta on the lac14ence or .dlabetee . . . 
ln obea1tJ ue ooatllotlq .an4 11$t.'f •tten talG,ieactlng 
t>eoauae Joae ·,at1ente 1ilo1u'd$d l• ,.._. ol)fltee srou; 
mttJ ,C)oa '.to hoaplta.1 onir btc'fl(&$e atlP,: is 'fo86 
Ia th&Lr ur1~te (t!:m'Oletoa. 19;8) ~· 
(19) .. ~!-.1 
' ' 
of cU.abete·a . me111,ua '"-. fell.tilta. .$$ aaut twloe that . 
ln ~lea ·(Bat'i.oaal B·dltb .BU'f'O'eg tr.s .A .•. 1935 ·• J6 )·. 
Before that age, s•:Jt ls .flo:t an tmpOI'tat fae'bo~. 
Gout atte•t• males at.alg • a4 thus, th$ 
· · tlztcllng of a lnottttaaecl tacS.ftAce ot abAot-mal 
carbobfdnte to 1eNnce S.a a predomtuntlJ male SN\I.P; . 
enhcmotte the elgat.tl~umce or t:bJ..a· .ttacU.ng. 
' ' ' 
· !.rae soutr gMup oott81tted •' 74 ales W 
8 femel••• tho numb&~ of deflbtte dlabettee in 
tbt.a gNup waa maae up ot 9 at,e8 ana 1 female, t..e. 
amt. 4l4 aot ~eau,· bave _, sl$1tiltlcut iat·tu.eAoe. 
Xc the ertb.lttt!.o gl'OUfi ~here uero 4 
malel aad 2J tema1eth 'fbe ••• lttaa, auott ea S.t le, 





'Pb.f'J tollow11lS .. table &bows tba age 
eompoettlon of tbe goutg ana the atttbJ:tlt1c groups~ 
uaaer · 30 · · 2 ·1·.2•41'. · · ... ! 
51 • 40 . J 1$ 16 1i. 
41 • ;o. 1 !J 28 -
51 • .6o .I a3 aa·~ ' . . I. . 
.. ' 1 
•• 
•• 
.. ) 61 - 70 I , 11a. 117 iJ 2 .. 
. I. . , 
~. " ~~~I . ~.1 ~.~~ ... J · ~- .•• • .u.....·~~-~~~....._.· -~~-_. ,_ 
A. oomparlaon· ot •• ·,qes ot the 2 · aroupa· 
shows a tG1v1J etmllu .age: :dle~r$.1>uti~n ·· pa1iteft1.· 
Moeentbal et .ai (1950) · te>un<t that ~lJ.sa• 
tol.,rance· lc o14 age tlld not dltter trom that tn 
;rou.ager- psNona : "In the · age4 ~et'e was · ao l~Apal.,~t 
ot glucose ·tolt)rtmce. 'lb.i.s le eofit.Pal"f to ac•eptoa 
beitets, whl.ch bave been la•a•~ · baaed ·on b.oapt. ta1lae4 




Ul'lc. ac:ld and oHotf.A'M 1$vels wll1oh UJ 
be H.lr:.ed 1a _goat woQ.td produce u lR&'18llltteut ett&ct 
ftus- 1t waa f'cttnd that 9•4 GIJ-~ -ot ·urto ac14 
n<tdU:ced 6 ••tu.clns 11•lu.e tohl.oh We.$ negl.ts:Lble •. vlz.-
1 mg.,; bJ the ·Jiage4t~>m·-l~aen lt&thod. 15•6 mB• 
treatlnl-ne produceti a r.auclttg .-Q.ue or eniJ 9 ~s-~ 
·{.Rl.ller, Lltl6&l' Q.d van Sl,ke 1925)• 
'l!bt.e .has agalo been contlnoa t-e«Htnt.1J : 
tltphe NdLloi.na val® ot urle rutld and ~r:eot1rt1ae ln 'b.& 
ambu.lml t goatJ patient wot1ld .-us not M li't" than 
S ~·-• •• a 1tbsJial eetS.mate :(~fQ• .Linder • Personal 
commu.nlcatloa, 19;6).• 
,Patle.ata wltb. u-tbtttl6 anti ~p\lt tlr'e :Otten 
troated ws. tb. .cr.trtle()ne "' -
- . -
pou.p ·hat ;cc,rtteoae wltb.oat or o'bvlot~~~ lmpal~ment. 
' l 
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bl"a e\lsu 1eveu. 
ar• utt<lU1J $Uso.ept1b1e to the 4S.abe~oseatc etteo' . 
. . 
of oortl•cne, l.e. tt\Qt .. the aoutr grot.tp •J ~. 
pH•dle.b(ftlc. ~hl$ U atscht_.&.d ~.ir-UleJ. J.n tbe 
llatb.ogeneale ot »1abetel•i.A-Gou.t •.... · 
~ven wha all these B4ltgltts toetora 
are taken into iacoouat. tlieJ etl11 4o ao·ti •x,laln. 
thts lnc•eaaed J.ne~4enco ot abaor:mal tD&t<bOliJdP&te 
tolerance aao l:l1&h ta&tlng blo~ ~u.sa• val~s la 
go'lt·• ·· fhu 1 ao~Jo tactor. ep"l:tt.oa11J zte1ate4 to 
cou.t, •r be res;po~elble toJ:t·. tl\.,, &1,)l'!¢il'lm11f)J &a· 
ouh0i\f4l'att metabolt.1m. · 
it s.a tt).be ~otetl tut tho .HPOJt"t bJ 
V&tet et al (1,57) tbl\t a l\1#1 p~,.eataae of ao~'' 
pattfn-te have ·ele'fated blooS eu,au le'lela, •44a 
&Gp}iiOrt to the tJ.n41np of mt tzr~n~:etlptt••• 
rtt 
The ettttactJUtnl fori!1ulae C)f Ul'1o aald ad 
alloxaa are abo1-nu 
Hi-1=0 H~-y=O 
O=C C-NH O=C C=O 
I I )c=o I I 
HN-C-NH · HN-C=O 
URIC ACID ALLOXAN 
2.4.5.6 TETRA-
0XYPYRIMIDINE 
All.ouu le one ot tbe beet J.m.otm ana moat 
•tu.~U·•<~ ct dlabetogonlo agent• in cut1mal• (Dwm •t al 
1'4') • and tt bne beeD clearly shown that ~MD 1• •• 
atUJceptS.blre an othe' 11peoles (Oomt (Itt al 1948). 
the dittloultJ 1b 4s,eettag alloxan lo 
tweaan plaea DJ be 4ae tc ltl extreme •••etlvltJ 
(I.ou'batleres 1954>• 
:tt b.a• been euggeated tbat a11oan or a 
related eubetance ma: ocour aa ac tnto•me4la•r product 
17:L 
. ·. 
'the -PJrlad.cllae ttl'n.g Of url·o aolc1 l'et.e!DbUa' 
.alluen atNeturallJ end ur be . •••betogenlo ttr 
vlrtu.e ot S.·te ·•ontlsuntloa at poaltloaa 1, 2 ,llJUI J• 
Dlabetea melll tu.e baa "''n tn4uce4 ln 
slutatb·tone 6&f1olent rabblts bf .lnJeotl.ttg tb.em •S.th 
urtc aold (Gi'lftltb8 19li.S ·ad 19SO), 
A t'emartcable correlatS.tm between go11t ana 
cU.abetoa cuclata ln th• plaeon 11b.ere ~· lb.Jeetloa 
or alloxan waa show to caaae the ·develop.rneAt ot 
diabetes -.111tua and aa ln.teaae to..- ot '9laoeral 
~goat (Golaner et .a]. 1945, Gouaex- 1945>• 
In ..-•.. ttte ~l'l\1D1bo·z' · o_t ·;iltl:ata wJ.th soat 
ooour1as l~· ass·o·clation ui·t.b..-atcd.Mtee 1bel11tua ••• 
toa4 bJ loatb (19;2 .) to be e:UJ.1, vs.z. lea a tl\at& 1 
(See Adaexutam at end ol tb.le .&octlon for - ' . ' . . ·- -· 
.tarihet- e&p$P1e•o• at OW!' 4la-etil.o cllnlc ) • However, 
a blgb. lnctdence ot dlabetoe me11lttaa baa l,)•en reported 
·~ ' 
ln 'he temJ.).tea of pa·tlenta wtth gou•J arthl-lt$.a (Iebmae1 
194') •. 
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Apart from the tact that gout and. diabetes 
melli tua are both dlatarbances of metabol1sm, theJ 
sbare certain other features, v1z• Both con41t1oas 
occur more eommonlJ in association with obesltyJ 
their late oompl1cat1ons too ax-e a1m11ar, e.g. k14neJ• 
disease with tho emphasis on vascular sc~erosiSJ 
there is an 1ncrease4 1no1denoe ot h"Jpertens1onJ anci 
there le a high 1no14enoe ot hfpercholesterolaem1a 
with aooompaDJ1ng ooronarJ atberoaclerosis 1n both 
conditions. 
'l'ba features that are common to both gout and 
diabetes can be shown d.lagrammat1callJ as follows 1 










A to11ow•u.p of tl\Oillt:patl~P ·ta tb.tl aoatJ 
' 
&JIG liP whO were touad tO ~be dlatittlc, ew.a4·. :that.- · · · 
theJ be1oras•B to the zne. turl tJ.WO:QSt·t•tJP'· ot -4&abetos. -
All· but one .ttetpoJldod to t;be uua1 to•as ot treatment. 
9le. diet oa- oral b.J'Poalroatlll.o .,,.,.. fbt -•• ·· 
exoeptlon WhO .l'e4,\ll'r•d lASU,ila Wfl8 a Baatll• !he 
ooclll'r&nce of e:ltbef aoat o• dla~ee ·t.a the ik\n-u 
./75 
.-aoe le sald :to It tar• 1 the tlatJlGg of the ta · 1H~get'ber 
dl.s t~H.tf)H alll'prlslns and perhlPJ a~ipt.tlcuc. · 
fttt1lm1llUJ obser11ati.OJ:l$ .·(See. ~IG!IOJ Vll) \)J 
the :6\ltbor atem to G\lSSct&t that •\ltJ pa,s.ea•• m&\J be 
W'ldllll p"ne to the 4labe,ogel)lo effect ot oortla••• 
fl\le doea not .appear to 'be to 1n tbe artnri tlc group.. so• 
· ot Whom Md eorts.eone. 
Cona et a1 (1948 (a) an4 ('b) ) llave .sugtated 
that the ~baottall·tr ct car'boltr4.-ate metabo1l•• 
tollowt.ns coJttJ.eone adtamle\;ra~l.ou puallels _the lnoreae&cl 
pz-odactlon ot urlc act.d (Fottaha·m ot al 1948)~ .mo 
pr•aua•1.Jt also 8A 1noreaae,d p!'o<i.aotloa or S.atepmedlariee 
in ~u.to acid Mtab011am. 
tbat aoao 1ntel'lltldJ.ar, pro<Juot of pvlne metabollam· 
lu aout ts reapoaail)ltt ffn! ·th& deve1op•nt of ta• 
am.,.aa11tJ 111 oarbobf4raw metabolism. aortl•CJA• 
•1 aoo.ato.ate tbl• abAormallti,. 
COtUl et al (1948 (a) an.d (b), 194.9) b.ava 
eb.own a re4uotS.on 111 bloOd gluta.iihlone dllrlns A.c .• T.H. 
admlalet.ratton. Alloxan alao prodY.cea a prmopt atu:l 
eeven rteduoticm SA glu,atb.lone (Leeltb ., al 1945). 
D1abetea hu bee:a ln&loed wlth urlc ao.S.4 
lD glatat!done aetJ.cleat· ••'bblt;a (Orlftltha· 1948 ). 
A poeelble mechut.am ot. production ot diabetes 
la geU:t OQU be dlat..ra.ats.o.-111 ehovn thus' 
. ' 
t~le~ance \wac to•d la a. g.l*O~f ot 82 acnbulut so"'' . 
patlentth file taat~llS blood .G\lSS:P levela we•e 
ai.pttleaatll hlgbe.- in •• aotltJ patients aa OOJ$ueci 
wlth-tho coatro1 group of a•th»ltl.oa. 
·' - " 
' 
the elplft.oonce ot ·t;n·ts ant~ tbe pathoaeaeala 
ot <liabetea ln. gena' a" CIJ.tops•~<~ ln tills •rt·lclo • 
. ·• 
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ID •• dt.abetlo cltalo tbeN 'DN • fUJ.Ithe• 4 
oaaec ·or 41.abettt I.e asooolatl4m :vl'* pmt. ('lta.eee 
•• ,. _.,.,,, .,..,. tb& eomple't~l .tJI ., .•tll4J ., 
oe.rbOhJdnt• tol••anoe 1-r. goat1 a\1 ••• net ltlol·acted 
ln tbe· f~llill*B &a tbla etud»;l• 
· U.) .. a~,.A• . (fld!t · ll .t. t. Q.l ... tt ~.. Mt<l .Sl .Jo~•• 
<Jl®Oae toleJ':naoo ·ttot.t ·. -2$0. JSJ• 480.,. tt.ot. )61. · 
Ctl) u.w. (Ou• 1'4»-• • ~poan m111. ag.a 6t geo.ra. 
(»l•o•••e4 1ft seotlo~t· VU) •. 
~-~t~ 111.e. 'laqe 401-8. Of' •a«G~IA. 
A.B. (Qat• ;ttl. a -~~- .a.· ,agd 47 jean. . . . . ~ - ., 
GiliU.Oifl tt~lel'~.mj$ te-• t · · 
,, lJO · ~;: 9 1 _ttov 12' ·••• 2 hot~• .110 liS• 
('fb~ pa~t.C\t ked . ;~n;~te•IJ. ba·d· diantle 
~ae's.D8 l~••ll autl bad ~ ••••te4 u • 
4la\:tltlo~ .. ' ' . . 
JI..G• (Cae, 1J9)~. ·A .&lDO!*lll'WlDll• ·. 
(t>t:_e;bete' eatabllO.ett tor- 2 J&•••· . i~l•at 
ettaok Of \JPleel aottte.soutJ utb~tlt~e Ia 
Mtat&"O~lanaed. :·j61,.nt. at -a•. Of 12 JbUI 
ocounf wbllo ···eotU.vt.qlhe au1Jb.OAJ1vea 
4Jiq.). ' . . ' . ' 
'I'll. 
$TUJ)ll!S OJ Tim Bl~''f'Mfi Olr TlW A~AL OOWl'lCAu 
i!C·rt -,.- JU:I z=lfilll-i.~1 ;e s·ro•=n=·)w=·····z- ~'f# iHGJl "'13!'#l_C.=r=li=tt=.=••Mffli.UJI tr ;;•; --, ! ll ~ !{= iilb!t&. 
ftJt:R~ ON OAftaollillM'SS. DASf$1SM at -
-1f:#~MIIt tlr i' f.Jt ;r __ 'I -· c•nel!" ]) $Jf_fli_C;¢W·-· Hjf41!!1ifllJ!I., li ···r==='."'* $1':ra 
COm.'l:OOIWF..BOltlS Aim DXAm~JmJ Di fi\1 
SfJ!HtAJS ,Atf£) :.maO})S 
ratleatG lD tld.o avu4s· 
mHODS ot STtmY 
CORlJ:SOW/GVJC0~•8 GISMN'CJI t;t~· 
' 
,._~tlon t<r~ :s 
lat~P'•·tat:loa 
Ob 3•• ot ttteae teet.a 
'*''· 
C0RT::tc0~8TER0lr.6 IS GOt~: 












aortlaoae h th• GoUtf Pat'leQt$ O.'t lalla Std)' 190 
~Vltfl ft I QOWJ PA!n~RS 192 
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II• COJll!J901m/OLU®SI 1!0tm'iAUC.il t.fSS!S 11\t PATIF..mca 
Uot 01$ BnOGLYCAmiXC IU&l!S 
A, P~.ttlate wltb IOBMAL Gluooae Toleren,ce teeet 198 
9. Patlsts wltb Dla'betea in BEMltSR til 100 
0;• P'IJlbe,loa DOt a S,ft'IO;lJMemlO A,SJfit.d~l 2€lJ 
Nlvett.MUIWo 8AfJ 6~t'1eGl'l$ tiJD'bQOOernent 20fS 
· Dt&cua.oJ.on. at Bernal's '(A, B;er c.) tOT 
·' 
ll~t PATlmt$ tBIAtrBD tflTB ISAI,i!fA,CCLOGIOAL 
:IDOGLYCUMIC .A~WIS • . . 211 
•• ,.,,. 22.J 
iHAL'IS;t& ~Iii RS'JJUtJrS 
tlmtf.tSOIE. Dm!AIO.Ef.UW · 15 .REU~tOit 'flO 'IBB 
flmDSQRJ.n GOGRIE ot lllA:BsrttS . 221· 
»JSCUSQ.ON OF RSSliiitS' 22t 
OWCJ.il&%011 2J8 
Jll.tb.erte ve have been 4ea1S:og wlth tb.e 
etteeta .ln man of pbJ&1olosl~fll o.r p1iar•eo1ogt.oa1 
aaeata wbtob Gt~& belteYetll to ltnpf'ove oarbohJdJtatt 
to1er-uoe by ·vl.rtue ot·theltt hfPtslroaemt.o ac~ton.. 
We aow co• ·to the adreot.l oor-.loal 
I'Ko 
aterold8,i Wheb etfect ·on eerbob74.-.te metabolism 
b.ae been ••t.,..11fe1J. atuc:tS.ed .$:J1 -'Vitro., ln tntact 
elf.peJtlt~ente.1 •~1mala ant ln ~. . The cortl.eosterol4& 
have !l>tttJft .shO'Wll to be dlebatogtltl.o l••se.lJ bJ virtue 
or their abt.lttr to ~stlmlllate. lttotteaeea b.epatS.o 
a1ucon.eogeneata _(~hori et a1 1951,. 
tzhe tlme lapae between tbe admlBistJtatto-a 
·ot the bo=oua ·-.4 the tlrlt · appear>anoe. ot . 
evleleue·al.taesti.na 1a.ereaee4 gh.looneos•neela 1a 
&fwe>xtma,•1J ono to t\Uto.e b.Ou:Jtl .cm4 1t ttle aam.e 
tn the latact.h\lta~n orgaa!am end ·tn tlaaa&a 
tsolated fttom trf>atea e.nf.ma1a. 
. .:· 
~hom et al (1951) ba,e. lJ.ated GOmtt .. 
. , etteota of glUOOO<:f.l'tioo.$.48 0¥'1 tlt811ttl l 
IftC1"······ s1JCOS6A ctepo$1.'t1on (1lve,,. 




(lll). IncreasacJ gluooae ep'tb.eate from·pgruvate (lS.ver). 
'" ,· ' 
(tv} 
(J} 
Iuoreaaea release. ot a:ms..o .... aotaa hnuaoie • llve•), 
Deo-.ea.eea llpos•••'• (l••••• l'tt&lilit!&U'J g1arul, 
oarcaas). 
" . ' "'. 1 ' 
fhtae ••tb.o•• potat· out· that ther ue 
u ,.,· unabi.e· •• aaa·t-· 4teo~•C.· aet81ij);l.u eltee 
. . ' . . . ~ 
to &aJ ot ·theae etteotl; let• alGJl~ .. aggseet;· a prla.DI 
al. tie ot oort~c;;oatorola .ao\lotl widoa coul4 •••••t 
£o.r all tbtd.r kncnm motabolle .er.teote • . ,, 
Wh& blah t~nct4eme(l· ;~ .t;'bnormal a1u.coae 
tolerance b :patlmto •t.Cb.· .Qubtng •• e.pci .. ome 
(whlon lc;J ae,ootated with· gluco<~~~rCortloota ••••••) · 
te . veil lmO'Wlh . 
Pt.Jau and o-. (19;4.)· ••• reported 
'hilt a1uooae toleraace teete c•r.•leci ou.t sllo•tlJ 
·' 
atter the aamlntstrat1on .. of gluco~corticoS.ds .,. ' 
unmask a ·group cf pot&rit~till d!.abetl.o patients •. 
a&.Nft Oompeasated bJ;ti.apptaoael'dug d8CJ?•P-~tat10nt 
t~e. tile1: iuav~ •sea the d1abt~to·g.en$.:c. ette•t ct 
:cotttlson~ _ e;e,- ·a maans or teru;tb.s i-ihJther . dlabetes 
votllti .4tV'·$W' .in t·ne f~t~tt; · . ·nts.e · met;hcxJ 'ot 
establl.shlng ·whethellf a $ubj$Ct 1~ · ·t.pl"e:•ataliettc ·• 
baa stln.tule.tES~· gJteat· 1a:t$t-&st and ·(tJtten$1Ve studies 
tt.1.. ' 
en' th~ae lu\ea have· bGen ·witSer~Jk&n in· V4J;'I~tt$ O@.tl!es •. 
Conn. himself bas ~stated that 1t .wettl.Cl take me.ny 3~a~s 
t¢ ~statblS.~b whether sub'jeets· a~agntu!h~d ~f!-·. h$l~s.,. 
p~$••H.ab8ttc bf "tbls ;te$t wpo.ld S,n te.tt d$Velop 
' . ' 
.al.a'betes .latel'. · 
ln th.la the•lt; the object was riot to 
repeat tb;e. wo~k tbat has be$n don• l)y · Oortn on· tilf;t · 
•$nhane&1Jl&nt ot · the glucose tole~tance ~est in. nQI-11la1 
eubJects, but ratb.er··to .:us.e ·cbrt!:s~&:~s • m"ana ,ot 
fiU'ther ·&l'ttc;t.aatlng ·,certain: ·problems wb.loh oec\Utred 
· tri the ooU&tae · ·ot · tbl~ · stua, • 
' ' . 
'Thus~·. in th~ .lnve$.t~s~tict1S earrte~ ·out. ·tn 
the present etua1 ~ the ·to!"t:S.aone/glueos,e tolerance 
' . 
Cf~t WU det ClB a~~·- ot ,fut'tht•·1nVG8~ia•tJas 
.oU.l.W$rttrate iote~nce ·tll ttt~ tollovtns .tj,.a .. 
' I .. , 
! · ( i. : '. ·, •.·· .. ' . r) : '., ;· ,·, 
A ,pou, ot goGtJ P$'til•t• •~• teatet 
. . ' ' , \ ' : ' ~ 
Sorru• of the :p•av . - .4laberttos · cb.ow•tt • 
· ttJ11tit» ·tn 4lalulttta ·•tob ~~s.ett«l la spl'e of 
•lt'b.Mla!.ng t~~at~Mm' eoP atebftteo~ l .• e. a . ' ' . . 
epOatetoua rcm:t.aa&tOAJ m oiae:H, • rem.l.ta1on 
·"at tnt•••• atl4 matatal.t.uJUJ )J ti$·lf11 bJ"J0&1Joceme 
agtratm. WhAt wou14 'be· tb.e wau.aoe of col'tlecu· 
'. '. 
StU.l1 otb&N •ea-e rete•w4 to the· 
<tlQI,:lo ollnlo vba 'ba4 bfee p"vlou1r conel4end 
4hbetlot ,.a t.Nated •• tt.~cb..~ e~s• ..d.tth. ~1la). 
lowtve~, $a ·tbe covse ot tae :lnvee:tJf.aat.lone a 
aotrma1 sl:aooee ttleraftce tist wae ~eoo1'4ed.i· In ~· 
. ; 
tolln .. ee~4iee. oor•t•o• tJ&& uaea to ••• Whe·tb.•• 
·ChtJ welle meretr 1n • lateat »u•e ot tu 4leeaa•. 
;, . 
. . ~ .. 
. . 
· Obaer·vat .. tcma <m t·hu tlc,tcm. os·· 
·~~.tto•et•rolde on ·oeatuobfd,_te 'toleP.Uoe •••• · · . 
ma•e ln ·the lo1101i.lr&g .sii'oapc of patl.en'e t• 
· zx. Jallenta' Vbo wo•• fcJWtd to . ab.n 
· ... ·. · ~etaoclon; ta jl:tihi,1es, tlthv 1adlil0el 
br b.Jpostrea•mt.o· .&a••• • · · · 
• ·. :I 
., •• .J "· 
\ .'. 
'lpfm.t•••W~ll. : . ' ... '' ; ~ ; " 
~ (·Ineltiae~· · lc tb.is :t;.~tc"p wette · • tett .. 
. pa\ileata who algh$ be ••&ldered to 
. ,· . ' - ..... ' . 
be latent .·Ol' pjt&att.al dlabt:tlca,, .·.'· · 
to• reasou sta,ea · ·ln tbe tent J • 
" ,. 
· C·Ol't.1GOlle/61UC05ie to14-~ce te1t1 twl~e 
perfcrmea • alt pri·tleata 1a Group X ana· OMup lt 
. I 
. ' ·> h. 
(eacept; one gottt;r patiteat (!h'W• (leae 154) eo bad 
l'tOel.v•d ool"tteorte as • tb.Orapeu~lc meuu.re oalJ• 
'. 
,.,,.,._,.·were pre~4 IO'Ii the stan4ar4 
gltleoee tolerance teats ae dalorlbtd In IIOJlOJ.%1 
toloN:nce· te•t• :(4·rl Guapeat&d · te&tt wu perotot'&e:d 
tho Mat :dtJ• as ,a general· rule,. . COJ:iitlaone ncetate 
. was &l'i'•n o~al.~l 1a aoeea of ;o -· or 2.5 lOS• 
(~t tb,.e patltn~ '$t(;l.ped mox-• •• 1 G ·1-.) 8 aft(ll 
• hiU ~"•· .a ·M•~ .a ho ..... &•t•re ·the aeeona . . : ·,\' ' .. ' . 
at-.d~U~4 ,gluo•• tol•~anoo tel$~• . . . 
~ date• ot ·the gluooatf tol~rano• ~eat• 
·ue recott•e.t ln. ·-• 11lastn,t1o• (page$ tq3-212.· ,) 
eo that the to ctepa·rt•e• irom. \l:ul pa't•r• .Of 
:gl.UeOtlO tolerance .teats Oil OO~Sfblltl•e. 4&J& ll 
.c1ar1flea. 
liS 
ln, a t•• ot the patl.ente wS.tb so\lt aDd 
a tew petleta vlth a prn1oualf auplclou 
glucoae tolerance curve cortlaaa. val \laed to teat 
Wb.etb.el', 8 franklJ 'a'bACU••l 01' dlabetlo SlGOOie 
tolerao• teat vould be provoked • v1 tb.ou.t the prlott 
res-tltlon ot tbe ataa4ud gluooae ~l••o• teat. 
Ill'rERPRBfATIOI AID IURPOSE OF HE CORfiSOIB/GIJJOOOB 
fOLEBA.ICE TDf II TBI.S S'l'UDYa 
Interpretation a 
!he at.S.Dgeut orlte•S.• u1ed tor tile 
dlap.o•S.• ot dlabet•• 'bJ the ate.Ddai'CI sl.aoo•• 
to1erano• teat bAve been dlaouaaed ln SEOIIOI 1% 
ot tbe theala. Eapbaala waa lald on tbe taatlng 
and 2 hou. tlsu.-. Wblob bad to be over 150 aB• 
(ln the ataDdU'd glucoae tolennoe teat) tor the 
dlasnoala ot a 41abetlc our••• 
Aa aeveral of the patS.•t• 1n tb.la atu4J 
were tmown to haw bad a dlabetlo O\Uive on a 
prev1oua oooaalon or oooaalou, tbe ool'tlaoae/gluooae 
to16l'M.c.e teat ••• not u•ea aa •· method ot 
4lapo•.t.Aa dlabf)tea, b11t rather to stu.dJ · tb.e 
lfttl.uen.ce ot its dtabetoaenlo tu1tt.:m on• the- fol'm 
4>f the s1ucOJ,t tol-erance tell• 
eou (1,9;$). •·• stated fb.at td .• orttert.a 
U.n tb,. enbqc~<i1 .aluooae toleHDet teet) for the 
tlagaoala ot f ,. .... t.abet•4 !: ounot be reaulfo4 •• 
a dettntte •tbod or eatt1r cllasao•t.s ot 41abetei:t 
onlr tt.e would tell whetbe~ d1:ab•tea wou.U evolvt.· 
X:a tb.te tJtwJr, ao clet1alte · olaea&rt.o.atlon .tor ·the 
,tJbrlOJtatCil 1e·v.,1G of tb.t O.Oi'tl.e•e Ct~Qtd Slti008e 
to1eranc• ttet ••• &1 ••n• ! b.••• pal4 a tta tlon 
to •lterattona procl'lCect ih ea$l. :$.tt41t-14t1al <nir'f6 
bJ col!itleone aod ba·ve · •valuated the~J ••pal'a:te1f·• 
(a) l:a •• sctutr group tib.e ebJeot •• 1io aee 
whe.heJt oortteone weald pJtOdllfi:t oolllSt. derable 
enblaoe•nt or wbe14\ep a tra~r.ctlab•ttc ourve 
could be proauoe4 lt1 tliloae in _,,.._m • pttevt.ows lJ 
ablio•ma(l glucose toJ.•raruu~ teal ha·d aot been. 
<'leOUtNtetl+ 
•, 
(b) Ia tbe ,pa,lenta 1ft •e•laetou th• ob~eot 
wu to ••• e•th•• • fe(t.n,l;,tlzf&•b•tt.o, C!£~1 
oot£14 be ln4uced wl.tb oorttaone. 
(o) ln the patlenta t~t•~$G4 wlth bJpoglroaemlc 
•s•ts., 'the olljeot waa to ••• bow the bfpoglroaemlo 
•gent• S.ntl\iet\M4 the ION Of the OOJ-tloone/gluooae 
tolerance teat. aom• ot tho.,._ patltrlta alao bad 
cortlaone/sl.looae toJ.ea-ance tee\m dono vhen not 
reoeS.vS.ns the hJPQ&lroaemto •seat .• 
•t 
ln the pr•oedlag •eotS.on, a .atudJ ot 
oaPbohJ4rate tol•llano• la gout ahowed • blah 
laolaenoe of 41abetlo glucoee tolerance teats (12~) 
'bJ the r1sl4 c,rl tet'l& uaed in tbe • tudJ. 
22$ of the go\ltJ patt.eata atu.dted would 
ha•• bten conalctered dl•Htlc bJ senera11J accepted 
orlttrl• tor tbe dlapoala ot 4iabetea. 
X t S.a a.ot•wortbt tb.at 39$ of the patleata 
bad a taatlaa slaooae 1•••1 •:ttov• 120 mg. (th• senera11J 
aooepted tt.e•• for tb.e ttpper 1lmlt ot noz-•1) •• 
oomptll'ed wt.tb. 4• ltl a ,coatrol peap of *Pthrltl.o patlerata. 
Woa1d the \UJ• ot cortltone ln eou.tr patlcta 
•••••1 tbat an •bnormalltJ ~ oarbob,drat• toleranc• 
could be eaellr pro•oke4 s.n tb1a sroup t Va.• tbere 
merely • aarl'OW dlv1d1rlg 1lrte between normal ed abnormal 
carbohJ4rate aetabo11am in patt«mtt v'bo ehow the 
•netenee ot U\e error ot •tabol1•m of soot t 
· A4nu1 oet14a1 at•~ot.t• touU tile espeoted 
to poter.tlate '1'1• ·alllofmalltt.·e• of ·tbe sluooae 
tole~oe c~•• ot'lll1l4 and ._atent·CSta:betel lD. gout 
ua e:o posstb11 belp to coatl.P.II'fl e bor4orltt'aa oaee,. •• 
•• predt.ot the later d&'VelOPlft&lit of ove~t 4la'betea. 
~a• obJeo/t ·waa t• aee •b.tthtJI' so~tr pa'len.ts w•r• 
p&l'tlouwlg tnlso•ptlble ·to ttw <ilalJetoaealo etftot 
ot·· -•o~ttd.tou .• 
. , . . ,. 
' I• • 
. l ! • 
-<'· 
,:: 
.11 .Qo.ta.t7 '~'lent' uore atud!;•·d· · the iol1owt8a 
t.e a ••~1 ot' the r-est.tlta tcuua 1ft theae 
.Piltietlta and la to11l3We4 b,J t1lus·trat1ou .ot 
the ;l,ueoae tolel"~Mt t•ts :end· ~~orttsone/g1\lcoee 
to1ettaee t••t•• 
w.M .• (96ft 
M.t. (66) .t 
v.a. (22) c 
I.A.S• (?)t 
J.t •. (91) t 
<J.W .• (161)t 
H.J. (1U)t 
CoJ~tleoae ba4 ·ltl(lllot4 41a•etea. · 
(let illuatn:tion ad oaa• repor• 
'Pi\SI 1'13 :GllUNlAS .Cl}.f,,Ta 4ut-~ and 
followtns· Oo~;tt!GOA$ Whel'.PJ') • 
. . \ 
Dla.bet ea 11a$ ooJ-'tl.aoae•ladu.oed Oft 
ellbanced. 
:Modettate eggi'$V&.tlon ot tlatJet'lc oDYe. 
.(a) Kot•~tate ~n9cMt\\ uh• :lrt a atate 
· ·Ot J'tE~ftt&s:lon.a. Dla\14ttlc curve • 
(h) A »o..neio&Loal. c.ur•e •• furtht!' 
v.eS.pt I.e lots·t. 
tn.abetlc tJpll ot ~~.s.ne $.11 t.\ pa'tl$nt vh.o 
"-<~ ~evS.Ot.t$:ly b._n tountt. to uve a 
feat~ns slucoee level 121 q. 
. . . . ' . 
Mode1'a.te onbanoot?llat. to a dlabettc · trpe 
·Ot cune •.. 
Mo4era" enta.aaoemeat wS.th COI'tlaone 'but 
c~ l«J not, dtabetl¢.. · 
Mll& emaaoe•nt. 
M114 ~no••nt. 
Klld .m.J~anoem&Jit i.;n • tatl eat \tho 
prevS.oulf bad aa a'buo~mal g1Q.oo&e 
toleJ~aace t.e8t• 
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/ 25·8·5~ 
ON 
NO STEROIDS STEROIDS NO STEROIDS STEROIDS NO STEROIDS 
G.T. T. & CORl:/G.T. T. 
FOR GOVT FROM JAN SS FROM 20·3·55 FROM 6·7·55 
FROM . 6·7·55 lOLBUTAMIDE I G. 





J.E. CASE 42 





3-9-59. • 17·9·59 
S·Or~G~X~T~.&~C~O~R~l:~/G~X~.T~ . .-----------~----------~ 
TREATMENT CARBuv.MIDE IG. N I L 
FROM 14·5·58 
vii viii ix 
1Cf3 
.1.~'· .: .. leu ~.. . c,tltv:tSt .-.~.as•.JM:t a••ta. 
(Wale case .111Wlt•atee t;lui evolution or tllab•t·•• d"rlq 
oor•t.eo•atero14 therapf)• 
tht.e JO\U'lS.; b.ealtbf :1ooktas oarpen.t•~ .bad aeveH sout 
tor ;fbt.ob be l'eoeS. "ltd :mett.oott•• He develo»-CI s.Jmptoa 
ot lllabetea a.nd a high tutlna alucote level (29.10.;4.) 
wa11e •atttns mett4ortl•• A Sl~COSe 'ole.-an.,e teat k1 
. ·March 195S U.l) t.tter $$tS.co¥ttsn had been ·dl$coat1Dued 
eb.oved a ,mlld .almoralS.tr otllf ot s1ueoae tolerance tet~Jt,. 
bGt tollowlas atf!~tol.4a f,oze J mmttha a marlet,41J abnor~~&l 
gluoote to.leranoe test qala 4Vt·&lope4 (111) (1•7•55.)• 
Wbm aMrotaa •••• e•oppea. a £e~bJ:e .. ~:eel~!.lS !§o,,e 
l'l0rt~•1 g1ueOtO to:ieranoe teet (lV) \1>D 25•8•55 1& ltOticul. 
0A 8•3•56, lt1 Spite ·O.f tl!.& tact tho• ltt!'Oldt U'ft ttlthb.e1d 
a .s~os•lr tl.bn.ora1 aluooae •lerrmoe teet (v) b.&$ 
spO,tlti\ftefUlJ evolv•d. (Tbe 1\bno~aa).l tJ of tb.e alacoa• 
toleJ-eAee teet I.e .ut much lafluenotd bJ ·the •alAiaiil'~~loa 
ot :tol'butaml.4e oil oaJ:~~butf1,m14e (Compa•e vl 1 'Vli • vlll,) • 
Ooftlacme hu ptteauoea o:alr 1. model'ate, cm.b.ar&ee.,..t ot the 
Slttooae U.l-ance tfitt ta 'hrl) and (vll) 1 wnen tile. patlct 
was btlfti wea,ed wt ttl bJpos1r~aemt.o ageata .) • 
I 
H.W. Case 164. Thla eld•rlJ Eureptan am agee! 
69 Je&l'l waa tll'lt ••• 1n April. 1957 wt.•b a hlltOI"J 
ot dla~etet of 9 IIOtlt'U • a.uratton. H• ba4 b•• 
reoelvtas tr•tmetat v1tll Mtf.oorten tor gout Whloh 
'ba4 beco• •n1teat one· raoatb. pa-lor to the onaet ot 
4S.abetea. The dlabetea vaa nla,i.velJ nalatant to 
ln.ulln and oontttol on 80 unlta Srulu11n waa poor 
131o0d glacoa6 eat1JUt1on• t 315 rl8• • 184 ••, 186 1'18•) J 
vhll• he vaa taki.Dg S ta'ble\1 l'llttlcorte da1lf. Oa 
4lecont1ru.llng •t•rotcla hla 4labetea rapl41J 1mprova4 and 
b1ul1D oou14 be stopped. Sterol4 tbeztaPJt t.n tl:d.• 
goU.'tJ patient. had brougbt on dla.betea or oaued an 
U&OeJlb&tion ot a prevlolltlJ eub-ollnloal dlabet••· 
Wheo laat ••• he ••• bet.QS aat1etaotor11J controlled 
wl tb ate ot the aulphollJ1u•• 4l'up. 
(Patt•nt B.w. ••• not 1nolwte4 ln tu flS\11'•• ot the 
at~J on oarbollfdrate toleranc• Ia gout • ••• Ad4•nch,ua 
to tb&t sec,loa). 




















A , ' 
f' \., 
I \ . 
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I 1·8·56 ~ 
,' ' " \. 
CORT./G.T.T. 
NO TREATMENT 















252 230 220 
.. , 
''· 
sor----------~--------------~------~--~ G.T. T. & CORT./G.T.T. G.T.T. & CORT./G.T.T. 







Thla patlent hu GOO!~ Oft 22•3•5£ t.Mre vaa 
a d1a'betlo our•• and to110111DS oortt.•on• the•• 
... ~~Ultad .... o.•:at ot tbe slu.oo•• tolerance 
teat. A gl.u.oo•• tol•ranoe wat in 1957 •t:Lll 
ahewed a ooDilderablJ ele'fated 2 hour tJ.aw."•• 1A 
addltlon to • b.lgb. ODe boV lne1, altbO"Sh the 
tatting 1Pe1 •• normal. . 
lfbS.a patlent wa• • v•rJ obe•• mill and an 
.xoeaalv• ••t•r who ha4 oour. 
A glwsoae colercoe teat lhowacl aever•l.J . 
hJ,.•81Jo&emlc levtl• (27•J.;6). Wltb 41•t 
aocS ••1Sht loet, a gluoo•• tolwanoe teat on .9•2•59 ..a vltbln n.ar normal ll~t•• A oortlaoae/slueoae 
tol••moe t1at ahowed ao4el'at• edlance•nt at thla 
atage (a peak 'f&loe ot 260 fiS• at one bov). 
Wlth tu~tther 1oas ot weS.ght the gluoost toleztanoe 
teat on 18.7.60 abowd ootaPlttelJ norMl taatlns 
anCI l.ow a0%'111&1 2 ·hoUI' le••l bat a hlsh one hOur 
level. BS.a oortd.aee/sluooae toleranc• teat 
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V-B· CASE 22 
21-6-57 




• 0 4-11·55 ,' \ ' ."\, 
~-~ § 100 
CD 
sor---------------~ 
G.T.T. & CORT./G.T.T. 
•t .. 
~·. -· 
Gortleae ••• pNcha.o•d llodera'e ~oemtnti · · 
ta J pall~nte : A ,n • , Cease 11&.$) • c .• ,.f. w. · (.caae 166 ) 
u.O. v ,,a.· · ~cue 22) • 
ln. A.a .• aao o.z.w. a "'•••tc tigpe ot c'lJtve 
·, . 
". . I 
1.: ' 
T 
J.l. CASE 91 
400 
300 




















G.T.T. a CORT./G.T.T. 
H.N. CASE Ill 


























G.T. T. & CORT/G.T. . 











11>16-9-58: G.T. T. 
<21 25-9-58, COR1i'G:T. 
13) 15-10511' ~T.T . 
) ~ 
I ·: ~---------::--:-:t-




~- . \ 
.. ;.-> . 
Col'tl•c.e• hal produoed e1r 11lld fmhanee•n.t 
1ft the 2 patltmta l.L. (Cae• 91), _,Cl J .Ad. 
(Cale 7)• 
!•L (g~a.t. JJllJ 
Tht.e patt.ent vas a JOWlS Elii'Opetn un, es•4 35 , .... , 
w1 tb ulc aold oaloull and !lZi!tt~Ht~S~!Bl but no 
eyapt01111 ot cout. 
A cortlaone/gluco.e toleraaoe taat 1b0ved ODlJ mild 
tl'lb.uoesnt over ttle •tanclard s1uco$e tolorane>e teat. 
Belther ot the gluooae toleratto• wata 11&1 abnorJDa1. 
As\1tt ••. 19!!! J:6~.) 1 
Tbta patient, a !urc,_cm J1arJ. qed SO reat'11, batt 00'01! 
aDd waa alto a •lld 41abetto. 
A col'tlaODe/Oluooae toleranoe teet (2) pro<tu.c•4 
praot1oaU1 ao enb.aJU:ement over the QOJ"Ml glucoae 
tolerance teat. 
he•tr•t•nt wl th nlootlnaa14a to,- 4 4aJ& be tore 
the nut eortS.sou eD.ballce4 teat aoemt4 co be 
reapoulble tor sllsht enb.anoemtnt t.n the aluooae 
tol•ranoe t••' *' ( 3) • 
eotr.riiO!E/GLICOSJt TOmRAIQI Tl&i:B IN f&fliJtiil 
)101! ON ·I!'POGi!CAiMIC t\ASIU •• 
.. Af Patl •. tq tllth..lli()BML slaooat 
to1e~anca t•at• 
.. (beton Co•tt.aone/alueoee 
~ole:raaoe teat). 
I.a. Oa·P 58. 
D.l. eaae 11· 
lhl• Ca•e 77 





















o.s. CASE II 
13 2 
<ll 26·8-58: G.T. T. 
<2i 3·9·58: GT.T. "AFTER CORTiSONE. 
C3) 24-9·58•G:T.T. AFTER CoRTISONE 
· FOLLOWING NICOTINAMIDE 
900 MG. FOR 4 DAYS. 
11-5·60 




' 11·5·60 -·-· 
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I \ 25-II·S9A 














. ~ '. .. 
J .H. (Oase 58 lt 
Tb.la JOUDS European man aged 18 yean vaa referred 
1n Aprll 1960 b•caWJe he had show pera1atent 
glrooaurta to11ow1ng a car accident 2 months 
prev1oua1J. 
D.B. (Oaee 11)1 a European man ased 3& zeara I 
Thla man waa referred to t~ dlabetlc cltnic tor 
g1Jcoeur1a ln 1958. The standard glucose tolerance 
test (1) was normal. Cortisone produced mild 
enhancement only (2). Pre-treatment with nicotinamide 
p~oduced cortisone/glucose tolerance teat (3} which waa 
better than e1thel" ot the preceding glucose tolerance 
teats. 
The glu.ooee tolerance teat repeated 2 1eara later 
(10.5.60) was normal. The cotttlaonetgluooae tolerance 
teat showed a a11ght1J enhanced but oompletelJ normal 
glucose tolerance teat. Theee results were an almost 
exaot reproduction of the tlnd1nse in 1958. 
In these 2 patlanta with renal ~1Jcoaur1a there 





Id.ntical twtn boother of P.K. 
(Oaae 74), one ot the long term 
atudJ caaea (page 113 ) • 
p 1 hr. 2 hr. 
103, 221,157, 107, 89, 152 
No enhancement ot gluooae tolerance teat by cortisone. 
tqq 
A.K. (Oaee 77): a zoung E•eant woman aged 28 zeara; 
Tb1s patient had a strong tam11J biatory of diabetes (her 
mother, father and brother were aeen w1tn diabetes). 
(a) Considerable enhance~nt of cortisone/glucose 
tolerance teat to a diabetic type of curve. 
(b) Ten months later glucose tolerance teat a till 
normal. Cortlaone/glucoae tolerance teat still ahows 
conaiterable enhancement. 
ll 
a.a •• •. ,, 
•••• 
x .• w .•
•••• (! 1J7 
Cue &a 
Cate 13S 
• •• 162 
.200 
>.· 
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G.T. T. & CORT./G.T.T. 
TREATMENT RIBOFLAVINE 30MG. 
23-12-55-30-9-56 









N I L 





~300 t\' ot. 
~ I ' 
~ !...>~. A 
~ 200 /--<----.----'\ -- -~~~:;?___ ---

















·;:1: St!~;l: to ~J::to~ as•«~ .,, r••• • was a 
A e~tteol)e/sl·llcoae .toienue te1t on a.,.&.$6 ••• · 
p~aott.oallf 'laie sue u .a ete.f.~ gluooae tolerance 
telt tone on 21.7.,5·5. .. ' 
A ac..sua alucoa• tolerance tQt oa 1.;.12.56 ehowa 
that the patient ls lft a ;Pha·&e ot J'eitilcslon. 
T~tt• patt.Jat, n .al•••lr BtWof;ean ·••••• had bea. 
tnate4 wl1b. t.aau.·lta. prS.or to ·b•lns seen at •• 
ata•etf.o oJ.luc. 
s. lt. •. ·.. wae ..-.· .•• •.···· aol·'. o-teft1eicu• • ... • .. · ... •u. ibs·•ca..: lltnt g'1u .. ··· ccse tolerace tftlta When ott !aeliU;Il we:te · UJI'al, 
A OfPtloone/sl\lceae toleraaoe· ~t tone •• ra tlme 
wllen. tb.e 2 a.oe level ••• elev•te:a, cowed molettat• 
enb.a:bOement aalo}f of tbe ,peat&. •~• ho• tts••• 
St.~~~ i ..• iSM• 82l;t 
.lot 
Tllte pati.enf;;, . • hNJMan man ••• jJ f•e&r$ t baa a b.-olhetP 
•o ·u dldetitc.. . ·· : · 
Thl.e patient bad ·art al'mortul. sluoose -.1••••• teat • an .. 
elella.te4 2 ·hoot fJ.g.VeJ bls glt~coae tolt~~roace .teat I'O'fe.rtu4 
to normal. · 
A ooz.tt.s•/s1ucoa• tolel'aoe teat oa 1;.e.,, ahwed .mfll'4lta 
enhancement and aa a\n\OJI:mal otlfttr. • r , . . 
On :14,.6•S1lt; la eeen that a diab&tto ''" o~ ofiQ've le 4eve~Pilftl•: 
I.W. CASE 162 









- ,., \ 
.~ I \ 
, '-----
2·6·55 I 
2·8·55 28-6·56 ' 
100 
soJ--------,--------~-r----------l~------FR~~I~B~OFF~L~A~V~I~N~E~300~M~G~.--------J 
!REDUciNG DIET I DIET !coRT./G.T.r. TREATMENTL~C~ONTRO~~~L-~,F~R~O~M~2~2~-4~-5~5~'--~------l~FROM~~I~2·~1·5~6~-----=------~--~~----~ 
. v vi jj jjj IV 
;; ' ., •' / . , .. 
z.w .• . c ;(ct41.~.,t62~~ 
MJ.ld .~nc·e~t bJ c~rt1aone/&a·\1CO$$·. : .. : 
toleranee ·teet While in, ·a Pb,ftl$ of · . 








c.. goll'}e.JS,gg(o,mggsBJG!iiHfSJt,:f!l!! .. i~."*»;n'\'BJ'OI 
IJS ... ".IUOI~Ya~u AFifDt t4)· 
1, ,.\4. (BQe 162) 
w .•v.,a.. '(0$Se 15,.) 
W -a ·• (Ot;OO 126 ) 
lt.v .L (Cue 87) 
lo3 
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I ' 
I ' 
I ' ' \ , ' , 
.... ------ 1
1 25·9·59 .. ------I 
\ : \ 
\ 4 ... · .. 
168 
" I• 4·11·591 ' 
p. I ' 
I '\ I \ , "".,/ \ 
' I .. ... 
50~---------.-------------r----------~ 
RIBOFLAVINE OFF lOLBlm'<MIOE. 









.. AftoP di.ebetos . hns ~ekpsta . tb.lD ~t~ttent . . · . . , ... 
. shows a paliactoxloal reapcmse to ,cortlsOae . · · · · · · 
( l••e.. st.ucose ·toJ.·tl'.-.o. iiQPl'OVement) t ·. 2S·•9•59, 
. ,&ltbQqh:tbe -all of tlle OtW'fe ll ''tll.bl&l\• 
·(It le to bet iJOttd t1M1d: ~- t.u~s· :~09Uited 
•• tollltttamt.d• ••• lltoppea,. ·hi. er»w,;; for 
ae. w•ek ).. ·· · ·' 
' ~ ~ ' . 
. • il· :,_ I 
.. •k 
\· . 
.' .. '1 .,_ 
lolf 
I . 


















9 I m 100 
I 
... ,-~ so TREATMENT 
.. 
W.R. CASE 126. G·.T.T.S & CORTJG.T.T."5. 
WEIGHT 
LBS. 139 
Ul G.T. T. 
!21 CORT/G. T. T. 
·400 (3JCOR11GT.T.AFTER NICOTINAMIDE 900MG. 
FOR 4 DAYS. 
164 167 




...i 30~ ::;; 
0 
0 














I ' ' \ •• 
9·12·59 ,, ... ;. . 












' ' .. 
50~------------,----~~---~--~~==~~~,-------------~_, 
TOLBU"PIMIOE CHLORPROPAMIDE CHLORPROPAMIDE LA 6023 1·5G. 
TREATMENT STOPPED O·SG. STOPPED FROM 1·7·60 
9·10·58 FROM 18·6·59 9+60 
..... 
...... ~ 




w.·v·!J•. ·.(Case .. 159)t 
. ~bie pat1ent. a Europe81.\ man aged 49 reare. 
waa a mild diabetic. 
~h•· ;eo.,t1aoll$/81ucose tol.G.,auce ttts:' ·. •ttowe~l · 
. no enhance•nt'i the 2 hour tl.gtu'e 'beti;J.s 'lower 
than l.n ·tb.• stan4a~a g1""'cs• ~l.Sruce tes\. 
~ - - "" 
':ids patl13nt1a Suopean man aged;:~l J$fUiS$ aihot~ed 
conslaerab1e enb.ancement ot the :tatter halt of 
the gluooae ·t·ol~itanc~ test. ' 
,·, 
l .. } ~. 
w: •. a: •.. ;, .(C.aa•, 12'l• · 
Both. dl.a,betlc · curv•a show mt.ld to Mde:Pate . . . 
el'll'.uUlC$fn~D.t 'On COi'tlsone I ~.10.i8. 8n4. 2thl.60,. . 












,/ ............. ~ 
<ll 26·8S8' G.T. T. 
<2l 3·9S8' CORT.(G.T. T. 
<3l 24-958: CORT.(G.T. T· 
FOLLOWING NICOTINAMIDE 
FOR 4 DAYS. (900 MG) 
/ <I) \ : ', 





' ... ·· ... (3) ' 
---~/ ......... -----·~··················· ..... \,:,,~_-,----:·------.-" 




















<21 CORT. G.T. T. 
400 
<3lCORT. G.T. T. 
- AFTER NICOTIN· 






. : ... 
I 
HOURS 
' . .. 
···... '~ ... 
l 
1,12 2 









0 Q 300 - " 0 
~ 
!II 16-9-58: G.T. T. 
. (2) 25·9·58, CORVG:r. I 
<3) 15-10511' ~T.T.; 
'./ 
......... 
• . ...... 
,· 
·Pill!Ja!llllffSJ!D zo,·IIU!fB·I~:t: ... PA~;tE!i~J.Jl!J 8 
· IP9fjJIC.AB,f4'0. A-S;J 
V'tt!l'f!:!M:!lfJ~ JM'~;&. t~cmt!flAIB ~MOEMIR ,gp ~- 'GPMO!B 
~-=-=- ... _. ~---=-L~J··~ '--= -~· tfl ~~~ ._4 _!I l. J;tt•i'• e: b :J:I.s ~--- ¢ 
.: (: ~ i t ' . , ') ~ ·. : ' ' , 
' ' 
i ' . . '· . ·~· 
2ot, 
BScotbuuild' peven• aUOXIlf Uiattoed at.abet.ea {.~er;•• 
' . ' " ' . . 1,• 
1947, ~Uuw •' ·a1. 19ft l • · Wool~. n.Lo, <A4m1at.stttatton 
ot atoottaa.ml.4• ·ta la•a• 4oaea· :tteveat oel'ti.IIOD.e 
•IWlc•••t of tt.o. sluone tote.-.o• tea' t 
:o.s. 
o.w., 
CO••• 11) lUld ·• notal a~.uo.,.• tolel!t••• •eat. 
(Cue 161) waa a ·dt.ab•tt4 b. reld.llal• .bd 'bad • · 
:P!'WflOlaalr »nol••4 1&1!'1J•· fo.s•a of ntcotS.:t'MU'd4it• 
· (.G•••· 124) waJ a 41.al»t~tei W!le bad alto btet' 
••••~• .S. • ·Jdo.tlu.mtte . _ •• past. 
!hee• '*''··ll- ...... had ' alU\lote t•le#att06 teat•: 
(1) Skn4D4 .e1ucose .tole.-c• ·teat · 
(2) · O~tlaone/a1ueoae to1e.-=c• ~·· t 
( J) Oo»tlton•lal•cose 'o1eJ[latl,~e · te$t aftt~ r•oti Ybll 
as.oott.aaD&4e tn dosea ot 9t3 1Jlll• tot! 4 4•r•• 
illtt E•!Bli•r :t~•Q t 
J.l.s. (G.ap ll)i Cur'Vt (J) Will b~tter than (l) ·Ozt (2). 
o.w. lCaee 161) ... w.n. (Qate U6):t (htr••• (J) .... 'WOl'IO 
tb.aft :ettbt• (l) o.- (2),. 
. ·-~ ........ , 
.• r.-.; '· 
Ot .U ,t;OU.tJ p&tS.e_Bt$ .Ia 1tholl tile :etleo' of 
' . i ,. 
,cortlaoat wa 'etaaled1 7 ooc14 ha\tt be•n OOl'lalflet"od ;to 
,allow eo•tla01t6.· -.'l'iano..Dt to a~t.et•a, o•· a 4J.fliK.ts.o 
ttpe of cune. 
. ' ~ ' ' . ; : . 
, •• ~.howea ·mild el'lbat&e .. ne <JalJ. 
2.t£ilJI!I•iti•!H• '~!!tr.l~"'lu~~';t!ll .,,m;,_o!f!eJ: .Pet&!ll•- Ill! 
..\n.&!d(~.Bxpoz11PII!!&P.,AUDS,It (.U ,atl•ta ). 
. !ISC:R.-19! .• ~. }mf~J.. 
1 o••t.s.aoa./al~oae ~filerqoa t:eeta snowed· 
.at ta tal& SIS> .t9l!!loawt ,of tb.e alueo.ae tol••anoe "at . ··-·· ,.. . - . :· ' .· ' .- - . 
' . 
2 casta •t s-dlol a'Jco·••lai 
I.a. (Gaee $8) ·• · 
D.-B. ·(Caae 11)· 
b :- · 1 .,H .. tttabeiS<i (·t·) ·:~t 
t,.a. . (9ast 198 l . (lf$At,cal· ·~"- P •'• .(caae 14) 
· tJl.al»~tt.e) .• 
u4 tn t• ··' ·· 
4 ,patlttD..tu~ · wt. tAi diahbea .ln reaealoa·a . 
~--·· .(tate lJ?) 
x.v.. (Caae \62 • 
W.o~ .s • · (·Ceee 1)9) 
o.w·. (Caee 161) (~lt patient bad·. sout. 
Be :ls lno1udet. ·in tb.·ls 
·eeott.oti aa well 'beeaaee tltt 
(;Qvtlsoae t&st waa ·. clone · 
~lltbtlot·tr b.t.s a&abet•.e •• ia 
Ji'Gmld101l)• 
'Rbs.• ••• • IUJtPl•lbs fta4S.as, •• thAI•• 4 
pa~teu •••• Jmovn to haYe had • ahn.OJIIMlltJ ot .. 
slucoae tola•anoe ~· or a dtab••lo ou.Y• beto••• 
lt Ch• oortllooe/.nbanoed ttat la to ~ ot 
.,alu• b. predS.otlng dlaot••, J.t •••• •••onable to 
expect a traklJ cilab•tlo oe•• t.n th••• ••••• 
Bllhaao•lltftt to a 12!1 . .11!\9F.!!!l. tga ot !9£.!! 
•• ••• in 2 oa•••• s.s. (Cue 1'5) and M.L. (O .. e 82). 
In th••• 2 ouea s,,. •1 M aa14 that tb.e uae 
ot oortlaon. bad oOAtS..•4 i)be t\.\tplclon tbat th••• 
pa.tleta w•n t•D41as to 4•••1op 4labet••• 
The Sl&leOie tol••••• o••• beoUI M£1 .M.e0£111 
atte" cortt.aou J.D 2 dlabet1o patt.•ntat w.a. Cc••• 126) 
ad Jt. • .L. (Cale 87) • 
Xa on• pa tleat wl ttl a OR£•1 slyq~p '· tgJ:•&!!l!! 
Itt! then vu • oontldettable eftbano••nt wl th COI'tlaou 1 
•. 
fllc.etSAalnl4• ta11e4 tfl Pt'·t>vtat oortlaoae 
•ano•mtnt ot 'h• aluoo•• toleJ'•o• te•t l.n 2 patlen~G 
ao bad. PJ'evt.~otu-'11 bad t'l'tmol'U1 oiif••• (o.v. ca w.R .• ) • 
. ln One patS.•••• D~B. (Case l:i) with ;a aol'lft&l gl:uc.oae 
:. 
re3ul,e4 ln a. corUlaone/stuoos.-. toltra•• ·teat; 14\lob 
·- ' . . . . . :- ·~ 
wae bette• ·thaft tbo pPevlous alu•f)OG tolel'moe teatfl• . . . 
... -,C~l1!6Jl!fmri OF, ~Bl1LB'TIOTS .op ·gf.am~ lB. ,ll, G9UTJ 
J:A:£18S. .,tJAlll. A,. Gft,O;tJl §!fSISJl~ 9f .. 1l .JJW!Il9S.,pJ 
. •:ra .. ·s .. ·.·D. I. tm.·.·.· .a.· ···•· .• . ,_, -· ..... ·. _ .. u··· 
It te of peat ta\uui•oa:~ ~o com,ue ttu• reaultl 
in tile soatr aroup vltb a noll~U'' aro~p ot 11. patltnte 
compoaed·oft 
D:ta'betloa UmOWD to have dLa'betlc slucose toleranot 
. . · ••ta)a a. 
fPeV$.0U$lJ bow to ~Ve & ·dl.atet.~O Ol' ctlabe\lo tJpe 
· · or our•• t 5•· . . . . · 
.•. :-
A •~>.r•dltkb&~lo. t·• (l.dantloa1 tt•la • ctla'btttlc) c 
1. 
P.tve ot the 1• ,patt.eats ebowed · eahaaoemaat 
wttt\, •••tt.J••• 
I 
tzhla woald • uggeat f)~t~ •the .. aoutJ a•oup riPe 
.• ! ' ,. 
at leal$ d &WJceJ)tlblO to tlie dlabe,Oger&S.O ttteot . . 
·ot •••1i1aae ae a etl'Onglg a:uapoet ttlabetLc' olt 
pre-cJJ.abetl• ·aro\lP• 
\, ' 
~eeo PGJ\l1te wqld· GUS8ett tut tu ao•ta 
sro'lp ._, • maatd.J •ll4•ol>ttb1e '' •he diabe~»s-.s.o 
etteot of cetl·eone. 
' .... ,
. . 
, . ... 
· .. ·' 
210 
· ... 
,J2, _,_ OrORtJ,-/!W§OSI, !OfiiWiOS)D!i§ .JR .. 16fJ!UI 
!!IATD. ,WBI !ialffAOOLt»aCA£ !iJ'lQiL!C&O, .AGm:fS! 
) , _ ~I _ . -.. :!4 - .. -,~I . . , .. t-- I . ,1 _ -I-- . . $0$11 
(22). 
:1o. •!!l\aa•l~Dli :Ja!~.JIR!A .&e•• 
., o.~p. Oaee !20 
o.~t. uaa• ?6 
au .. •JbU!!IIRSit.~;at 'O!i!l La . •·· 
w.a. 
~o.v • 
. '•"• w.o. 

























SO G.T.T. & CORT. G.T.T. 
TREATMENT CHL~IDE •S 
FROM 12-3-S9 
.. 













•' -~ ' -· j ... ; 
j 
:::!; 














so j ""··. 
G.T.T- & CORf./G.'f.T. NO 
TREATMENT TOLBUTAMIDE IG TOLBUTAMIDE 1: 
FROM 19-9-57 FROM2S9.S8 
'. 
thll ia:topee ••• · egad· -62. Jf~J~J.I abowt4· •· ~~ . 
._,poglroaeac ·retp.,..e to tb.l.o.,.pamwe, 'bat · 
•_. glu_co ___ ae_. Ml_. !l'aoo __ tt_at w_·l:l_t._1• __ ~'-'_·~l __ -~*.•_·_·· tq. 
·Cb.lori)NJNUd4e •• .ocmpltatG17. a~ml. : .. 
fb.e OOI',ltOft$/Ql,ao0$8 fJ01eiW&t8 .,.,, ,,. lt. U.Jtb;·l.fts, 
was lmpJtot•d• · · .. . . . · . 
. ... .. 
I i.' 
A- cortt•••/s1u.oo•e· '•l~~• ittt. ·~• atM•·t 
ldtmtloal - tba ., ... rd. a1ra•••• .ltranoe , .. , • 
taotb. •••• , ••.• havtag 'be'f# dotta alle -~ pat1ht 
••• balDS ttttate4 •l til ·tolb\ltiamt«•• 
'l!olbute:ed.de was 4lae•lln\te4 ·ott ·25•9··58 .af~r. :bt• 
ta,f\il:ftS slucoe• lev.tls· b.ad btm\ lolAn-d . ~- b. 
•aat.e·tentb nor.m(l. ·· . 
A ataodu4 .ll•o••• to1eZ~at)ct toe-t .deae .2 1101\tht .ta-ter 
waa almlla~J u t'ho4$t' 4en·e ··wldl• ·t&fd.ns ·to1b11tul.4•• 
tbl.a patient MJ u•• aone 'ato a epon,mtou• · rem1a11on • 
. ln iiiiUlQf ,,,,. __ glfOOIUk bad "eappe&NG _aad_ tb.e 
ta.atl- slao.-e 1•••1 ·(158 I!S•) vat ••ss••Uvelr 
dt.abe\lch .· . -
212 
w.R. CASE 126 
WEIGHT! 163 IS6 139 160 Las·, 
(I> G.T.T. 
<21 CORT. G.T. T. 
400- <31CORT. G.T. T. AFTER NICOTIN-
AMIDE FOR 4DI!.VS 
13·11·S8 (3) 
····~ 
300- j. ..... 
" \ .. (· ,J>o , 
. \ '6 ... ';)"!· ., ,, cs> 
'-...~ 
200- • .'"I·!~ 





















































































c.v. CASE 156 G.T.T.'S & CORT/G.T.T.'S. 
lSI ISO 
sor-----------~----~~~~~~~~----~ 
CARBUTAMIDE IG. CHLORPROPAMIDE 
TREATMENT FROM a.s.sa O·SG. FROM JUNE 59 (}125G'MARCH .60 
0·5 G• 10.6·60 
J.R. CASE 126 
WEIGHT 













TREATMENT NIL CHLORPROPAMIDE ·SG FROM 111-6-59 
. 
·~ ~ .... ~ . '<J 
.· rr .... 
,, ... 
_, .. .,. 
.-,.:· ··: _:f:",.l:.o 
.. , .::.~ . 
'fbla COl.ow.-of wt~U\n aget1 lt-9 JCll'titl ae a. mllt . 
dttabetlc ea bileS b&on obser>v~d ~t the' a1abe·t.S.c 
elt..ttl«). eil®f laur.J 1955• 
. ' . 
cwts.tume/cltteose tcloraace · tettl· .ahowef cmlr 
mltd tmhGI'lOO:l'MI'it on ~l:n1tamlfo ec4 oo enbaoemtm.t . 
on ob1•l'PPo,aa44e .t.a ~•Jttmber 1959 •• IIU\Ul'J lt't .• . ' - ' . 
'l!b.le patl.en' ·•*• • obete el4Qlf EfUVpee wolftWi,• 
The oo~tlloau/gl\ieos.t~ to1~~-- teat 1ib11e lletlDI 
trea4Htd ., ... c.b.J.epttopald.do- $b01J1(li. pra~n~l·callJ 
DO 6tlh8naament · . .. . · .· · 
. - . . . .
2./lf.= 
J.F. CASE 47. G.T.T.S & CORT./G.T.T:S. ., 
WEIGHT 















OBI IOOMG. + 
CHLORPROPAMIDE 
0·12SG. · · · 
LA 6023 I·SG. 
FROM 1-7·60 
'- -· 
------ ---.---- ---, 
. ~ 






















SO OBI ISOMG. + LA 6023 3G. + 
TREATMENT CHLORPROPAMIDE·"• CHLORPROP. 0·25 G 


































~(tP,t •. u . J§JI~;;,f47.l• ;A ,.,J'UP,OP!.M .& .f.Be.I.,.Ji7 ,J.eA£1 I 
'hl$ di.t.betlo 15t1 bet bee.n Oblt~J~v•l o•e• a peitt•d 
of e ,.... . . . . . 
'!he evatatt·OD ot De 81uone t»l~raee teat~ la 
alto dt·scuad cc. PD!OS 1o1 ~~ /o~. . . · 
ibt c•s.stui 4te,b.ttto c""•e: ·(2o~a.sa) 1$ · ta•••'"· 
·h. 9•2•60 • . ':·· . - • $l · Ia $1QO~& ~1·.~-· .·. 
te1t •• ve . . .. · 1 ~· :pat;$.Q't w., belft! · .·veat.S 
·v1tQ .a ooml'!fta,1on ·•t pbtaeQtJ14la81'44e .a,.S · 
obloPpMpud.tttb ·Ike oorrt3,s•l;s:1~• t«>lt~taao• 
. t$i'f $~~~ ldl« ~t•meat, ·t;tat. u atlll •••1• 
A a· .. btsc$4~·-.t .cos1lea;e/aluc,i• to.Jo:,...atice to,,. a.l.le 
oti. 4._mt:tl\7lbt:llwutl44 ab.~ii •b fi*n6~~' ~v~ ~,_,. 
eti.Uld. ···. ud ·ttt ose ttile~ee teat· .. ·· · · · . . . g 0 "! . . ' 
-
Tb.to ·it11ebett~ .pe~t,ea'·'· an ~1•. oa-1.r,· EiWortN'Ulh man. "_-•• 
at ene tlm& poo•lr· oentro114ld <* : ·:o • so. -.tte. ot.. . 
lasullth · · · . · · ·. · 
0a »B1 + oalepHpaat4e, And· aa,t.t¥1 oa 41Mtb.JlblgUM1CI4t 
+ cb:to~~amlclo. he ohQw"tf a ~ou,~.JW.fO&lrcaemlo raeponae 
wt :1\ aertnt•• ·dlabe,tc oallVth .. 'Wb.e. •ortl.aoA•/sJ.u.oo•e 
to:le,.ct te~trs · -•nov~ ,pJtac~l~J.ir J)O enbuoement• · 
.lt.9t .• ~.,IQ!I! . BlJ· . 
2/5 
This E;'*l'OPMB ·man.: """ .JS . J:I&N eAt :c:meet ot 4ta1Jtte-. Su 1948.t 
'·:.' 
J.E. CASE 42· G.T.T.'S &CORT./GT.T.'S: 
WEIGHT 

























I. . ~ . 
J.G. CASE 52 G.T.TS & CORT./G.T.TS. M.D. CASE 38 




:::! ::E 300 0 300 8 0 <:::. -~ 0 I 
::E ::E I 
UJ J.6.6o UJ 
cJl ;-, .... ~ 0 





0 ~ 22·7·59 ' ' 9 ' ' <0 i <0 • 100 100 
50 so 
CHLORPROPAMIDE LA 6023 
TREATMENT 
G.T. T. & CORT./G.T. T. 
TREATMENT O·SG. I·S-3G. CHLORI'ROA&.MIDE 




.Lt"t · -J•••• .. lt!Ut - !i!•! p1~o .!!'!B!c 1~3 ;• 
tb.lG patltnt W8.1: • Col.o\Uled mAl\ aa..S ~ pus. 
le ~·· aow •• vas· et e••t ·tnt•re•t. Sa. ~~• · 
COJI'tlooetetaolct •••Pf !*4n~;,,d!I.~ID!• 
'the oor:tlsmt/eluc~•• to1tfienc• t:o.o~ 4bo.ttei · · · 
cml.f #d.1·4 to modeJ~~ata -aatellttlt Vtil.le Cbe · 
.Pf.tlet\t •• :roeel'WlftS tollnltatdAe • ·O:u'tttt~«te. 
·. 
1-'ld.e patleat ·•e"_a la~p~ ,IM4 -~·•· 52 ~ef.U"th · 
0 • • 
.~.·.·.·.· .. ooru.s-..&t1g.·lootie·.· • ... :1.•.'·.··. AQ,o.· :at··.••. '.·•-···· a·h··· ... •. wed. •.o ·•tumcemeut vhtle on eb1epJ!io~tte, .a_, mtlt 
.~eement oalr· eu 4tmeta.rlbS.auattJe (U. ,6023)• 
MD ta··e··d): 
II... .$1 .: •. , ,),J:ill ... :a=.wJ 
Thla J4·ltent wae a iu..opean man· aatd 42· re••· 
the ·eo~tlson&/gluoet£UJ ·tolei'IJ.ttc$ '~"'' : sliow_, <mlJ 
ml1t Gnb&M•nmmt · ov•r tJh• prevtoW) gluooae tol.eruoe 
te•t.. . . . . · ·. ~ · 
' ., 
'2/6 









.:::. F• 0 
:::; 
w 





"~ F ··; .. Cl •• 0 
§ • m eF 
• F ••• IOQ-• •• •• 
so 
NO 
TREATMENT TREATMENT NIL 
FROM OCT. 56 
vii viii 





' 11 25·9·59 ,. 
'..lJ '. 















ISOBUZOLE I G. 







Iilla ,atle-.t wee a B\U!'Optan WOiftiO; ac•• 58 J8Ar$ •. 
lu. »Gee~~· 19tS tber;• wa.p. ,fU;. ·~~~~'batt·• of · · ·. · · 
· tl\«t a~&•et~Ja •" ·tbe patl·ent ••GO ,a ve: . 
eG.tlJtaoto•f· h.r~el.Joaeldo tffilt.~• ·to ·t . ttt&mtte. 
t'b.la patl.eat. oat tted ~aid- tctlbutut46 b ·•~vot 
foP.§ di.JI.-· .. p~~. ·le .. __ •.. ·.tho SlU~-~~.·t; .'O.leran. 00.· t.··e,;t · 
end the •»ttsoiic/slucce i;cl~r~ ~est; oa .24.9.~9 
and 25•9•5' J~8Spt(Ui1..flot1• Thf g);uaoae tolel'ance t•• .. t ... · a_.• rttow•a. •.• .. ••v•_ elr ...• :ou.r_·. •-•. ·Ci_t __ -.* . betLo_ o ..-ve • ... · 24·9•·59• . PoradosJ.talJ.J. the gll,looae ·toltu?eoe- tQat 
ltll•t. s!'*t.t!l!L .. &!!Rd. &mao!•••· . . . 
. . . . . 
On to1'bu--t~~ the· :eto.oo1e ·tol$ .. oe '"'t·.va.t . · 






.... ,. ..... 




















SO G.T. T. & CORT./G.T.T. 
LA 6023 3G. + 
TREATMENT OiLDRPRORIIMIDE·25 
FROM 28-4-60 



















SO G.T.T.& CORT./G.T.T. 












9.v,M1 oae• ~6oa 
'rtde patlent, an •lcJerlJ Evopean .aD, •• 
pl'tevloualJ on s.naulln. He tatle4 to reapond 
to UJ of the tollovlng bJPOglJoaeldo asnta a 
Tolbutalll4e, chlorpropall1de, ••tatwUid.d• ad 
l.aobuso1e. 
B• abowed aa .xoe11•nt .-epoDa• to a 
co•blna tlcm ot 2 b.Jpos1Joaetd.• •a•ta, 41.MthJ1blsv.atd• 
and chlorpro~ld.de. There weM 1ow taatlng blood 
gluoo•• 1•••1•· 'the aluoo•• toleJtanH , •• ,, too, vu 
a .oderat•lJ sood on.. 
T~r• vaa .oderate enbaDoe .. nt wlth oortlcona. 
(Sub••~•nt reapooae eo dl .. ~Jlblguan1de alone 
vaa aoocJ). 
A•<~,a, ."•!! J&o. 
Tbla patient, a E\U'Opean •n aged 52 1••••• b.ad 
bean. on lnaulJ.n. Be tailed to ab.ov &ll.J reaponae 
to tolbutallide (Blood gluooae ,co •·). Be•pon•• 
to •tah.u.ralde vaa -..naatlataotorJ. On oblorpropalllde 
be ahoved an 11\1 tlal reaponae but tal led to alntaln 
tb.la atter 4. aontha. IaobGaole pJt04uo•4 no 
•••poue. Ph•ne"'lJlctlgv.anlde 125 1'1118. produced 
little reapona•# but when ohlorpropaalde wa• added 
~ .......... sood tt.Jpoglycaemic· response. 
on cll•thflblau.anlde + oblorpropulde tbt• 
re•poa.•• vaa ulotalnect. B•en att.• sl\looae, the 
~l•~c· t .. t did not abow &real ~JperalJC&e.ta 
levela. Co~tlaon• produc•4 .oderite enbanoe .. nt. 
217! 
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G.S. CASE 136. G.T.T.'s & CORT./G.T.T's. 
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. ~ .':. ,r· ~ ... ~ , ..... 
•. 
.'1 r , 
l,.q·,, .. J!~te. SJJ · 
fh1& pa,tt.••• •• aa e14er1J BQ~fopeaa ••uaan• 
Sb.e was a . rd.ld 4iabetlc eeen slnoe 19Sia.J 
ber dlal)etee shoved aa . ~utaoel'bt.tl•n b 1958. . . . . I . . , 
·OD. chlorprvpamt.de ·thor., waa mo48fato 
emeu·oema,. u oompre4 w1tl\ the 
o"ttdlda•a sl.ueoee tol&t'MN test, 
She eho._..·.aooe~at• eeaao·emer.t iOft ootttlscm.e 
wl'd.J.e ta~t,ns eblorpropatalde + toltu1tat.de . · . 

















G.T.1:'s & CORT. G.T.l:'s. 
SO OBI 75 MG. + . LA 6023 1·5-+3G. 
TREATME CHLORPROPAMIDE O·SG. 



















14·6-60.~1 ,,..-., I 
I 
I I 
,. ....... ~ ·,~
--~-
OBI ISOMG. . 







s.o* ICtt• ,iil; 
·tfb.l& ,patl·tmb, ·flli·_ e16et'1J' BV~PfUi tt<tMa, -
w.s e. mll4 d~.-n.tetl.o b\lt poorlJ _ C~flt;Jto11e4 -
on :&U .tJ;JPO.SlJe&:•mt.o ageata w~leh wen -
tr:le6, · _ $M uas re1atl'Mlr bl=;Jll.).tll 
rest~ta.nt too. · -
t .. 
Tbel'e ~•• •ttkeO •nban.oemeat ():n eovti&olut 
.obtle -taklnJ HI +chlenN~tte ana alao_ 
wb.S.16 taltift! 4tmethJlbi.SGGAI.de (LA 6G2J) 
+ oblOl'JPOpam14ee 
A!fl (Qailu• It§} .• 
1 _,, : ·• · v_-.nt9 ·J' 
'l'b.la patleatt1 Gh el-d$1'lJ Colo\U'ef. _ WOm&fl., 
wu_-. •_ we_ 1_ t .. coa_.troll_·_ea __ • ph_ e_ae_tbll_ b_l ___ s_ uan.lde 
<DB:£ 150 cas .. ). A_ cos-tlson•/gl\1008$ __ _ _ 
tole•ane>e ttrtt em ·)4.&.60 4\b.OBei ~onetderavle 
enhmooment-• · · - · -
A ·•ttk _ 1a\•r the. prootHI\ltt• was .r&poated . . 
e.aotlr •••pt tl'Ult tlle patient took ,0 mg. 
ot :om ou the mornt.ng ot 1he ,glo.ooa-e tole~ee 
~~t •• well. _ Although tha ttatl vere at a 
low•r level. there vaJ 1111~ oonsldf)reltle 
·~•llen.t to11ow.tcs oo~ttleon.,. 
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SO TOLBUUIMIDE IG. 
TREATMENT FROM IS·S·59 
R.l. CASE 79 
ISO 























; 24·6·57 ',. ------------------------/ 
I pl· 
50~-------,--------~~~~--~ COR'tiG.T.T. 
TREATMENT NO CARBUTAMIDE TOLBUTAMIDE I G. 
FROM 2·8·56 tllQ.S6 
•• - ~:-. f!': 
t· 
laP; .. lOu• H2J.J 
'l'ht.e patient,, an eltt&rlr Evopeu woJDU, 
shOwed marked ~e~ent tc1loutng ecrttaone 
wbll.e on tolbutamde. On ob.1orpropaasl4e. 
nowe9er, tilero t~ee no etlbencement. 
~,L1 (,0,18! 7S lt 
Tb1a patlent, u e1clerlJ Bul'Opean woua. 
ahovecJ a near normal gl.uoo•• toler&Doe , .. , 
wh11o \O.kbs wlbutamt.de. · 
A oortlsone/stuooa• toleNnoe teat on 24•6•57 




















O.R. CASE I 2 7 
160 165 157 
~ 
I \ 25·6·57 / ,, 
,' \\ 
l 't 
- 11·4·57-- - ---- : - c -·- - c-- \ 
1\ , ' 




~r-~~~~~--------~~~==~~ TOLBUTAMIDE IG. G.T.T.& CORT./G.T.T. 























G.H. CASE 55. G.T.T.S & CORT./G.T.T:s. 















,.~ ••. r seas• 127)! 
The cou.rse ~of •he dtabetee of ·tll:ls pa,let 
waa olosel.J .. followed alue oru,tet la ··1947 • 
Wb.eft she waa ased lt.J geaz,a, · 
!1\ett$ Wat a aol'mt\l . 81\tOt'ae .oieP&MO tAieti .. 
on to'lb.atamtte on J.:J.•4•.57 ·bll' .a: ·~~ttt;e~•l•· 
glu~oae teltrqce teat 2 ·II!Oatba •••e• (25•6•57) 
showed· oones.:aerattle enunoe:mnt. On 17.6.59 
a gluooa• 'ol.eNnoe teet whl.le t$ltlns 
ohlorp"paiiJI.dt ·wat •sat.a Jtl&ottca11f normal 
(e1t0$pt tott ~ rebollJld ot tb.t 2 hour tl.;~e). 
A oo•tleone/alucos• tole:Paace •••t ·e ob.lorpropamlde· 
sb.otfe« oonal.t1erati1• •••ee:mut. . 
P.~ ·e.· .•. J ca.i ~Slr• .. •. :!Sillt*D..JI!!M .• I.SUn5S. .1!1£! .* 
fh!3re waa onlr mt14. enl'ltmo•aDt ttbL1e. :on. · · .. . . 
ohlOfl>.t'flPtldde (Apr.il .19;9l. and en pllenet11Jlblsuam.cte 
;(Ap!t1l: 19,0)• but moderate· to tsttke4 enbtl\acemeat when 
~- 41-tth:Vlb1guan14e ·(U .602:J) 1;n. June 196ow 
222 
2.23 . 
AflALDlS· OF llFStl!n'St . C!!!!l$0.1. J.!e.· ..~r.u.···n .•. :s.) .. 'f_OLml, ....A, .tJmi,-·. ,.T ... ~fl ··t, ¢. . J ._~·tort·· -· ·-_· _ . ··a t J ~ 0111' z.;_~ 
I!,! .PA!l~!: Ott ;MUR'eCO!!!'!CAL .Jt,J?liJ.:ft. ~ 1 
1 ::. •• _ ::.:.:. :.:= . -~ 1=::::.: 4 . 
10 Patt.ent;e 1 
{11 tests) 
7 Pa_ t_l•.··. ' ... •• (9 teste) · 
tl .. ' 'i ,. 
lo ellhu.o4;molit.• ·' patla.~•• (o.p., ChHe 1 M.P .• } 
Hark•c.t eDhancemeatt .1 patleat' . 
(n.a.) 
•daitate· enh6UlCemODit: · · J po.tl•·t11: 
(a.v.M-., A.a.~h, G.s.) . . . 
lit pa tleat,a. . · 
(D.R., R.P., R~tL• j W .R. (xiii) See 
· . page 114 SECTION V) • 
. · '· . 
! 
lAtlSM' ·•· M 6021 ALOHfh.ll J "' '-i - - ' - , __ . ' ' ' -" ,. . 
.1 patteat 
.(w.a .• ) 
:2 · pat·lenu .. · · 
(P.L., ;u,.Q, •. ) 
Modopate enbanceJHD.t s 2 patl&ntl:h• . . , ., , .. <~·v·•···• A·-.a.~s .• ) 
'.... . . .' 
I . 
' ' 
Mattlled eabAtlc,•••': 1. . 
(A.F,• .2 ttltfl);. 
Mild eb.lUlftoetneftt l ,2 ·• 
(l~F •• r.r...) · · 
Kartc•d clhanoemcu,ta .1.. 




ataw. _· .tr --~~,. 
. o.,. 
128 
. , .. ~ . 
... g 
1..17 
r : a• rt - ·-1 ·- 1 - :n f'T r n _., -. ·avr. 
1•••• &.tz.t .• -peslttd. .· 
artw tol.bQtat~S.de dleoootll$ll80• 
feJ'elet.eue ot low tutt.-a 
letela on aaa11 doses fOP 
J. ,._ 1 JAw t•et:JD~ 1•••1 
ttM• :omi,tha ohlo•~ia 
.to' 2 wnk•· . · 
Qbl.o . ,HP~ttlde ·liftt.·: .. ·.· . teat ..tng .. · . 1e.· .. • .. ··.·•S...·  . 'f8"··· t.eltd ·. . ttw aeve•a,l mtatba atte . · 
· · · · ·atMoattnulaa ~ObtorpHpamWo. 
Chl_,...palll.t• .:·G~t .• t~.l ,__. atte• . · 
· •~e.ment ot ebioPpPopamttt 
...... tt.U'tllle~~ lQ~VetcOd 
. _...dt ooPma1.-·. ·(tvov.oaaJ.r ••••t• 1'800l'4d· .,, •• 
klalllSD·dt.IO'OD.tln.u.eG)• 
OblotpHpaaalae rou nor:mal e.tt .<~ ·•,• 8M 
:atO!'M1 taattas le"U.I1s oa 
vaattoua •s•ta • t &a 
~temt.t.$!OJt .• 
tueiettntl.J lew fae:tlt~~, ... 
ln•1• a ema11 ctoeo ... of··· "' 
. $10t1>!0PU1d611' · = ;·:!o~.'::~!: rt!:;:r·. 
bJJOSlJOQOrdo aaa,e., . 
2.2.S 
/ 
.Uf· DtB•· ·'IOlbUi;aa4fo 
. Cf'11o~JJfOpollLte 
·, 
W ••~'•: 'lo1bia~L"e 
:·· ,,! •·• 
·.·. 
DI&!JUUIOI, <P Til . l!a.,~IFS 01 .o~~A~LOf:VCO&E, ,1f9ptMMOE 
~- II ·'•t!ll" I~ BYPOC!JMCA•!HS AG!!If,! 
AD auS.,al• ef tba NR1tl lbOtd tbat tM 
leal' eabMo•'*'' •• prodQo .. bJ eo•""• wb•• tu 
patt.••• bad b•• •••• .. wS.th 81!£E!I!!Id.d! tl99!• 
tbSI .• ff410' vae 1•11 WU • .- tllb.ere 
oblor.pNpud.f• •• u.ed la ooajaattloa wltb uotber 
bJpollJOuak aact to oonbo1 tbAt dla.,.tee. 
ftlu e ,.,,... (ot • •otal 10) co v•• 
'••••tt wltb oblorJQ'Opaald• alene ahowet eS.tur 19. 
(C!Ji J!lld) f!11!no••!,• lo tb• tolt)atald4e tN&te4 
iroDt ·• the otbest batld• 5 ,a•t•t• (ot • tou1 7) 
•bow•cl _,.,_..,. k;. -..li:.S·· •flbaoo•Mil'i 
f!bi.t dltt•»••• l.:o ... ..,.,.. •• •trt.klqlJ 
.no. 1o ,. patl•' "•'• tou• Ul)t Wbl24 tnat•t 
tdtb •olbt.l••••• (1 o. daS.lJ) til•· eor•l•oa• ebaDoeant 
ot the ala.oo.• to1eN1'lo. ., •• , wa oeul4•abJ.e, but 
Oil eblorJNpaal.d• · (0.25 G .• ) tbe· ... patlat a•e4 
. 
ao ebaftaeMDt• A •1•1J.u t.rPI ot ... u.lt :wt.tb to1b.ataal4• 
ad eiorpopald.4e ... ••• SA 11•11• (C.•• 126). 
Cort11a• ---··-· 'ttbll• patS.•ta ..... Mlna 
v•W wlta ehlepropaala. •• feund t.o h leea.!MB 
"' th •• ott.e• bfpoa1J•••Ido llll.tl • 
23o 
fO*alble uplau'1_. tw W• aotlon (vbloh 
_. ve11 •XU~P1S.tt.•d 1ft oana v•t.M with both 
oblorpopalll•• cd tolbotud.d•) .,.. •· 
1. '1M dunUea of MUon •t OblOI'PJIIOpaald• S.a 
loopP. ft• balt•llt• ot oblepPJOpulde t.a 34.5 bOtilN 
(8..._. •• a11959). fh• balt•Ut• or tol~taat.te 
,. ctD.1J 2 - 5 b0Ul'8. 
ln. tbla •oocntloo, lt. Ia to Ita ootad tb&t 
1n A.P. (Oa•• 46) •• -..-. ..,... •urled nt ln the 
uual tJaJ ac• var• ••PM'M ., ... • prellala&17 doae 
ot 50 ... ot Dll oo the •ftli.Aaa ot tb• ...- aerl•• 
ot ••t•• 'fa• 1•••1 ot .,. aluoH• toluuoe teat• 
•• lwu Ia .. aeooad •••'" tt\lt •barlo•.-nt .. 
••111 -.tt ... 1••• lD. aplt• ot b taet tba' 
oonoeatntlon ot tbt auaclde to til• patl•t'• blood 
bad latl\l000.-1 \b• 1w•1 of ttut bJ..04 aluoo••• lt 
414 n•' •lpttloantl,J ohllp tb• 'JIM' of •hano••nt 
pztetfto., 'bJ oortl•cm•. 
.. ebte.-pa&tl4e •• ·fl -.& ,. .... d. 
bJ.pj8boaelo ~eff.eei .• 
: . • ..-••M bfpoaiJCMlelllio ._.,, ••• do.e aot aM~ 
to bo • ltkolJ eap1aGatloat t• .~ft .. o.a. lOu• 12?) 
if!·•~}) '" 1\JJOiliUttG' ett•t*···11$$ ,eaatt.o, ..
coptl,_t ••• .._, •·• etll$ ·taalttea})lea kl 
W•l• .(oue ·a;.a,),. bl •• ib.e ~hOftiJ: aba#cemcmt 
wtuf-ohl'J ttl\•t• oilt•p.os-mft 4tt no' »•otaee a 
etl'lld.eg &ap!'OteMat lo tld t1Gt(;•• t·C)le~e teeti. 
I 
the thl· ,,. ot etibllii'HtUAt ••a .ut • 
l.btea or b1~ta\Jta•d:o ef:ftVJtl . ,~,,,., 
An .-lral• ot tbAti H•Ha .. ot.ttw ,,_ 
ot •••tt.etGO ·•••••• :tit ·t$twrahc-.. ·tol~oe 
teet enr~ k). ,a.:.le#'l vt'b a .. AWD~ $18080; to1·--~· 
testo ...... tbat1 tU.t tell lPB ,;a 8f"QIJ C!·N GROV" 
~~~ x; ~a22.1~22.~,). 
•••• .lft. ? ,atl•'• (5 t•••W wttb a~••••• l ttt• o~lde + tu, mut· 1 '!ld·th e.J.~~Nt61d4•l• 
23.2. 
' . . . . 
IX4f •••• ellt\mtoameat WM ,.,_ Sa. ' pat;leat•·• 
(tiles...,.,. -.atot wltt& ioiW_.o•t Meet tb.ea• 
patill\U .l'etNb4fd a.lt4-'la~Jlf taMa ~attl •ltll 
. . . '. . ~ 
~~-~&•••fl•• ,Cfi~!--.!l'li•1.ti!I&Jle ~*· SS!U8!. 
ltila!l!,. ·, ,., 
1.. ·sa •• patleate' wJi.o -~ alJ :a1likt 
) . 
-••••mrn.ttt I ata••tQe<i a ~,_. slaoo•• tolefttlM 
:• 
M8·t dteP tveotMftt vae otof.)pl$ (Gtlt .• case ?6ll .u•• 
paliet :maintaine:t. ·• ll*C.&aL-.·-- tnt-. btf•lo ' 
''•••· o-.aae 118).,. Ia dl ,_ ~· ••••·•· (•••Pt. 1·41· 
CAM ·~7) •• ·tho .tu'-•tiiflllt ne~· to ·.a.. hJpogljoa•m1c 
as•• n•tat• •••net <• '-""•4 tutu•) aact , • 
.u· •••r ••••••ve tb*t ·•e•~•Ma!l,.ki.JI!a ·a,,a 
.atalllr·l!' J!!I!UitJU\ 
11. irt ••• . ., .sbftftf. _._. enblftqe-.t ot 
tu atuo•e ·tohtaoe t•t .ta -cett.ac•·• 
tal o.a. (Cae·e 12?) tU.ca • eev•••lr abavmll 
ll•os• tole:Nfto• ••• •• tM _,_,l,•••' :•set 
.. fttt00iltta84J 
(bJ. a,~. (C.ce ?') 'b.t'lt nev& .. :ILJ.f.ft\WG. a ,poaa!J 
· a~ltlal r.a-oat tol•naoe ieai ea o•lliiitiUe -
vat oldttel f.OI' • vht.1•J 
,· 
(t) z••• Clae .JQ!) ·lito allowed a o0tlll4etta\"l'y &IOona,l 
oun• ••~ to-lltQtald.tt· 1118 ttopp&f to• 1 Htk (21J,.f•S9l. 
. I 
. .b Mt&olfl8 ot tbe £latlap ia ONtlf l ad ,%1 · 
u ·"-' fte eol'tt·a~/.ollaooae $ole~ . _,, &a paUata 
,,..,_, tdtb· ..,_slJ....S.e •••• ··"' J»>Ve to oe • . . 
iAdea ot aat · atst\t •••, 1-1 ·• 'Jposlfaatmd.• AS•' .......... ,, •.. 
. I 
.. ii'&U. II PMfiOd ., ._._.., jJluotle 
to16 ... tl&\ (ftli!lf!l .•• ,., ..... lias· ... 
sb.ooo tal•••• •••t ot •onletaa + tlfposlro•emlo 
8.1fllit ue soa ltl the .toltO\tb:s patlGfits : 
·a·•· c,,, 19 
o.tt. Oleo II? 
o.s:.. ·Cuo ?6 
w.a. Cate P' 
t.v. •••• ,.., 
AD IUJMtloa ot lllfltl.&tal Nlt.llt• I# 
'be '*''•• 1tho ebcNed oaJ.J· ·~· enbauetlliA' 
•lith oortd-IOM ·~utt to tOS84Yit *bat· C)f -.. •••tal.q 
' pa:tleatt • ' ••• 1ft a ata•·• of ._.$._.,.. thu #a 
' ... ,, ........... :b,at ,,~·- - ,., .... ~ 
l.a SlUOUt Wlelmlle ttat .ad to G--~hfW I tMI'O 
' w•a •t~l811tiQ eYldoaQ tbat lt tf;Oil~ .- · 
t:.t '$.8 "•'"" to ., .... , •. -~~- -
trltKPH*IOB· of tU .-e~t~ltJ ••• .Ia or.up I ._._,. 
tleae · ,atlata 1f8tit.· :t.ra o pllGGe ·Of. welldcttlm . _ 
•• •••tl._/ .... uoa• ,..,.lfi»artOt ••• ua •••• ~•• 
' ' 
••adta , • .., auaa••t;lve· btaat oot· J*\:leftt. • to'lhtalllle 
:IIQ.t: f pat&•·• oa _.s..,.,..,_,.,, :•t ._. &ate ••••t•• 
F~ et~J c. tl\t.a pc:tift;tf if ·•Ht:4H4. 
(t• as.. ouuo\lJ.oa ''· 11• l.atef!eetloi to· aoh 
·~t o.aavt.J1t~IIMB eti el .:C·l9JJ) .lad :•es»•tod 
. ' . 
tsQt • alooMe~ toleNtlDe •••t •• ·1ottd ·-.~004 le9ell 
· ·P6.f.ltttf tu ·••• • mea• ._.., • 6 week nun• t1 
--~~-·,··' 
... ,;·~· tbo ,..,_w ••• ot ~- .tQt&oa 
.Sob ••ld ·w. • .-w • ~t.WI· ,, 
GlaaOfe tel•._..• ••·'· C•o-rd..a•• + br»>aircaett~.o 
·astntY=thooao to1enaoc• · teet;· Cttit't\wt oittwl' ). 
!, l ·~ ·. •. ,· ~. ' 
. . . 
t.t tble aeotua .. e:ve ue··••••••ae••s the 




. . . 
atuooa•a•••l• 'bJ.·tt&e l~, ..... ._,.,.,dtlfta. .u. • 
. ' 
t.aw•oe• til ll••~ wauaduee l\t~lvitr•· IM•ea.eetl. 
11.vw ._Alllaao ·••tt•tt,J baD •• ·l•~•tod · Ia 
aJ.md.e a.e a _..1t ot "''~•.,..,.t.ntetN•t• ·<·•• ~ 
ett ollt$6• ftYOito ·•t a11t·t?J• 
hla hU ·o.hO t.nwil oet&J.M4 bf. suea et •1 (lftfJ) 
-tlbtl euaaeat t;'hfit the .ate'Hl41 .. _,, tbeiJ; $1MOA•oa-.etf.O 
·•••t.v·&tt tit ·f'lJit:u. ot .. lilellt' •ltiOt • ll!tU•van•••S..•• 
I 
. / »••t.• •• ai (l9St)· P'iotn oct tul •••loaa 
coa4t.tl.- •· .sluoto,tloo&<l atDJ1t&U·tfatlcn. td.stl P'OMLD 
' . 
.135 
be.,...aeetl ltwe• !d;l,'iuoo.a•"*••le·•' ·•• uo•~s.ftf .· .• ~~· .. · ,•. ··- ' ---- ' .• ,Q' -'---,-.-~-······:· ' ·-·~ 
··if· a laoitai'e a WiU.-ateiOR#tl··· 
It aae ~»&e Npotlef ·Uo tb.Ot us f4:1.m . 
dtaltetlo Mtl:, t·heN :t.e :& 4U.,_, 'tile»••• .SA · 
.ltt;er tftftlamltulee aottv·llJ ·(O~er •t ·allf51l. 
,_.._. ~ al (19Stl e-..s UU~t ltt _,, 
of tu oa•• t~t tlabetea tk«t -.ee•tcatt4• tho 
t•atlitamttaat• t.ctltltl ef tht U¥•• oe11 t• Ntaet 
bJ v•tlllbt of the Ua'betlo ••• ·• •oael141eaa of 
Ube· IJPJ et 4labfttu •d wtttJe• ·Ctc•·tdlat •••· .,, ~ 
d$.-tt atou ol' iaaalS.u as weU, 
. ._, • .,,,. (19i1'J aat ~-..uaw :_.,bltta 
ot d.ea'*- U.••••••• bJ •• wo eutJ;hoaf1w .. 
·~•· oal'liata1d4• •• to1bllt~4• •• •• auuuted 
that tuM t,U,IIJOW\41• -'tlit -·~· l9JtOsiJ086rAO, ef.teot bJ 
• •+'*JJt.~ftt'l' ·~····-*-·ttAwl ·- , .• ~0:. •ftu. ... tf:&,.~  ... ,~ . ~ r,JifiA ., . ·. t 
dee•••• tiit ~PG,te ot ••sl•oc••Ar• .-a •••. ·1•~•• . 
••• blood suaat-• . tacJtfU:eit be»atio· atuoonosea.eeio 
f.e. tht _., ~teafllJ 4emoaotrat.O ;motat.llie etfett ot· 
til• et••otcta at •• bela ••'-t'bll&'t SA leol.atlt 1t.ver 
,. ·va~.,.- ·-· :il._ ......... ~-··--t -~~ant )k-o•-ft ·-:1\f~af,;·· ... , . . ;".·~'~..a~ ,•_',.,-_ ·-·~- g ... -. 
CtbOm e' al 1H1)• 
.DO lbe tlf»O&IS'O&aio llta\a- .. Gblblt 
-tl~eoa~ta at h;q ••il ~-~ bi ~toto 
(1957) ' 
il~ ·t~ .ruulta tOU'.Id iD tld.a· ~~wAr et 
tbe- o.p,oslos etfec,'h ot bfpo~td.:o- aJJ•~ aaa 
oo~tlo•• lil-e U&ed- •· fl'fldtma• tbiat tlle rqpoatpoul'l44 
$8-.ta -t\\oe. ft8 ou,~elted IJ!l lo-mttdftt 'bJ blli.Wr.tlOD 
ot ei.MIP tNUuda&eeJ. 
~· COl',leoa,e bat ilet'J.M. to :p~aoe 
~~~•meat ctoa ate _Gllftlll -.. -. bJ:~oaQd,o 
qed .ill Pll'Oi'IOH l.ta t>ftHt llJ :~l•ma- tlMJ 
aotl<m· ol ton~<••• ll••• bJ ~tlJlt,f.ns btfpatlo 
slt~Gatoaeu•t• • a~(; ,~ ... eeaott·ot.tr) ·t 
It -~- bJP04l:JCllsd.O ISae p•lk1Utti lf* ett•ot ia 
-~ • ., 1.1 .,, tl\4lt ••• ._ •• ~--t ...... la 
GOI\e MHI ·ellO ut -·W$11 omt.,t.l t~J.eb iht 
·~qpoal,.y,eaer4o eant ' 
fbie wdd sqpa' ·tWit s.. ~ea•· · .aeu · 
at ie•'• ""' .br..S'lroauto etfeti lD a•lne4 tar 
A mt4~ Otb&J' •a \!JJ alar4tte ~IM 
btbltllti.i·ta;.' 
l.a • •••• dett••'~ ·1ft· tblc •••1.14\• ttw 
·~. ····- ~··~t ., be· - ..... ,,. '"*' .-.,ueat o•OI'll• or •• :P'tlet, 1Mlt a•t ot •• 
biPOel1r• .. •· etf:~c!tlwv•••• ot. ttt\t opats. 
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,The . e.ct.t.on ot .1n$ll:U.l'l: 
From the avtd.lab1e evl($Gnoe Ed~ the. prtsent 
time lt s>G&ms tl:ua.t the suggestl.:~n .tnade .bY ~vlne 
and h1.s nollet3.gu.es (1949 and 1·9'50) that the 1$:&7 point 
.tn. the action of 1n$ulln. b ·On· t~ perm$ablli tr or 
the cell$ to glucoe$• ta the cCt'l'Ele·t •one. · 
Tb.1s sugg~stton M:$ a+eo 'been suppott~ed 
by tbe wovlt ot Pe.rak (l9.5Jl and 'by. ·Dr.U!IJ et Ql fl952). 
Insulin acceteratee the tranate:t of gluooae from the 
blood or exttsacellul.U tl't11d J.nto the. tl.x•d tissues 
' 
of tbe body. lts pr1nc1pa1. $1te or .e.ct1on, the~efo!'&, 
'.rhette 1& now n(? .r~al e:vi.<Jence to suppert tne 
pre'Vlously held vtew ot an acc$lerat1ng &ftect .ot 
' . 
insulin on the intracellular eatabGl$..em ·Of g1uoo~Uh 
· the work of Vi.l.l~e. et a1 . (.194.9 ) on ttl;e 
· 1nt1'*&Ce].lule,t' ao.tion .<>t ~nsulin 1-n ·ti). \t.lti'O . 
. pr&parat1:(;)na , has not been iS\lpp<>rted by th• resulti3 
ot experiments on intact living animals where the 
rate or disposal or p~uvate and lactate did not 
188m to depend on the presence or absence or 
insulin (Flock et al 1938). More recent experimental 
work on completely diabetic animals (Ingle 1951) baa 
demonstrated an increased utilisation of glucose by 
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muscle during muscular exercise in the complete absence of 
insulin. 
In discussing the mechanisms of insulin 
action, Stadie (1955) baa indicated that the possible 
biochemical lesions .in diabetes may be concerned with: 
(1) the permeation of glucose through the cellular 
barriers to sites or enzymatic action. 
(2) the activation of glucose by reaction with adenosine 
triphosphate to form glucose-6-phoaphate, 
(3) the production and storage or high-energy phosphate 
compounds such as ATP and creatine phosphate, 
(4) the detects in the oxidative reactions particularly 
ot derivatives of glucose. 
Whereas the action of insulin on the cell 
membrane aeeme well establ1ah$d1 "the suggested 
action on the hexokinase reaction (2) as ve11 1a . . 
:still unctJrtatn. . It seams 11keir tb•n1 that •ttet-
alucoee has . ar:tteracl the -oell 1t 1G not 4epen4ent 
on the action of ~su11n. 
Inside the oellt gluco·se tollowa one ot 
3 main ,athsa 
(1) Oonve~&ion lnto glrcogen 
( 11} Convers1on .i;nto tat eto. protein 
and. U.i1) Ox1CS.at1on to C02 at:16 H20• 
'lhe ptteaent· evi4ence to~ the ealste.noe " 
of 2 mn!n types ot 41a.betes 1n man it . oone1derab1e .• 
and probablV aenePallr accepted~ 
'Two c1tn1oa1 t7pes or diab&ttos .have 
long been reoosn1eed~ 
. weight ani 'becoli$S ketotic vtthout 1nsulifti the 
so•oa11ed 3utt$n1le tJ·pe or · 'Gt-owth-o:cu:&·•t • type •. 
(Thla type occt.Ui"e at :S.nJ age, bu.t malnly ln the 7:0W'!S• ) 
2. The 1l•Tatur1ty-onset• t;rpe ot diabetica 
obeae and or an older age g~oup Who can generally 
be managed without insulin. 
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According to their mode of response to 
insulin the 2 types have also sometimes been classified 
as the insulin sensitive group (the juvenile type) 
o~ the insulin resistant group (Maturity•onset type). 
Pathologists had noted that in a large 
percentage or diabetics they were unable to detect 
any morphologic~l changes 1n the islets ot the 
pancreas at autopsy. Warren (1938) reported that 
26~ ot the autopsies in his series of diabetica 
revealed essentially normal isleta. Wrenshall et 
al (1952) found that Whereas the growth-onset type 
of diabetics have practically no insulin in the 
pancreas; the insulin-content ot the pancreas ot the 
matur1ty•onset diabetics was approximately half that 
ot non-diabetics. 
The final evidence in support ot the 
clinical subdivision came with the report b7 
.. 
Bornstein and Lawrence (1951) that there waa n2 
available inDUlin in the plasma of the juvenile 
type but that the plasma o! the maturity-onset 
diabetics contains available insulin (roughly 70% 
ot normal controls). The 2 groups can therefore 
be broadly divided into: 
(a) Diabetics with insulin deficiency and 
(b) Diabetics-without-insulin-deticiency. 
From the available evidence it might be 
deduced that an insulin lack is probabl1 not the 
factor responsible tor the maturity-onset type of 
diabetic. 
From this. it would appear that while 
diabetes due to insulin deficiency will be corrected 
by the administration of insulin• d1abetes-w1thout-
·1nsuli:n•de!'1ciency will not be fully corrected bJ the 
administration o!' insulin alone. 
The metabolic lesion in this type of diabetes 
seems to occur in the intracellular metaboliam ot 
glucose. Is it due to an interference with the 
enzyme systems (i.e. the enzymes or coenzymes) which 
-·.,. 
-.'" ,~· 
are concerned with activitles ot lnte:t-med1a:ry metabolism 
such as_ ox1dat1on•reduct1,on, elGavage; gro~p transfer 
and removal or addition o.t water• ph,Qsphate, ... o'02 and 
ammonia? Is such an 1ntertet'enee independent of 
hormonal control? 
~~ . ' . . 
The intracellular metabolism ot gluco.se is 
..dependent on the integz-1tyof var>1ous $nZJme-eoenzyme 
systems. ln SECTION III or this thesis the tmportaru'Je 
cr the coen~rmes DPN and 'rPN .in 1ntermedial'y metabolism 
was. disou.sse.d~ Does·the metabolic lesion in diabetes • 
the· eaP11eat deviation from normal 1- oc.cur tn these 
coenzymes? 
.A defect ln the coenzymes would :PI'oduee a 
widespread derangement ot carbohJdrate metabolism, and 
' 
or the inte%'con.nected pl-otein and t~at .metabolism as 
1s appal"ent .af"teP the considera.t·1on of. its niult1p1e 
: l ~ • 
1"unctions in intermed1a.t>y metabcill.sm plleviously . 
d.iscussed (SECTION III page ',?..(, .) ... • . ;Jt·: 
That a bl:oek in 1r.~;te~medta:.t>y. meta'bcl~sm 
oa.n produce wide$pread $f.t'ects,·~rom·a dtaturbance of 
tunct ion to death of ce)..:ts • ls scan. lt~ sod:t~ 
- . 
fluoroacetate (•SFA') poisoning.~ Thus in sodium 
fluoroacetate poisoning (the toxic principle of the 
\ 
South African plant, 'glfblaar•), Peters was able to 
demonstrate that fluoroacetic acid was transformed to 
!'luoroc1trate and this jammed the· oxidation of citrate 
leading to abnormal accumulation of citrate (Peters 
1954, Liebecq and Peters 1949). 
In •sPA' poisoned rata diabetes was noted 
(Engel et al 1954). The hyperglycaem1a and ketonaemia 
ot the 'SFA' poisoned rats was interpreted as 
representing diabetes mellitus secondary to the metabolic 
effect or 1SPA' on the tissues in general, or to a more 
specific effect ot tSFAt on 1nsulin production by the 
beta cells of the pancreas. The metabolism of both 
carbohydrate and fat w1 thin the cell is t jammed • at the 
citric acid stage and metabolism is slowed or stopped. 
This is an excellent example of a purelx 
biochemical leaion in the cell producing a widespread 
disruption ot cellular metabolism. Can diabetes be 
similarly produced by an interference at the 
- -
enzyme-coenzyme-substrate levelf 
DPN is of vital importance 1n carbohydrate 
metabolism~ Does the metabolic lesion in diabetes 
occur at this point? 
Disturbances ot DPN (See also SECTION III page§ 37- ~9 ) : 
DPN may be interfered with in various ways. 
Nicotinamide is its most active component. lt bas 
been shown that a variety of analogues of nicotinamide 
i.e. anti-metabolites can replace nicotinamide in 
the molecule of DPN (Woolley 1945). INH is one such 
anti-metabolite of nicotinamide (Zatman et al 1954 (a) 
and (b)) and there have been reports of aggravation of 
diabetes and a disturbance of carbohydrate metabolism 
in non-diabetic tuberculous patients treated with INH 
(Lunta et al 1953). Whether a mechanism similar to this 
occurs naturally is still problematical. It such a 
mechanism were shown to operate naturally, !t would be 
ot ~eat interest. 
Substances_ rel§ted . to nicotinam&(\e tfhich_iare ~mow 
to ocour .lnurnet":oollsm in .. man: 
In manli nicotinamide 1$ roz-med f'rom trrptoph.an~ 
' . . . . ' . 
· In SEC1'ION II~ ·it was stated th6\t. xanthurenic 
ileld can be forme4 fttom tryptophan-~ lts .fo.rmatton can 
be di.agrattnne.t1cally shown l:l$ tollowtn . 
/~ophan~· 
7 metaboliSm Fa~etabolism 
Nicotinamide X.antnurenic acid 
· O:>iabetogen1c ? ). 
'fh1s ~ay pr>QVG to be a product of great interest 
in studle$ (Jf di.abetes,t Kotake ( 1955) has summarised. 
.a series or exp~r1mente carried out by him and hie 
associates whtch -indicate that xanthurenic acid aause4 
diabetes 1n rats and that 1t may be a .factor mich 1,1 
operative 1n .man as well • 
. . . , '\ft 
TJ:xptophe.n. mEitabolism in t"~latton to nicotinalni.de 
!.n$&.XJnthurenig_f:e1Cl! 
Animal expeti1ment.a indicate that tr-yptophan 
-
appeared to be more important than nicotinamide 1n 
.. intaining liver pyridine nucleotidea even though 
nicotinamide is present in these nucleotidee (Williams 
et al 1950 and 1951). 
Pyridoxine has been shown to be necessary 
for the conversion of tryptophan to t1asue pyridine 
nucleotide& (Kring et. al 1952) and for the conversion 
of tryptophan to nicotinic acid (Sarett 1950, Sarett 
et al 1950). When there is a pyridoxine defioienc7 
xanthurenic acid 1a formed instead ot nicotinic acid. 
An increase in xanthurenic acid excretion 
vaa found atter high doses of · INH when tryptophan 
waa administered (Biehl et al 1954 (a) and (b)). 
(Compare the finding of Lunts et al (195') of an aggravation 
ot carbohydrate tolerance when INH was given to· 
tuberculous patients). 
Xanthurenic aoid baa been found to be 
present in the urine of diabetic patients in greater 
quantities than in normal man (Roaen et al 1955) .• 
Xanthurenic acid baa a •tructure similar 
- -
to oxl.ne (8•hy~oxyqu1noline) which .. has been sl',lown 
to be diabetogenic in rats (Kadota 1950) • · . 
2SO 
The structUl'e.l .formulae of oxine, xanthurenic 
















Ar.e the substances,, ~nthtwenie :acid and 
ox1ne; diabetogenic by virtue ot an action which 
interferes with nicotinamide in GPN, 1,e. are these 
substances a.ntil""mete:bolites of nicotinamide? 
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Kadota had attributed the diabetogenic 
ettect of ox1ne to its chelating action) but subsequently 
(Kadota 1951) he has found that several related products 
did not produce diabetes in spite or the tact that they 
were equally or more effective as chelatins agents. 
The chelating action doos not seem to be 
the likely explanation, therefore, and ue are lett with 
the previous suagestion that xanthurenic acid and 
products stmilar to it may be diabetogenic by virtuo or 
a possible anti-metabolic action in relation to 
nicotinamide. 
It has been pointed out that a low concentra-
tion of a critical enzyme or coenzyme in the beta cells 
may be responsible for the produetion of diabetes 
(Lazarow 1949)., It has been shown (in the production 
or diabetes) that the interference or cellular metabolism 
need not occur only in the beta cells, e.g. SPA diabetes 
(also, 1n view of the tact that the diabetes of maturity 
onset is not dependent on insulin deficiency are we perhaps 
not overstressing the part played by pancreatic 
destruction when considering the diabetogenic activitJ 
ot a substance?) 
. 252.' 
- -
The question tor consideration here is 
whether a low concentration, or a qualitative or 
quantitative alteration, ot the coen&ymee DPB and TPH 
are responsible for the production or diabetes? 
An anti-metabolite could bring about such 
an alteration in the coenzymes and it 1s very 
tempting to postulate that substances like xanthurenic 
acid and related diabetogenic products act in this way. 
Up to the present time there baa been no evidence 
that this actually occurs. 
It haa already been stated 1n SECTION III 
that nicotinamide bas been reported to prevent 
alloxan induced diabetes 1n animal expertmenta 
(Lazarow et al 1950 and Banerjee 1947>• 
In Yiew or the 1m~ortant role of nicotinamide 
1n the coenzymes DPN and ~PN, it was decided to teat 
the effect of nicotinamide administration in large doses 
over a long period to patients with diabetes. (In man 
the concentration ot DPN and TPN can be increased by 
the ingestion or large amounts of nicotinamide (Axelrod 
et al 1940, Kohn et al 1938, Handler et al 1943). 
Blood glucose levels and glucose tolerance 
testa were used as the index of progress 1n these 
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oases. It was found (see SECTION IV) that several (20) 
of the nicotinamide treated group showed improvement and 
in same of these patients a remarkable improvement 1n 
glucose tolerance tests waa noted to normal or near 
normalJ 1n the majority of the treated diabetics (28), 
however, no Change waa recorded. 
It ia difficult to aaeeas the part played b7 
nicotinamide 1n produ.oing such complete remissions as 
seen in some of the cases of the study. There is a 
dearth of such long term studies of diabetes in the 
literatureJ but remissions in diabetes are recorded. 
These reported cases of remission have not been studied 
as comprehensively (with recorda of glucose tolerance 
teats before and after remission occurred). It is 
possible that if there were reports of similar long 
term studies, remissions similar to those demonstrated 
1n this thesis may be recorded in the natural course 
ot the disease. At present there is suggestive 
evidence only that nicotinamide may have played a part 
1n producing the completeness of the remissions seen. 
It aeemea· possible that nicotinamide mar 
have favourabl1 1ntluencad the cou·~se ot· the dt.e.betes . 
1n some or the 4.1abet1c pat1(:ttlts o·r the study; · but 
1t must be pointed out that a failure ot response 
to nitiotinamide administration doesnot rule out the 
possibility of the existence of a mechan!em of 
production ot. diabetes ·CJ.e,pendent on interference 
w1 th the coenzymes l>PN and TPN, ·e.g.. 1t 1rreversible 
intracellular _changes have ·already_occ~red as a r&sult 
ot the changes p~od.uced. In this eonne()t.ion 1 t may b$ 
polnted out that there 1 s evidence of &. change .in 
41$bet1e respon.se» (to treatment) .with the passage of 
t1ma, $ •i• 
(l) .GDJ.taslons have been nt>ted to occur in diabetes (of 
recent onaet) shorply e.tter the commencement ot treatment 
with insulin .... i.e. the insulin Ffqu.i:remen~ may decrease 
tor a while. 
(2) Remissions in diabetes can be induced_, by weight 
los.s ... :-.r these pa ti.en ts have .a relapse , 1n, d.la betes 
artett regaf.~tng weight (1 second attempt at .inducing 
a rem.1s.s1on by weight loss will .not t9t1cceed,. 1'h1e 




since then I have been able to confirm thia in 
patients obse~ved at the diabetic clinic. 
This latter type of response was aeen in 
other instances as well. Remissions aeen in the 
nicotinamide treated patients lasted tor a variable 
time (in aome tor years) and were then followed by 
a relapse of diabetes when there waa a failure ot 
response to nicotinamide treatment. These same 
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patients in whom there was this relapse or diabetes, 
when treated with tolbutamide, showed an excellent 
remiaaion - in some to a normal glucose tolerance 
teat. After the passage of a variable time, this 
response was followed bJ a relapse in the diabetes 
once again (or the recurrence ot grossly abnormal 
carbohydrate tolerance) 1n spite or continued tolbutamide 
administration (secondary tolbutamide failure). 
At this point it might have been thought that 
theae·patienta had developed a more severe type of 
diabetes (e.g. the juvenile type), yet c11n1cally, 
they were still behaving in the aame way aa the 
maturity onset diabetioa and this was confirmed by a 
25b 
- . 
good hypoglycaemic response to another sulphonylurea 
drug, chlorpropamide. 
Riboflavine 1n Diabetesa 
A point worthy ot mention ~~s the incidental 
observation that 1n the patients Who received riboflavine 
(15 • 45 mg.) over a long period of time, there seemed 
to be some elevation ot the tasting blood glucose levels 
and of the glucose tolerance test. Thus, riboflavine 
may have seemed to behave as e. diabetogenic agent in 
these patientas. It is ot interest that some workers 
should have suggested that 1n the metabolic breakdown 
ot riboflavine, alloxan may be formed (Banerjee et al: 
1945>. 
Potaasium Salts in Diabetic Pat1entsa 
The observations on the effect ot the 
administration of potassium salts (300 m.Eq. daily) 
were continued tor up to 2 months. It was found 
that potassit~~ produced a uniform olovat1on ot the 
tasting blood glucose level in these diabetic patients. 
The most etr1k1ng outcome of the long term 
study on the.se patients was the demonstrati<Jn of 
remissions in glucose toleranc• test to normal or 
near normf:ll f!Ltter adm.1nis.tr.e.t1on ot these_ agent.s. 
This study showed. that there were gros$, 
fluctuat1.cn.s in glu,eose tolerance- tests \mder tbe 
influence or various agents. - Patients who had 'been 
I ,-
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shown to have severe abnormal1_t1es_ in glucose tol:erance 
test were shown to r~m1t to the extent or having a 
normal _glucose tolel"ance ~test. l:n the same patient 
the form ot the curve was shown to vary considerably 
trom time to tlmth Tbis oou1d be&t be seen bJ an 
-examina.ti.on of the illustrations 1n .the individual e~ses• 
tt was possible to elasstty th~ p~ti.en.ta 
who shewed a good. f'aatiyhzposlxcaemt.c res:e.onse into 
2 typeel 
(1) those wo had e. norma.l ~.r"almost normal· 
s1uoose tole:rance~curve d~1ng t:reatment1 
(2) those who had a low normal, a normal, or 
near normal fasting level but considerable 
elevation of tho regt of the glucose 
toleranee curveL 
This long term study of fluctuations in 
glucose tolerance tests during· diabetes showed that 
the previously held view that there was merely a general 
lowering ot the curve after treatment could not be 
applied to the results seen in the patients of the study. 
Although 2 cases in the first group may have 
demonstrated this effect by merely a general lowering 
ot the curve, the majority showed a change in torm ot 
the curve, e.g. low tasting and 2 hour levels were often 
demonstrated 1n the glucose tolerance tests. 
The Mechanism of Action of the Hypog!lcnomic Asenta! 
This isatill not understood. Various 
suggestions have been made for tho mode of action ot 
sulphonylureas. Loubat1eres bad suggested a stimulation 
of insulin secretion. Pancreatectamised animals showed 
l.SCf 
no tall 1n blood sugar f<t11ow1ng.IPTll but.partlallr 
panereatectomised animals <11d show this respon$& 
(tcubatieres 1944 and 1946)~ Mi:rskf (1956) postulated 
that they ected, as ·e ~sulinas~·· tnh1 bitora ·1 ; t. e '·• the 
action of i:nsulin was enhanced by .1nh1b1t1on of its 
. . 
deatr-uetton~~; 
Th.e.se are the view.s most gene!'ally held at 
present., t.e.. ·the .sul.pnonylureas act b7 1noxs~as.tng the 
amOUl'lt, OP th.e etfeetiv&nef'S., of insulin. 
It .s.&ems likelJ that their erteot 1$ 
lndependent ot insulin... The cU.abetics Wh'ii) are benefited 
by the sulphonylureaa~ have been shown to he.ve plasma 
insulin; the· erU.lphonyl~ea.s do not enhance the action 
ot administered ,insuUn .l:n the Juvenile.tzp$,;. It &eems 
far more 1'-kely that their action· 1s· ·on the ·1nti'acellu.lar 
.ma~a~ol1e of gl:ueose, i.e •. beyond tb.o .1n$J.tl1n l·evel. 
In th1.t.S study the bi81$n14e.$ we.re shown to 
be efftH~t1•e 1~ a group ot .diabetics who w~ra not 
benefited by a trial_ of all the au1ph()ny1urea drugs .• 
.26o 
_/ 
~· J •.• ~ 
lheoo .volfto all ot tbe ditv..S:tr onset. With 
the eatep,loa of one, vnoae ccrmt&fte.-ment •• w~ kD 
roars, 1111 weN eld&Jtlr ·dlabetios. Some ot ·them, .bo'Wovor. 
, we!'e b&1ng ·~~t:ro1led: VS.th lnsulib. prlol* to tho 
Snat·itutlflft or tbe· blguaol4tt thel'APJ'• 
lt vas touncl too,_ tbat t.u a few or the fOtmaez. _ 
-t.tlabettce, Who ba4 aevero juvonlla ·t,-pe dlabetea. 
. . 
'teatab1Sabe4 tor ·IOfiO tears) and. Who nqut•e« ~a• 
4oaee ot wui1n.t tbe b1SQQ:nt.<lea tmpl'OVtt6 Gta'betS.o 
oontttol en a _.ll&l"' doce o.t -l.nsulith ftite e.trects waa 
novo• aocm in osta'b11tbet.t O:tabetee of tbe 8GVonl1e tJPCt 
td.th the ·i11u1Pb.Onrlurea. 4rustt. Wb.e bigUan14ee acb1&1'& 
tbe1r ettect .ln 6\ 4S.ttel'en.t; •t frOM tho eulpbOnJ1eoae. 
nm lt.t~l t.be 'blood e\lSnr ln. alloxan .. 
4la'bot1c (~ ot a1 1957) ., am\ hepateotozgeed (Ulelaen 
et; al 1958) aq1ma1e, 'he ae&.eo of ·-·s~nse \Je.I:D.s 
p4!Jate.- ln tbr, intact at~lmal. 
fbe, latter wottkel'a. e~at tha' OBI 4eQHaeee 
sluocmeeaeno&S.a, anti that tb1a maJ be -ono va; la whlob 
1t a.otd.ovee lta efteot. 
! 
Both DBI and guanidine appear partially 
to inhibit, within the tricarboxylic acid cycle, the 
energy transfer dependent upon the coupling of 
oxi~ation with phosphorylation (Hollunger 1955). 
Regarding the mechanism of action of the 
hypoglycaemic agents: it was hoped that interesting 
information might be obtained from a etudy or the 
cortisone enhanced glucose tolerance test particularly 
in the patients who bad shown a good hypoglycaemic 
response to a pharmacological agent. It waa suggested 
by Bornstein (1957) that the hypoglycaemic agents 
produced their effect by an inh1bi~1on or alanine 
transaminase, i.e. that they inhibited hepatic 
neoglucogenesia. 
Would they 1nh1b1t this ac.tion ot cortisone 
(see page 223 ') it cort1aone were given! It was found 
that some ot the cases who showed an excellent response 
to the hJpoglycaemic agent (e.g. with a normal glucose 
tolerance curve) snowed marked enhancement or the 
glucose tolerance curve when cortisone was given aa 
well. In these oases it seemed unlikely that there 
was an .lnhibition of n.e.oglucogenesis by the 
hypoglycaemic agent. 
!be use of cortisone in these eases did 
reveal en interesting point~ It was round that the 
cortisone test enabled a prediction ot the further 
course of diabetes were the hypoglycaem1c agent to 
be omitted. The response seen could be equated thus 1 
G.T. T. (Cortisone + Hypoglycaem1C agent) = d~ '1:'. T. bt1thout 
either). 
In those patients 1n whom a good remission in Ci1abetea 
' 
was seen (e .• g. a normal glucose tolerance test) and no 
enht\ncement We.s produced by cort1S$t'1Gj was 1t pcuJsi~le 
to predict that the diabetes was ·in ·l*emissi.ont · The 
evidence was suggestive bu.t l'lUlr& observations would have 
to be tila4e:~ 
It coUld bt .Qp~culated whether the hypoglycs.emic 
agent had in fact ach1ev-ecl 1ta effect &n these casaA 
b7 an lnh1b1tion of hepatic neog11,tcogenesie. 
In a study of carboh,-dr&.te tolettance ~ 
gout it was found that there was a high incidence 
ot abnormality of glucose tolerance. 12% ot the 
cases showed a frankly diabetic curve. 
This study on gout was undertaken to eee 
whether a product of intermediary metabolism • of 
normal or faulty metabolism • might play a part 1n 
the pathogenesis ot diabetes. 
In discussing the significance of the h1sh 
incidence of abnormal carbohydrate tolerance in gout 
in SECTION VI, it was suggested that thls finding vas 
related to the faulty metabolism in gout itself. 
(Herman 1958). This would imply that naturally 
occurring substances might interfere with intermediar7 
metabolism of carbohydrate 1n man •. 
!he effect of the cortico-steroids on 
carbohydrate metabolism has been extensively studied. 
Cortisone is now known to have a diabeto• 
genic action in man by virtue of its action on 
hepatic neoglucogenesia. It has become an important 
' / 
research tool in the discovetty of potentia1.e.nd 
latent d1tUJetes.. · 1 ts effE!ct tn prod;u()ifi8 enhane>ement 
· ot the glucose tolerance teat ln dia:~tes bas been 
' . ' . 
extensi ve1r studied bJ Fajans lind Conn (1954) ,and 
th1$ type ·Of WOPlt bas been ca:rl*ied out in1'ar1our; centres 
now. 
In th1s study the Wluenoe or cort 1'$one on 
the glucose tol~rance test of! gouty pa·ts.ents has been 
.lnve.l!ltlgated.i\ The result.s have suggested that the 
gouty pat;1ente are at least as au.soept1ble to the 
~c.U.abetogenic .effe·cts of cortisone $8 are a creup ot 
patients who we.re selected. b8cause they were Qonsidered 
to 'be latent diabetics oztwho were known to have b.a-4 
a diabetic cur-ve or an abnormal cu.z.ve bef:ore;jj: 
. . . ···-;<.~ 
This could .'be cited as acid1 t:t:.orial support 
tor the sugge$t1tJn that s,ome inh$l"~nt det'(Jot. ot. 
oarboh;rdrate m$t&.b()).1.$m. exists 1n gout'~ 
A surprising .finding \fa,s . the· ta:1lurtt' ,of 
oortlson& to ·px-oduce s1gnlt'1o~t en.b&lncelfl&nt -in mot'e 
. . 
bt the patients who we,..e pr&viously knoWJ'i to na'Ve· had. 
' ; 
an enhanced curve. If' these patients were mettely- in 
.-a. latent phase of diabetes (d'Ul'itlg _ thet:r. rern1ss;1:onsJ 
.ltwtts to be suspected that eortlaone would ptso~oke e. 
:1'11Qn1testly d1abst.1c curve. 
Although nicotinamide had been shown in 
animal &XJ>$rr1ntents to prevent allo~en·lnduaed dlabete$1 
the administration of.n1oot1naldd~·tailed to pi'event 
.. 
_. - . . ' 
dla.betic curve tand the other·wh.o was in a state of 
remission). In one pat .lent though 11 with: a rtaroiua.l curv•, 
the cortisone/ glucose tolerance c1:wve following 
n1ooti.namide was better than the 2 preceding curve.s 
( i"e.. a preee~ing standa.rd glucose tolel'ance test ·and 
B 
A UNIFYING CONCEPT 
A UNIFYING CONCEPr : 
~ stud7 or diabetes mel11tua over the 
years has proved taac1nat1ng. In the beg1nn1ng 
certain questions were posed and Jet more have 
arleen as the study bas progressed. 
There are atlll maDJ unsolved problema 
1n diabetes. Some ot them are connected wlth 
the moat fundamental aapeota of the dlseaae, e.g. 
we stlll do not know where ~· metabollo lea1on 
1n diabetes llea; we do not understand 1Ull7 the 
mechanism of action of' 1naul1D 1n dlabeteaa 'What 
was the algnlflcance ot von Noordents (190') 
provocatlve,but universally conf1rmed>t1nd1ng ot 
the benetlclal influence of the oatmeal diet which 
was destroyed by the addition or protein toods f 
There seems to be little doubt that the 
compo~ltlan ot the diet,partlcularly with reference 
to lta protein content,may influence tbe development 
ot diabetes in man (Mlnkowskl 1892~ Allen 1913, 
Marks and Young 1939). 
What taotora 1n man lead to the 
production ot d1abetet f Alloxan la the beet 
known d1abetogen1o agent. Does a au-atanoe 
resembling alloxan occur aa an tntermediarJ tn 
metabollam ln man. Loubatierea (19~) baa done 
1ntereat1ng work on thle aspect but the t1nal 
answer la not Jet known. 
Xanthurenic acid too has been reported 
to be diabetogenic. Th1a aubetance 11 related 
to nlcot1namtde ancl both are derived from the 
eame parent eubatance trJptophan. 
ln my atud1ee I have sought thoae tactora 
occurr1ng in the error• of metabolilm which maJ 
1nfluenoe the development ot dlabetea. 
I was atruck bJ the many 1ntereat1ng 
correlations 1n the 2 molt atudled metabolic 
d11turbances, gout and diabetes. The experimental. 
evidence 1n animals made me go on t.o a atudy of 
the 1nteroonnect1ona ot tO.•• conditions ln man ae 
well. 
Tb.e .Pl't4uctton. .of: ·:the:.a. metabolle 
d,1,$,tt.ll'beu~<uua 1 .;ou.~ an<! dl•be·tasl:Jg the· &&111$' ·aaent, 
al:Loxan, ,tn :tb.e. ptg~on. I.e, .of rase1natlng· .·relevance I 
w~~ this .to:prf,ta.ge e. .. oommen \ind•r1y1ng :meehan1$m ot . ' ... . 
prod'uqtton ct tb.e .2 d1.s·turbancea, ?:· · ~) · ~ 
·' ' . . 
~ . . . . i . . ' : ' ·. .t.' . .-' . . ' 
Thel'e are other teatU!'e$ whleb. tb.ese 2 
·dlstttrbances of me·taboll$m a'1ao $tw-e f obesltf, . 
b.ypercho1e~Jte:rpla&m1a • ,atberoscl~:ew()s1a • nephropathy, 
etc. .(it .1a. intf)r~_stl.ng .. to compare. the ·s.nct.aence 
ot thea.e. assoeia tea metabolic disturbances w1 th · 
thlltf tound .ltt'th~ l!01.tth~Afr.tcarf Bantu· people .1n whom 
aev&ra1 studS.es ha'te shown the str1ltliigiy low lnc14ence 
of. ·41abetea mellltWJ '' (foll.tmer et al 19§0). . . ~ .. 1011 ' 
atheroscle~o•t.s. Their s4u~um ~ono1esterol ts low' and 
· th1Jr~ is a low ;~er~ urie. ao14 bitbaahan 1959J}. 
. The · b.l'Sh . 1nc1dance ot 41abetes ana 'abnormal. 
oa~bohyd!tate(tole~ance tn_gout ..f,ound l.n my. stu.dy. •ar 
1.(:8 
! 
·. .. ,, .· 
be coitatderea·a further 11nk 1n ttl$ association.· or these .2 
., .. '. 
' 
1 
' , _. , ' • !. 
1 
, ' I : L '• • • •• _. ; ; ~ L • ' 
mettl.boltc disturbances• 
. ; . '' 
The oo.litisone enhanced test ln. a group ot gou.~r 
pat.1enta ln thts stu.4J .suggest«ad that tile gouty patients 
:mtly ~ unclu1r ,u.oeptlble to 'the 4la'betogealo 
ettect$ \ <)t C:~rt1aon&. Tilts· p(}~n.t requires tur:ther 
. \ .. ' 
t 
'.·:. l . . ' 
. ' '·' . 
. 'l'he aclnd.~t•t!'~t1on ot _ . •o .T .s. t:auses an 
u.pheav.fl.l o.t p~rlne Jnetabollsm ~d ·s.t ha.t1 been 
&Suggested b~ Cono. · (1948) that· a ?lU'lne metabollt• 
ex•rts an a11oxan~l.lke· ·eft(lc·t':bf ~s r••ponatble< 
tor redttc!lrig the' lntraoe:tlulv : .~a\ta11e.bl·11 tr o.t t~e• ' 
su.lpbJdrri grotips·ua th1s1ead$ to the -de1relopmeat 
ot diabeteth .. Both glutathlon¢ (Conn •Gt e.1 1949) 
and :n·tcotlnamido ·nave been ,lh'Own to .afford :protection 
a'galnet a11otan-i:nduo&d'. dl•abtttts '1-n' anS.mals ... 
Do aU.oxe.n•ltke · substan~ee : eae·rt ·thelr 
.. '·' 
t.J1tlo.ence br an •tt .. ot on· r;.1eotJ.nrun1<1e (Rack,er 19_55) 
and g1utath~one_ f 
•.' ,' ,; 
.IU.el.eopt"o\elns ·ma;, Sf/~~ a$ a. reselcv~1t-' 
. ' ' 
~t .~EH'UI11g ;a,ve.tl«l>le a~e.,.S.al_ .for._.-use ae ooenll,yme,s 
(Scodak l'55)• ·. Wlll it \;)e ,lfllQW that .the a4~nt.ae · 
componf!tnt ot the .eo.nzJ~eai may 'be tU.eturbed ln ·the· 





• •• !, 
!I~ tae:r-e .. u. lnters.,onne,?t!ng. 'link.· bet)JFien 
. '''·' . •,- &I• --.- ~ ,.,.- ~- ••. --.-.- .. il -~ ;__ ',• ' .. ···,"·.* :~~--~~~- ,-_,; ··-·:.··:· .. ? ... 
these d1$t~banc·••t Wtlll 1t. b$ .!ihown e•s• that .. there 
I ' • . 
is st)mt tau1tt.dlve~s1Qn ln.. e;~o-t?~S;,n ...• et,a:~~lt,sm~. (e.g. at 
the Krebs tare!t ·~yC:l.t3 ~ a ·m~etl.ug po:1rtt ot ea~boh)"dt-at•, 
. 
·. proteln; ana· PUi'lne· metabollsm • ·l tow~ as ·lne&teatut~ . 
p~oduetlon of p}tr;tmlCISne (or aesodlate<l' alloxan~llke 
' .. 
ln. ·tb.1s the•ts I have .PQ!ated out tb.• Vt1l'J 
' ' 
Co!*tlsone has been ua.ea. as a means ot · '';' _-. ·-.... , . 
fttl'thett l.nves·ts.gattng tb.ls .tulsoelai;l.on and al!l'o ·tt;,'r · 
studylng lts effect on the action or the b.yp<»81Jct:u~m1c 
,: •I: 
. Pb1Jiolog1cal and pha..-ueo.l.ogt·6a.l• · 
. . . . · . .:, . . . · i I' .i 
'l\ypogl)'oa•mic ·&8etite b.a,e 'been $.~veatlge,ted• 
CONCWSIONS t 
The most sisplfloant outcome of the Studya 
1. In the atudJ or the influence of 
n1cot1nam14e on tbe glucose tolerance teat, it 
was seen that patients Who had grossly abnormal 
glucose tolerance curves developed glucose tolerance 
teats which had reverted to normal. Th18 remission 
ln diabetes lasted 1n some cases tor a period of 
1eara. 
2. Patients treated w1th the pharmacological 
agenta showed considerable tluctuatlons in their 
glucose tolerance curves. Glucose tolerance curves 
during treatment differed fl'Om those before and atter 
treatment. Some patients developed a normal curve. 
3· A considerable proportion of the patients 
with gout showed diabetic glucose tolerance curves, 
or other abnormalities of the glucose tolerance curve. 
4. Patients w1~ gout were found to be more 
susceptible to cortisone enhancement or the curve 




;. Gortlson.e enhanoem.ent of the ·gll.lOO$e 
tolex-ance cu.rv• was lese pronounoea w1th cnloxapropamlde 
than wttb any ot the oth,er h7pogly:eaemto· agents used. 
t ,; \I; . ,. 
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